#  @AponiaAnalytics aponia_analytics
Several biotech companies have recently made significant announcements. TG Therapeutics reported a strong Q3 revenue of $161.7m, driven by Briumvi sales, and raised its [----] guidance. Regeneron also posted a 13% increase in Q3 revenue to $3.68b, driven by Dupixent and Eylea HD. Additionally, Pfizer reported solid Q3 results, with a revenue of $16.7b and raised its [----] EPS guidance.
### Engagements: [-----] [#](/creator/twitter::1816152863069925376/interactions)
- [--] Week [-------] +1,546%
- [--] Month [-------] +30%
- [--] Months [---------] +36%
- [--] Year [---------] +1,121%
### Mentions: [--] [#](/creator/twitter::1816152863069925376/posts_active)
- [--] Month [---] -59%
- [--] Months [-----] +28%
- [--] Year [------] +707%
### Followers: [-----] [#](/creator/twitter::1816152863069925376/followers)
- [--] Week [-----] +0.63%
- [--] Month [-----] +0.77%
- [--] Months [-----] -0.27%
- [--] Year [-----] +72%
### CreatorRank: [-------] [#](/creator/twitter::1816152863069925376/influencer_rank)
### Social Influence
**Social category influence**
[stocks](/list/stocks) 73.58% [finance](/list/finance) 17.92% [cryptocurrencies](/list/cryptocurrencies) 2.36% [financial services](/list/financial-services) #998 [technology brands](/list/technology-brands) 0.94% [countries](/list/countries) 0.94% [celebrities](/list/celebrities) 0.94% [currencies](/list/currencies) 0.94% [exchanges](/list/exchanges) 0.47% [travel destinations](/list/travel-destinations) 0.47%
**Social topic influence**
[$hims](/topic/$hims) #98, [$nvo](/topic/$nvo) #123, [$ibrx](/topic/$ibrx) #13, [$nwbo](/topic/$nwbo) #5, [novo](/topic/novo) #3041, [$lly](/topic/$lly) #85, [in the](/topic/in-the) 4.72%, [$unh](/topic/$unh) #253, [$vktx](/topic/$vktx) #56, [ceo](/topic/ceo) 3.3%
**Top accounts mentioned or mentioned by**
[@fda](/creator/undefined) [@drpatrick](/creator/undefined) [@andrewdudum](/creator/undefined) [@immunitybio](/creator/undefined) [@saiseiinvesting](/creator/undefined) [@againstheliars](/creator/undefined) [@jfais20](/creator/undefined) [@abalakum](/creator/undefined) [@cremieuxrecueil](/creator/undefined) [@thekiwikapital](/creator/undefined) [@matthewherper](/creator/undefined) [@pharmalot](/creator/undefined) [@damiangarde](/creator/undefined) [@benzinga](/creator/undefined) [@sanofis](/creator/undefined) [@lawliepop](/creator/undefined) [@michaeljburry](/creator/undefined) [@theroaringkitty](/creator/undefined) [@investinc_intel](/creator/undefined)
**Top assets mentioned**
[Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Novo-Nordisk (NVO)](/topic/$nvo) [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) [Eli Lilly and Company (LLY)](/topic/$lly) [UnitedHealth Group (UNH)](/topic/$unh) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Oscar Health, Inc. (OSCR)](/topic/$oscr) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Unicycive Therapeutics, Inc. (UNCY)](/topic/$uncy) [Merck & Co., Inc. (MRK)](/topic/$mrk) [uniQure N.V. (QURE)](/topic/$qure) [Royalty Pharma plc (RPRX)](/topic/$rprx) [Pfizer, Inc. (PFE)](/topic/$pfe) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Synthetify (SNY)](/topic/$sny) [Morgan Stanley (MS)](/topic/morgan-stanley) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [OnKure Therapeutics, Inc. (OKUR)](/topic/$okur) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Fractyl Health, Inc. (GUTS)](/topic/$guts) [Abivax SA (ABVX)](/topic/$abvx) [Revolution Medicines, Inc. (RVMD)](/topic/$rvmd) [Amgen, Inc. (AMGN)](/topic/$amgn) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [The 99% Community (99)](/topic/$99) [Vaxcyte, Inc. (PCVX)](/topic/$pcvx) [Neumora Therapeutics, Inc. (NMRA)](/topic/$nmra) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Centessa Pharmaceuticals plc (CNTA)](/topic/$cnta) [Schrodinger, Inc. (SDGR)](/topic/$sdgr) [Edgewise Therapeutics, Inc. (EWTX)](/topic/$ewtx) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [Janux Therapeutics, Inc. (JANX)](/topic/$janx) [HSBC Holdings PLC (HSBC)](/topic/$hsbc) [Liquidia Corporation Common Stock (LQDA)](/topic/$lqda) [Dana Incorporated (DAN)](/topic/$dan) [Wave Life Sciences Ltd. Ordinary Shares (WVE)](/topic/$wve)
### Top Social Posts
Top posts by engagements in the last [--] hours
"$IBRX @DrPatrick Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): Its fully approved in the US for one rare form of bladder cancer but not for the common form most patients have. So even though the same drug is already FDA-approved and https://t.co/jb46zpPbPL Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): Its fully approved in the US for one rare form of bladder cancer but not for the common form most patients have. So even though the same drug is already FDA-approved and"
[X Link](https://x.com/AponiaAnalytics/status/2022023146325643666) 2026-02-12T19:01Z [----] followers, [---] engagements
"$IBRX $IBRX shorts got PLAYED. They piled in heavy on insider FDA dirtbetting on papillary rejection/delays thinking ANKTIVA was dead in the water. Then Dr. Pat drops the HAMMER: Saudi FDA slams accelerated approvals for ANKTIVA in BLADDER AND NSCLC first worldwide subQ IL-15 wins $IBRX shorts got PLAYED. They piled in heavy on insider FDA dirtbetting on papillary rejection/delays thinking ANKTIVA was dead in the water. Then Dr. Pat drops the HAMMER: Saudi FDA slams accelerated approvals for ANKTIVA in BLADDER AND NSCLC first worldwide subQ IL-15 wins"
[X Link](https://x.com/AponiaAnalytics/status/2022024877092618365) 2026-02-12T19:07Z [----] followers, [---] engagements
"$VKTX $VKTX Stifel $VKTX remains undeterred by expanding competition in the obesity landscape. Notably VKTX is aligning its programs with next- generation profiles that not only address tolerability but issues with treatment duration exploring both weeklymonthly and weeklyoral $VKTX Stifel $VKTX remains undeterred by expanding competition in the obesity landscape. Notably VKTX is aligning its programs with next- generation profiles that not only address tolerability but issues with treatment duration exploring both weeklymonthly and weeklyoral"
[X Link](https://x.com/AponiaAnalytics/status/2022032226876326289) 2026-02-12T19:37Z [----] followers, [---] engagements
"$AKBA $QTTB $AKBA $QTTB Akebia Announces Establishment of Rare Kidney Disease Pipeline - QTTB BioPharmCatalyst https://t.co/L22GgQEWAC $AKBA $QTTB Akebia Announces Establishment of Rare Kidney Disease Pipeline - QTTB BioPharmCatalyst https://t.co/L22GgQEWAC"
[X Link](https://x.com/AponiaAnalytics/status/1995589336218391038) 2025-12-01T20:22Z [----] followers, [---] engagements
"$RPRX $DNLI $RPRX $DNLI Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement BioPharmCatalyst https://t.co/wGUQ4rSYTI $RPRX $DNLI Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement BioPharmCatalyst https://t.co/wGUQ4rSYTI"
[X Link](https://x.com/AponiaAnalytics/status/1996634088950976661) 2025-12-04T17:33Z [----] followers, [---] engagements
"$DNLI $RPRX $DNLI and $RPRX Announce $275 Million Royalty Funding Agreement https://t.co/IsG6su0xFN $DNLI and $RPRX Announce $275 Million Royalty Funding Agreement https://t.co/IsG6su0xFN"
[X Link](https://x.com/AponiaAnalytics/status/1996635427961532726) 2025-12-04T17:39Z [----] followers, [---] engagements
"$SDGR 🦉Schrdinger granted RSUs covering [----] shares to six new hires on Dec. [--] under its [----] inducement plan. Awards vest over four years starting with 25% after year one. https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4-ff9b7e0d0/default.aspx https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4-ff9b7e0d0/default.aspx"
[X Link](https://x.com/AponiaAnalytics/status/2001363979332129119) 2025-12-17T18:48Z [----] followers, [---] engagements
"$OKUR 🦉 CEO Nicholas Saccomano sold [--] shares at $2.97 to cover RSU tax withholding. Post-transaction ownership totals [----] shares per filing. #form_4 https://onkuretherapeutics.gcs-web.com/static-files/def41edf-4764-480a-b892-155b1032652a https://onkuretherapeutics.gcs-web.com/static-files/def41edf-4764-480a-b892-155b1032652a"
[X Link](https://x.com/AponiaAnalytics/status/2003939572779237781) 2025-12-24T21:23Z [----] followers, [---] engagements
"$UNCY $UNCY resubmits Oxylanthanum Carbonate (OLC) NDA $UNCY resubmits Oxylanthanum Carbonate (OLC) NDA"
[X Link](https://x.com/AponiaAnalytics/status/2005699049249542555) 2025-12-29T17:54Z [----] followers, [---] engagements
"$RPRX $RPRX Acquires Remaining Royalty Interest in Roches Evrysdi for $240M and Potential Milestones $RPRX Acquires Remaining Royalty Interest in Roches Evrysdi for $240M and Potential Milestones"
[X Link](https://x.com/AponiaAnalytics/status/2006028647950356571) 2025-12-30T15:44Z [----] followers, [---] engagements
"$CYTK $BMY $EWTX Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies added If successful it could open up aficamten in nHCM which Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies added If successful it could open up aficamten in nHCM which"
[X Link](https://x.com/AponiaAnalytics/status/2009656094088704141) 2026-01-09T15:58Z [----] followers, [---] engagements
"$JNXT 🦉 Janux Therapeutics names William Go ex-Kite and A2 Bio CMO effective Jan [--] replacing Zachariah McIver. Go led ZUMA-1 to Yescarta FDA/EMA approval and joins as JANX007 and JANX008 run Phase [--]. https://investors.januxrx.com/investor-media/news/news-details/2026/Janux-Therapeutics-Appoints-William-Go-M-D--Ph-D--as-Chief-Medical-Officer/default.aspx https://investors.januxrx.com/investor-media/news/news-details/2026/Janux-Therapeutics-Appoints-William-Go-M-D--Ph-D--as-Chief-Medical-Officer/default.aspx"
[X Link](https://x.com/AponiaAnalytics/status/2015871431846900199) 2026-01-26T19:36Z [----] followers, [--] engagements
"$NWBO $PFE $HSBC $NWBO rubbing shoulders now with some bigger names like $PFE $HSBC #AARC as they all join forces in a global think tank to advance the development of cancer vaccines in #immunotherapy. https://t.co/m6cDnOncoB $NWBO rubbing shoulders now with some bigger names like $PFE $HSBC #AARC as they all join forces in a global think tank to advance the development of cancer vaccines in #immunotherapy. https://t.co/m6cDnOncoB"
[X Link](https://x.com/AponiaAnalytics/status/2016559158644928648) 2026-01-28T17:09Z [----] followers, [---] engagements
"$LQDA 🦉 Chief Accounting Officer Dana Boyle sold [----] shares at $41.65 under a 10b5-1 plan to cover RSU tax withholding. Post-sale beneficial ownership stands at 178.8k shares largely unvested equity. #form_4 https://www.liquidia.com/static-files/f3ffc534-a174-4fd3-8638-e1c0858300af https://www.liquidia.com/static-files/f3ffc534-a174-4fd3-8638-e1c0858300af"
[X Link](https://x.com/AponiaAnalytics/status/2016627127135723625) 2026-01-28T21:39Z [----] followers, [---] engagements
"$GUTS $GUTS Anticipated Catalysts https://t.co/bGEXb7eL7b $GUTS Anticipated Catalysts https://t.co/bGEXb7eL7b"
[X Link](https://x.com/AponiaAnalytics/status/2016902369464762438) 2026-01-29T15:52Z [----] followers, [---] engagements
"$GUTS #FDA $GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo pathway in Q2 $GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo pathway in Q2"
[X Link](https://x.com/AponiaAnalytics/status/2016902600805753242) 2026-01-29T15:53Z [----] followers, [--] engagements
"$UNCY #FDA $UNCY FDA Accepts Oxylanthanum Carbonate (OLC) NDA Resubmission. PDUFA 06/27/26 $UNCY FDA Accepts Oxylanthanum Carbonate (OLC) NDA Resubmission. PDUFA 06/27/26"
[X Link](https://x.com/AponiaAnalytics/status/2016939323027755450) 2026-01-29T18:19Z [----] followers, [---] engagements
"$ABVX $ABVX hang this slide up in a museum https://t.co/ApagfLw0FM $ABVX hang this slide up in a museum https://t.co/ApagfLw0FM"
[X Link](https://x.com/AponiaAnalytics/status/2016939501398921313) 2026-01-29T18:20Z [----] followers, [---] engagements
"$RVMD $RVMD Doses First Patient in Clinical Trial Evaluating RMC-5127 a RAS(ON) G12V-Selective Inhibitor $RVMD Doses First Patient in Clinical Trial Evaluating RMC-5127 a RAS(ON) G12V-Selective Inhibitor"
[X Link](https://x.com/AponiaAnalytics/status/2016953611926774171) 2026-01-29T19:16Z [----] followers, [--] engagements
"$NVO $LLY $VKTX The data is in for the week that ended [--] January and the trend reversal is undeniable. $NVO New-to-Brand (NBRx) prescriptions for Wegovy just exploded +71.9% week-over-week. While the market was worried Novo just printed one of its strongest growth weeks in history. Lets https://t.co/fOhxgDMlzF The data is in for the week that ended [--] January and the trend reversal is undeniable. $NVO New-to-Brand (NBRx) prescriptions for Wegovy just exploded +71.9% week-over-week. While the market was worried Novo just printed one of its strongest growth weeks in history. Lets"
[X Link](https://x.com/AponiaAnalytics/status/2016954563257844144) 2026-01-29T19:20Z [----] followers, [---] engagements
"$UNCY $UNCY: The Class II designation and a tough day for the indexes $IWM explains todays volatility. FDA accepted the OLC resubmission as Class II with a PDUFA target 6/27/26a longer review window not a clinical negative. Cash was $41.3M at YE25 with stated runway into [----] $UNCY: The Class II designation and a tough day for the indexes $IWM explains todays volatility. FDA accepted the OLC resubmission as Class II with a PDUFA target 6/27/26a longer review window not a clinical negative. Cash was $41.3M at YE25 with stated runway into 2027"
[X Link](https://x.com/AponiaAnalytics/status/2016957009677931005) 2026-01-29T19:29Z [----] followers, [---] engagements
"$RVMD LIFESCI $RVMD Mgmt Discussion Takeaways: Incremental Color on RASolute [---] Dynamics Pipeline Execution and Early Clinical-Stage Assets January [--] [----] OUTPERFORM PRICE TARGET: $144.00 LIFESCI $RVMD Mgmt Discussion Takeaways: Incremental Color on RASolute [---] Dynamics Pipeline Execution and Early Clinical-Stage Assets January [--] [----] OUTPERFORM PRICE TARGET: $144.00"
[X Link](https://x.com/AponiaAnalytics/status/2017056922894291176) 2026-01-30T02:07Z [----] followers, [--] engagements
"$REGN $REGN on ox40 and the bar needed to compete with dupi $AMGN $SNY https://t.co/tUPGtYtB1c $REGN on ox40 and the bar needed to compete with dupi $AMGN $SNY https://t.co/tUPGtYtB1c"
[X Link](https://x.com/AponiaAnalytics/status/2017260386722971883) 2026-01-30T15:35Z [----] followers, [--] engagements
"$QURE 🦉 UniQure to meet with U.S. Food and Drug Administration on Huntingtons gene therapy after the agency changed its view on the trial; patients discussed petitions on STATs The Readout LOUD https://www.statnews.com/2026/01/29/readout-loud-podcast-huntingtons-patients-uniqure-gene-therapy/ https://www.statnews.com/2026/01/29/readout-loud-podcast-huntingtons-patients-uniqure-gene-therapy/"
[X Link](https://x.com/AponiaAnalytics/status/2017261748244434966) 2026-01-30T15:40Z [----] followers, [---] engagements
"$QURE @jfais20 One of the less understood things about HD is the very high suicide rate. During yesterday's podcast it was understated and the actual rate of suicide during "normal" times for HD community is 10-12 TIMES MORE likely than gen pop. FDA needs to give them hope now $QURE https://t.co/voZeRdlvYc @jfais20 One of the less understood things about HD is the very high suicide rate. During yesterday's podcast it was understated and the actual rate of suicide during "normal" times for HD community is 10-12 TIMES MORE likely than gen pop. FDA needs to give them hope now $QURE"
[X Link](https://x.com/AponiaAnalytics/status/2017276866411762019) 2026-01-30T16:40Z [----] followers, [---] engagements
"$IBRX #ANKTIVA $GILD $MRK ImmunityBio $IBRX Target Valuation & Market Cap Projections Current Valuation (Intrinsic Fair Value) Estimated Market Cap: $18B $25B Revenue Explosion: FY2025 net product revenue grew by 700% year-over-year to approximately $113M. This performance demonstrates the https://t.co/CylwZCjkQp ImmunityBio $IBRX Target Valuation & Market Cap Projections Current Valuation (Intrinsic Fair Value) Estimated Market Cap: $18B $25B Revenue Explosion: FY2025 net product revenue grew by 700% year-over-year to approximately $113M. This performance demonstrates the"
[X Link](https://x.com/AponiaAnalytics/status/2017282312669454479) 2026-01-30T17:02Z [----] followers, [---] engagements
"$UNH $UNH 🐳🚨 🚨Monster accumulation: 1.3M+ shares in [--] blocks within an hour and a half midday buyers paid premiums up to $1.01 over ask on blocks 164k400k. $373M notional scooped on💰 🐂For a $500B+ market cap name like UNH this kind of size on dips (post-earnings/guidance https://t.co/cvQPF3U3F2 $UNH 🐳🚨 🚨Monster accumulation: 1.3M+ shares in [--] blocks within an hour and a half midday buyers paid premiums up to $1.01 over ask on blocks 164k400k. $373M notional scooped on💰 🐂For a $500B+ market cap name like UNH this kind of size on dips (post-earnings/guidance https://t.co/cvQPF3U3F2"
[X Link](https://x.com/AponiaAnalytics/status/2017711844241166828) 2026-01-31T21:29Z [----] followers, [---] engagements
"$UNH Torray Funds added some more $UNH shares. Is $UNH going to be most bought stock [--] quarters in a row for superinvestors 🤯🤯 https://t.co/o61W0OovPW Torray Funds added some more $UNH shares. Is $UNH going to be most bought stock [--] quarters in a row for superinvestors 🤯🤯 https://t.co/o61W0OovPW"
[X Link](https://x.com/AponiaAnalytics/status/2017712063347331540) 2026-01-31T21:30Z [----] followers, [--] engagements
"$UNH UnitedHealth $UNH forms first Golden Cross since July [----] ✅📈👀 https://t.co/MceSrTl42N UnitedHealth $UNH forms first Golden Cross since July [----] ✅📈👀 https://t.co/MceSrTl42N"
[X Link](https://x.com/AponiaAnalytics/status/2017712463047729461) 2026-01-31T21:31Z [----] followers, [---] engagements
"$WVE This is the Grade [--] SAE version of "our partner doesn't like or want our drug so they gave it back." Wave Life Sciences $WVE announces plans to accelerate regulatory engagement with full control of WVE-006 for alpha-1 antitrypsin deficiency This is the Grade [--] SAE version of "our partner doesn't like or want our drug so they gave it back." Wave Life Sciences $WVE announces plans to accelerate regulatory engagement with full control of WVE-006 for alpha-1 antitrypsin deficiency"
[X Link](https://x.com/AponiaAnalytics/status/2018337383519760474) 2026-02-02T14:55Z [----] followers, [--] engagements
"$NWBO #MHRA $NWBO Anticipatory MHRA approval signs continue with new Job Posting https://t.co/coeCDJQQWp https://t.co/khJvvT1sVx $NWBO Anticipatory MHRA approval signs continue with new Job Posting https://t.co/coeCDJQQWp https://t.co/khJvvT1sVx"
[X Link](https://x.com/AponiaAnalytics/status/2018724639543832797) 2026-02-03T16:33Z [----] followers, [---] engagements
"$NWBO $NWBO The Pfizer guy was totally amazed by the results from DC vaccine trials on GBM breast cancer and melanoma. He probably didn't see the results from the DC vaccine trials on ovarian cancer. Otherwise he could have been amazed even more. LP mentioned that the collaboration https://t.co/16gpPn6CZ0 $NWBO The Pfizer guy was totally amazed by the results from DC vaccine trials on GBM breast cancer and melanoma. He probably didn't see the results from the DC vaccine trials on ovarian cancer. Otherwise he could have been amazed even more. LP mentioned that the collaboration"
[X Link](https://x.com/AponiaAnalytics/status/2019518641969197302) 2026-02-05T21:08Z [----] followers, [---] engagements
"$NWBO #DCVax"
[X Link](https://x.com/AponiaAnalytics/status/2019518710181224777) 2026-02-05T21:09Z [----] followers, [---] engagements
"$UNH Unfortunately when it rains it pours and there could be more bad news heading $UNH's way regarding Medicare. The Centers for Medicare & Medicaid Services (CMS) proposed increasing payments to private insurers by only 0.09% in [----]. If you're wondering how the market reacted https://t.co/CdlnHULNHY Unfortunately when it rains it pours and there could be more bad news heading $UNH's way regarding Medicare. The Centers for Medicare & Medicaid Services (CMS) proposed increasing payments to private insurers by only 0.09% in [----]. If you're wondering how the market reacted"
[X Link](https://x.com/AponiaAnalytics/status/2019518857283858923) 2026-02-05T21:09Z [----] followers, [---] engagements
"$NWBO $NWBO It seems like @abalakum was really impressed with the trial results from DC vaccines. He should know that Pfizer's Prevnar has been combined with DC vaccine in various trials conducted by Mayo Clinic which produced truly amazing results. I suppose he could bring his boss https://t.co/iybdW9KuFB $NWBO It seems like @abalakum was really impressed with the trial results from DC vaccines. He should know that Pfizer's Prevnar has been combined with DC vaccine in various trials conducted by Mayo Clinic which produced truly amazing results. I suppose he could bring his boss"
[X Link](https://x.com/AponiaAnalytics/status/2019519727836754130) 2026-02-05T21:13Z [----] followers, [---] engagements
"$NWBO #DCVax 🧬 Englands New Cancer Operating System: A Forensic Reading of the [----] National Cancer Plan and Where $NWBO #DCVax Fits #UnitedByUnique #WorldCancerDay TL;DR: Englands National Cancer Plan (February 2026) is a ten-year rebuild of cancer care as an engineered measurable https://t.co/SEiG2IoRGu 🧬 Englands New Cancer Operating System: A Forensic Reading of the [----] National Cancer Plan and Where $NWBO #DCVax Fits #UnitedByUnique #WorldCancerDay TL;DR: Englands National Cancer Plan (February 2026) is a ten-year rebuild of cancer care as an engineered measurable"
[X Link](https://x.com/AponiaAnalytics/status/2019522165289427249) 2026-02-05T21:22Z [----] followers, [---] engagements
"#DCVax $NWBO #UnitedByUnique #WorldCancerDay #CancerImmunotherapy #PersonalizedMedicine #DCVax $NWBO Cancer is not one enemy. It is a thousand disguises. Two patients can share the same diagnosis and still have different tumors different escape routes different immune histories and #UnitedByUnique #WorldCancerDay #CancerImmunotherapy #PersonalizedMedicine #DCVax $NWBO Cancer is not one enemy. It is a thousand disguises. Two patients can share the same diagnosis and still have different tumors different escape routes different immune histories and"
[X Link](https://x.com/AponiaAnalytics/status/2019528702275567639) 2026-02-05T21:48Z [----] followers, [---] engagements
"$NWBO $NWBO Dr. Keith Knutson from Mayo Clinic also attended the conference organized by Cancer Vaccine Coalition. I assume by now Arun Balakumaran may have read some publications by Keith Knutson and other researchers at Mayo Clinic. Mayo once conducted a trial on advanced ovarian https://t.co/wlObsVmLbN $NWBO Dr. Keith Knutson from Mayo Clinic also attended the conference organized by Cancer Vaccine Coalition. I assume by now Arun Balakumaran may have read some publications by Keith Knutson and other researchers at Mayo Clinic. Mayo once conducted a trial on advanced ovarian"
[X Link](https://x.com/AponiaAnalytics/status/2019528756575023105) 2026-02-05T21:49Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: $HIMS JUST ADDED THE "GLP-1 MICRODOSE" TAG TO THIS GRAPHIC ON ITS WEBSITE https://t.co/a1wGcJFTLK 🚨 BREAKING: $HIMS JUST ADDED THE "GLP-1 MICRODOSE" TAG TO THIS GRAPHIC ON ITS WEBSITE https://t.co/a1wGcJFTLK"
[X Link](https://x.com/AponiaAnalytics/status/2019528933298074080) 2026-02-05T21:49Z [----] followers, [---] engagements
"#dcvax $nwbo #dcvax $nwbo #gbm Interesting notes on Dr. Balakumaran's extensive background below:- "The "CAR T moment" for solid tumors is here. For decades we've watched survival curves drop like a staircase. But the latest signals from the CVC Think Tank and the data across GBM https://t.co/BXLVWWxulN #dcvax $nwbo #gbm Interesting notes on Dr. Balakumaran's extensive background below:- "The "CAR T moment" for solid tumors is here. For decades we've watched survival curves drop like a staircase. But the latest signals from the CVC Think Tank and the data across GBM https://t.co/BXLVWWxulN"
[X Link](https://x.com/AponiaAnalytics/status/2019529037526499719) 2026-02-05T21:50Z [----] followers, [---] engagements
"$NVO $HIMS Novo Nordisk $NVO accused Hims & Hers $HIMS of illegal mass compounding after the telehealth platform said it would offer a cheaper compounded version of the Wegovy pill - WSJ https://t.co/THw0ygs1Jh Novo Nordisk $NVO accused Hims & Hers $HIMS of illegal mass compounding after the telehealth platform said it would offer a cheaper compounded version of the Wegovy pill - WSJ https://t.co/THw0ygs1Jh"
[X Link](https://x.com/AponiaAnalytics/status/2019529121299071436) 2026-02-05T21:50Z [----] followers, [---] engagements
"$NVO $HIMS As expected $NVO just announced its taking legal and regulatory action against $HIMS. This is another example of $HIMS' historic behaviour of duping the American public with knock-off GLP-1 products and the FDA has previously warned them about their deceptive advertising of As expected $NVO just announced its taking legal and regulatory action against $HIMS. This is another example of $HIMS' historic behaviour of duping the American public with knock-off GLP-1 products and the FDA has previously warned them about their deceptive advertising of"
[X Link](https://x.com/AponiaAnalytics/status/2019529227188728029) 2026-02-05T21:51Z [----] followers, [---] engagements
"$NWBO $NWBO while investors wring their hands in frustration and fall for shorts tricks real work goes on in the important places. Follow science not charts. https://t.co/8p1VGVjg9L $NWBO while investors wring their hands in frustration and fall for shorts tricks real work goes on in the important places. Follow science not charts. https://t.co/8p1VGVjg9L"
[X Link](https://x.com/AponiaAnalytics/status/2019550810355400732) 2026-02-05T23:16Z [----] followers, [---] engagements
"$NWBO $NWBO The real meaning of Eikon Therapeutics' TLR7/8 agonist is about activating DCs which have tumor target proteins on their surface so that anti-tumor immune response can be boosted even more. https://t.co/OTowi66hzw $NWBO The real meaning of Eikon Therapeutics' TLR7/8 agonist is about activating DCs which have tumor target proteins on their surface so that anti-tumor immune response can be boosted even more. https://t.co/OTowi66hzw"
[X Link](https://x.com/AponiaAnalytics/status/2019550864281842160) 2026-02-05T23:17Z [----] followers, [---] engagements
"$HIMS $NVO Heres some additional context: $HIMS is allegedly not infringing $NVO's patent because it isnt using SNAC technology the mechanism that enables oral absorption of semaglutide. But without SNAC the drug shouldnt work. So what exactly are people paying $49/month for $HIMS Heres some additional context: $HIMS is allegedly not infringing $NVO's patent because it isnt using SNAC technology the mechanism that enables oral absorption of semaglutide. But without SNAC the drug shouldnt work. So what exactly are people paying $49/month for $HIMS"
[X Link](https://x.com/AponiaAnalytics/status/2019550977528156652) 2026-02-05T23:17Z [----] followers, [---] engagements
"$NVO $LLY $HIMS $HIMS is down 15% from the daily high. This is what you get when you literally scam your own patients. $NVO $LLY $HIMS https://t.co/r8Z14SGCKV $HIMS is down 15% from the daily high. This is what you get when you literally scam your own patients. $NVO $LLY $HIMS https://t.co/r8Z14SGCKV"
[X Link](https://x.com/AponiaAnalytics/status/2019551096872587710) 2026-02-05T23:17Z [----] followers, [---] engagements
"$HIMS $NVO 🚨 EMERGENCY POD $HIMS LAUNCHES GLP-1 PILL $NVO THREATENS LAWSUIT Thanks to @cremieuxrecueil for coming on the show 02:24 Initial reaction to the news 03:56 Science deep dive: liposomal delivery vs. SNAC 06:02 Legal implications and possible lawsuit 18:38 Future of the https://t.co/PtxWY4dyE8 🚨 EMERGENCY POD $HIMS LAUNCHES GLP-1 PILL $NVO THREATENS LAWSUIT Thanks to @cremieuxrecueil for coming on the show 02:24 Initial reaction to the news 03:56 Science deep dive: liposomal delivery vs. SNAC 06:02 Legal implications and possible lawsuit 18:38 Future of the https://t.co/PtxWY4dyE8"
[X Link](https://x.com/AponiaAnalytics/status/2019551829571563643) 2026-02-05T23:20Z [----] followers, [---] engagements
"$HIMS $LLY $NVO 🚨 BREAKING: JUDGE DISMISSES ELI LILLY'S LAWSUIT AGAINST WILLOW HEALTH $HIMS $LLY $NVO 🚨 BREAKING: JUDGE DISMISSES ELI LILLY'S LAWSUIT AGAINST WILLOW HEALTH $HIMS $LLY $NVO"
[X Link](https://x.com/AponiaAnalytics/status/2019551921607176555) 2026-02-05T23:21Z [----] followers, [---] engagements
"$NVO $HIMS $NVO calling $HIMS basically the corner store drug dealer lol https://t.co/hDPgukSvX3 $NVO calling $HIMS basically the corner store drug dealer lol https://t.co/hDPgukSvX3"
[X Link](https://x.com/AponiaAnalytics/status/2019552903296696694) 2026-02-05T23:25Z [----] followers, [---] engagements
"$HIMS 🦉 Feb [--] 2026: Hims & Hers said providers can prescribe compounded semaglutide pills. Intro price $49 for month one then $99. Product is not FDA-approved and differs from approved oral semaglutide. https://investors.hims.com/news/news-details/2026/Hims--Hers-Expands-Personalized-Weight-Loss-Portfolio-with-Access-to-Compounded-Semaglutide-Pills-Starting-at-49Month/default.aspx https://investors.hims.com/news/news-details/2026/Hims--Hers-Expands-Personalized-Weight-Loss-Portfolio-with-Access-to-Compounded-Semaglutide-Pills-Starting-at-49Month/default.aspx"
[X Link](https://x.com/AponiaAnalytics/status/2019554760979017968) 2026-02-05T23:32Z [----] followers, [---] engagements
"$NVO 🦉 Feb [--] 2026: Novo Nordisk said Hims & Hers plans to mass-market an unapproved compounded semaglutide pill are illegal. Novo said only its Wegovy pill is FDA-approved and warned compounded versions may have impurities. https://ml-eu.globenewswire.com/Resource/Download/300bdcca-d316-4e74-8d4c-8f6fcbb0dfec https://ml-eu.globenewswire.com/Resource/Download/300bdcca-d316-4e74-8d4c-8f6fcbb0dfec"
[X Link](https://x.com/AponiaAnalytics/status/2019555378384580642) 2026-02-05T23:34Z [----] followers, [---] engagements
"$NVO 🦉 Novo Nordisk insiders transferred thousands of shares on Feb [--] under long-term plans including CEO Doustdars [-----] shares and others at zero cost. CFO Knudsen moved [-----] shares; some execs sold stock on Nasdaq Copenhagen. https://ml-eu.globenewswire.com/Resource/Download/56263a8d-9be6-4a3a-98a4-8d4f30521f06 https://ml-eu.globenewswire.com/Resource/Download/56263a8d-9be6-4a3a-98a4-8d4f30521f06"
[X Link](https://x.com/AponiaAnalytics/status/2019556493750935859) 2026-02-05T23:39Z [----] followers, [---] engagements
"$HIMS $NVO 🚨 $HIMS LAUNCHES COPY OF WEGOVY PILL AT $49/MO - Price undercuts Novo brand by roughly $100 monthly - Monthly price rises to $99 after introductory offer - Novo is facing unprecedented pricing pressure from cash-pay market "We're excited to find ways to continue bringing 🚨 $HIMS LAUNCHES COPY OF WEGOVY PILL AT $49/MO - Price undercuts Novo brand by roughly $100 monthly - Monthly price rises to $99 after introductory offer - Novo is facing unprecedented pricing pressure from cash-pay market "We're excited to find ways to continue bringing"
[X Link](https://x.com/AponiaAnalytics/status/2019561111700558127) 2026-02-05T23:57Z [----] followers, [---] engagements
"$HIMS $NVO I can assure you $HIMS did their legal DD before going to market with this How is it that a $5 Billion Market Cap company like $HIMS can petrify these big pharmas like this Because they know their value now and identified it to the market $HIMs at the very least is a $50 https://t.co/n14gha058H I can assure you $HIMS did their legal DD before going to market with this How is it that a $5 Billion Market Cap company like $HIMS can petrify these big pharmas like this Because they know their value now and identified it to the market $HIMs at the very least is a $50"
[X Link](https://x.com/AponiaAnalytics/status/2019561679374426547) 2026-02-06T00:00Z [----] followers, [---] engagements
"$HIMS $HIMS SHARES AVAILABLE TO SHORT WENT FROM ZERO TO [---] MILLION JUST BEFORE MARKET OPEN LAST NIGHT WAS BELOW [--] MILLION FOR THE FIRST TIME IN A LONG TIME CRAZY ACTION FROM SHORTS RIGHT NOW h/t @thekiwikapital https://t.co/T5K4BnGzyH $HIMS SHARES AVAILABLE TO SHORT WENT FROM ZERO TO [---] MILLION JUST BEFORE MARKET OPEN LAST NIGHT WAS BELOW [--] MILLION FOR THE FIRST TIME IN A LONG TIME CRAZY ACTION FROM SHORTS RIGHT NOW h/t @thekiwikapital https://t.co/T5K4BnGzyH"
[X Link](https://x.com/AponiaAnalytics/status/2019561816133898678) 2026-02-06T00:00Z [----] followers, [---] engagements
"$HIMS $HIMS WEEKLY - WHAT A WEEK 😳 - GLP-1 pill launch ($49) - Liposomal delivery not SNAC - $NVO vows legal action 👿 - Makary pours gasoline on the fire - Stock craters to 52-week low - $LLY lawsuit vs. Willow dismissed - Oh and Hims launched cancer testing (link below) https://t.co/dKVqjF1Vb3 $HIMS WEEKLY - WHAT A WEEK 😳 - GLP-1 pill launch ($49) - Liposomal delivery not SNAC - $NVO vows legal action 👿 - Makary pours gasoline on the fire - Stock craters to 52-week low - $LLY lawsuit vs. Willow dismissed - Oh and Hims launched cancer testing (link below) https://t.co/dKVqjF1Vb3"
[X Link](https://x.com/AponiaAnalytics/status/2019756634424082453) 2026-02-06T12:54Z [----] followers, [---] engagements
"$HIMS $NVO #FDA 🚨 JUST IN: FDA Commissioner Dr. Marty Makary just issued a statement on the $HIMS x $NVO conflict. Oh boy. https://t.co/sU95BfjdSb 🚨 JUST IN: FDA Commissioner Dr. Marty Makary just issued a statement on the $HIMS x $NVO conflict. Oh boy. https://t.co/sU95BfjdSb"
[X Link](https://x.com/AponiaAnalytics/status/2019757133336572184) 2026-02-06T12:56Z [----] followers, [---] engagements
"#FDA $NVO $HIMS FDA will take swift action against companies mass-marketing illegal copycat drugs claiming they are similar to FDA-approved products. The FDA cannot verify the quality safety or effectiveness of non-approved drugs. FDA will take swift action against companies mass-marketing illegal copycat drugs claiming they are similar to FDA-approved products. The FDA cannot verify the quality safety or effectiveness of non-approved drugs"
[X Link](https://x.com/AponiaAnalytics/status/2019758381276238228) 2026-02-06T13:01Z [----] followers, [---] engagements
"$MRK $PFE $AMGN $REGN $NWBO 🧭 The Tail They Learned to Trust Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK $PFE $AMGN $REGN and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained 🧭 The Tail They Learned to Trust Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK $PFE $AMGN $REGN and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained"
[X Link](https://x.com/AponiaAnalytics/status/2019760224282812520) 2026-02-06T13:08Z [----] followers, [---] engagements
"$HIMS #FDA The current $HIMS panic reminds me of when I first went all in around September [----]. Read this: Please stop panicking. The recent post from the FDA about "not tollerating mass-compounding of illegal drugs classified" as "FDA approved" is just a scare tactic. ** $HIMS does https://t.co/nTsadDWRL1 The current $HIMS panic reminds me of when I first went all in around September [----]. Read this: Please stop panicking. The recent post from the FDA about "not tollerating mass-compounding of illegal drugs classified" as "FDA approved" is just a scare tactic. ** $HIMS does"
[X Link](https://x.com/AponiaAnalytics/status/2019760520262218067) 2026-02-06T13:10Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: LEERINK REITERATES $HIMS $41 PRICE TARGET - MARKET PERFORM RATING Leerink called the GLP-1 pill "an extremely logical new product offering" And noted that the current legal environment creates favorable conditions to expand its offerings to other weight loss 🚨 BREAKING: LEERINK REITERATES $HIMS $41 PRICE TARGET - MARKET PERFORM RATING Leerink called the GLP-1 pill "an extremely logical new product offering" And noted that the current legal environment creates favorable conditions to expand its offerings to other weight loss"
[X Link](https://x.com/AponiaAnalytics/status/2019760593759015067) 2026-02-06T13:10Z [----] followers, [---] engagements
"$HIMS The market is wrong about $HIMS. $HIMS is moving towards a $PLTR-style non-linear value creation even that brings the world's most valuable subscription service to the life. https://t.co/yg4HEow5YW The market is wrong about $HIMS. $HIMS is moving towards a $PLTR-style non-linear value creation even that brings the world's most valuable subscription service to the life. https://t.co/yg4HEow5YW"
[X Link](https://x.com/AponiaAnalytics/status/2019760854346981760) 2026-02-06T13:11Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: MORGAN STANLEY REITERATES $HIMS $40 PRICE TARGET - HOLD RATING 🚨 BREAKING: MORGAN STANLEY REITERATES $HIMS $40 PRICE TARGET - HOLD RATING"
[X Link](https://x.com/AponiaAnalytics/status/2019762888643125627) 2026-02-06T13:19Z [----] followers, [---] engagements
"$HIMS #GLP1 🚨 UBS SKEPTICAL OF $HIMS GLP-1 PILL EFFICACY https://t.co/3r6oFCIJbR 🚨 UBS SKEPTICAL OF $HIMS GLP-1 PILL EFFICACY https://t.co/3r6oFCIJbR"
[X Link](https://x.com/AponiaAnalytics/status/2019763013851492801) 2026-02-06T13:20Z [----] followers, [---] engagements
"$PFE #FDA 🦉 FDA granted Priority Review for marstacimab sBLA expanding hemophilia A and B use; PDUFA action date set for Q2 [----] https://investors.pfizer.com/Investors/News/news-details/2026/FDA-Grants-Priority-Review-for-HYMPAVZI-marstacimab-sBLA-for-the-Treatment-of-Two-Hemophilia-A-or-B-Patient-Populations-with-Significant-Medical-Need/default.aspx https://investors.pfizer.com/Investors/News/news-details/2026/FDA-Grants-Priority-Review-for-HYMPAVZI-marstacimab-sBLA-for-the-Treatment-of-Two-Hemophilia-A-or-B-Patient-Populations-with-Significant-Medical-Need/default.aspx"
[X Link](https://x.com/AponiaAnalytics/status/2019881819601097184) 2026-02-06T21:12Z [----] followers, [--] engagements
"$GILD @FDA 🦉 FDA removed the prior use limitation for Yescarta in relapsed or refractory primary CNS lymphoma. The CAR-T label now covers PCNSL patients previously excluded based on a small Phase [--] safety study showing frequent neurologic toxicity. https://investors.gilead.com/news/news-details/2026/FDA-Approves-Label-Update-for-Kites-Yescarta-for-RelapsedRefractory-Primary-Central-Nervous-System-Lymphoma/default.aspx https://investors.gilead.com/news/news-details/2026/FDA-Approves-Label-Update-for-Kites-Yescarta-for-RelapsedRefractory-Primary-Central-Nervous-System-Lymphoma/default.aspx"
[X Link](https://x.com/AponiaAnalytics/status/2019887111281783080) 2026-02-06T21:33Z [----] followers, [--] engagements
"$HIMS $NVO 🦉 FDA said its ready to act on illegal copycat drugs after Hims rolled out a $49 compounded Wegovy pill; Novo says a lawsuit is coming. Compounded GLP-1s had lived in a shortage loophole. That shelter looks thinner. https://ts2.tech/en/hims-hers-hims-stock-slips-again-as-49-wegovy-copy-draws-fda-heat-and-novo-legal-threat/ https://ts2.tech/en/hims-hers-hims-stock-slips-again-as-49-wegovy-copy-draws-fda-heat-and-novo-legal-threat/"
[X Link](https://x.com/AponiaAnalytics/status/2019897220167004348) 2026-02-06T22:13Z [----] followers, [---] engagements
"🦉 $HIMS @FDA #GLP1 FDA to restrict GLP-1 ingredients used in non-approved compounded drugs https://www.marketscreener.com/news/fda-to-restrict-glp-1-ingredients-used-in-non-approved-compounded-drugs-ce7e5ad9de8cf122 https://www.marketscreener.com/news/fda-to-restrict-glp-1-ingredients-used-in-non-approved-compounded-drugs-ce7e5ad9de8cf122"
[X Link](https://x.com/AponiaAnalytics/status/2019898225944326646) 2026-02-06T22:17Z [----] followers, [---] engagements
"🦉 $HIMS #investigation HHS general counsel Mike Stuart says based on review of applicable facts referred Hims to DOJ for investigation for potential violations"
[X Link](https://x.com/AponiaAnalytics/status/2019898703436239163) 2026-02-06T22:19Z [----] followers, [---] engagements
"$NVO $HIMS 🦉 NVO rebounded after an 8% drop tied to Hims $49 compounded Wegovy launch that pushed shares to post-2021 lows. https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-shares-rebound-fda-targets-illegal-drug-copies-2026-02-06/ https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-shares-rebound-fda-targets-illegal-drug-copies-2026-02-06/"
[X Link](https://x.com/AponiaAnalytics/status/2019900776437391559) 2026-02-06T22:27Z [----] followers, [---] engagements
"$OSCR [--] days before $OSCR earnings. I want to remember Bright Health. Same playbook. Tech-first ACA insurer IPO'd in [----] massive growth ambitions. Bright hit 103% MLR burned through hundreds of millions and is gone from the market. They rebranded sold off the pieces and went https://t.co/bk1F6dzdQz [--] days before $OSCR earnings. I want to remember Bright Health. Same playbook. Tech-first ACA insurer IPO'd in [----] massive growth ambitions. Bright hit 103% MLR burned through hundreds of millions and is gone from the market. They rebranded sold off the pieces and went https://t.co/bk1F6dzdQz"
[X Link](https://x.com/AponiaAnalytics/status/2020215591672442928) 2026-02-07T19:18Z [----] followers, [---] engagements
"@FDA #GLP1 $HIMS FDA says it will go after telehealth compounders and Hims and Hers specifically. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs https://t.co/jd5rs1Y9d8 FDA says it will go after telehealth compounders and Hims and Hers specifically. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs https://t.co/jd5rs1Y9d8"
[X Link](https://x.com/AponiaAnalytics/status/2020216819693306224) 2026-02-07T19:23Z [----] followers, [---] engagements
"$HIMS #GLP1 🚨 BREAKING: $HIMS STOPS OFFERING GLP-1 PILL LAUNCHED EARLIER THIS WEEK https://t.co/FbslxBzbZO 🚨 BREAKING: $HIMS STOPS OFFERING GLP-1 PILL LAUNCHED EARLIER THIS WEEK https://t.co/FbslxBzbZO"
[X Link](https://x.com/AponiaAnalytics/status/2020218176512934238) 2026-02-07T19:28Z [----] followers, [---] engagements
"$HIMS $NVO The Streisand Effect in action with $HIMS and $NVO 👇 The Streisand Effect occurs when an attempt to suppress censor or discredit information (or a product) backfires spectacularly drawing far more public attention to it than would have happened otherwise. Heres how its https://t.co/pgMd2wpLTa The Streisand Effect in action with $HIMS and $NVO 👇 The Streisand Effect occurs when an attempt to suppress censor or discredit information (or a product) backfires spectacularly drawing far more public attention to it than would have happened otherwise. Heres how its https://t.co/pgMd2wpLTa"
[X Link](https://x.com/AponiaAnalytics/status/2020219959003971608) 2026-02-07T19:35Z [----] followers, [---] engagements
"$MRK $NWBO #DCVax ❄PROJECT WINTERFELL $MRK Silent Manufacturing Network and the $NWBO #DCVax Immune Kit Platform PREFACE This is not a story about one building. It is a story about an ecosystem being assembled to function as a unit. Along a short corridor in Montgomery County Pennsylvania https://t.co/NXIqUpWfOe ❄PROJECT WINTERFELL $MRK Silent Manufacturing Network and the $NWBO #DCVax Immune Kit Platform PREFACE This is not a story about one building. It is a story about an ecosystem being assembled to function as a unit. Along a short corridor in Montgomery County Pennsylvania"
[X Link](https://x.com/AponiaAnalytics/status/2020220694735265930) 2026-02-07T19:38Z [----] followers, [---] engagements
"$HIMS $NVO $HIMS has more than 2X the performance of $NVO since going public in late [----]. $HIMS +132% $NVO +63% Hims is a health disruptor Novo Nordisk do not like it and continue to threaten to sue Hims because they are a clear threat. $HIMS isn't going anywhere and will continue https://t.co/d70OqdAUcs $HIMS has more than 2X the performance of $NVO since going public in late [----]. $HIMS +132% $NVO +63% Hims is a health disruptor Novo Nordisk do not like it and continue to threaten to sue Hims because they are a clear threat. $HIMS isn't going anywhere and will continue"
[X Link](https://x.com/AponiaAnalytics/status/2020225433858633805) 2026-02-07T19:57Z [----] followers, [---] engagements
"$HIMS #FDA $NVO Prediction: [--]. $HIMS turns quarrel with FDA and $NVO into massive marketing campaign with SuperBowl Ad. [--]. Ends in a fine. [--]. Business does fine long term. Prediction: [--]. $HIMS turns quarrel with FDA and $NVO into massive marketing campaign with SuperBowl Ad. [--]. Ends in a fine. [--]. Business does fine long term"
[X Link](https://x.com/AponiaAnalytics/status/2020226460716605833) 2026-02-07T20:01Z [----] followers, [---] engagements
"$NVO $LLY $HIMS $NVO $LLY $HIMS Reuters also wrote about the FDAs crackdown on compounded GLP-1 drugs The U.S. FDA said it plans to crack down on compounded weight-loss drugs citing safety quality and potential violations of federal law. The agency may restrict access to GLP-1 ingredients $NVO $LLY $HIMS Reuters also wrote about the FDAs crackdown on compounded GLP-1 drugs The U.S. FDA said it plans to crack down on compounded weight-loss drugs citing safety quality and potential violations of federal law. The agency may restrict access to GLP-1 ingredients"
[X Link](https://x.com/AponiaAnalytics/status/2020227536429424771) 2026-02-07T20:05Z [----] followers, [---] engagements
"$HIMS $HIMS has announced it will stop offering the GLP-1 pill. $NVO keeps claiming that compounded versions of Wegovy harm patients and arent effective but reality tells a different story. When it comes to weight loss conventional GLP-1s like those from $NVO often cause people https://t.co/rAEMxOGysW $HIMS has announced it will stop offering the GLP-1 pill. $NVO keeps claiming that compounded versions of Wegovy harm patients and arent effective but reality tells a different story. When it comes to weight loss conventional GLP-1s like those from $NVO often cause people https://t.co/rAEMxOGysW"
[X Link](https://x.com/AponiaAnalytics/status/2020274487716184105) 2026-02-07T23:12Z [----] followers, [---] engagements
"$HIMS $UBER $HIMS versus pharma is going to make $UBER versus taxis look like Cinderella. This is the biggest disruption story since the foundation of the United States. $HIMS versus pharma is going to make $UBER versus taxis look like Cinderella. This is the biggest disruption story since the foundation of the United States"
[X Link](https://x.com/AponiaAnalytics/status/2020274777689301142) 2026-02-07T23:13Z [----] followers, [---] engagements
"$HIMS @AndrewDudum .@AndrewDudum on the culture at $HIMS: "The team has a stomach of steel. Whether the stock's $70 or $2.87 most of the executive team and myself will retire here." "We're a team that's heads down and focuses on what can be accomplished in the next decade not the next quarter." https://t.co/CgNLv8Tz1Y .@AndrewDudum on the culture at $HIMS: "The team has a stomach of steel. Whether the stock's $70 or $2.87 most of the executive team and myself will retire here." "We're a team that's heads down and focuses on what can be accomplished in the next decade not the next quarter.""
[X Link](https://x.com/AponiaAnalytics/status/2020274985613611010) 2026-02-07T23:14Z [----] followers, [---] engagements
"$HIMS Hims & Hers Health $HIMS just said it will stop selling its compounded weight-loss pill just days after initially offering it This comes after an announcement by federal regulators that they were launching an investigation into the company due to the launch - Bloomberg Hims & Hers Health $HIMS just said it will stop selling its compounded weight-loss pill just days after initially offering it This comes after an announcement by federal regulators that they were launching an investigation into the company due to the launch - Bloomberg"
[X Link](https://x.com/AponiaAnalytics/status/2020275388111520180) 2026-02-07T23:16Z [----] followers, [---] engagements
"$HIMS $HIMS back to where it was [--] days ago But now the world knows $HIMS No need for the superbowl ad now Monday we are green $HIMS back to where it was [--] days ago But now the world knows $HIMS No need for the superbowl ad now Monday we are green"
[X Link](https://x.com/AponiaAnalytics/status/2020275785584767487) 2026-02-07T23:17Z [----] followers, [---] engagements
"$HIMS $NVO $HIMS $NVO $HIMS was able to offer the weight loss pill for just $49. Why is nobody talking about how bullish this is for $NVO $NVO clearly has a lot of flexibility now with the pricing etc and margins. I'm even more bullish on $NVO than I was before https://t.co/sVLPsZ7rFZ $HIMS $NVO $HIMS was able to offer the weight loss pill for just $49. Why is nobody talking about how bullish this is for $NVO $NVO clearly has a lot of flexibility now with the pricing etc and margins. I'm even more bullish on $NVO than I was before https://t.co/sVLPsZ7rFZ"
[X Link](https://x.com/AponiaAnalytics/status/2020276141718732977) 2026-02-07T23:19Z [----] followers, [---] engagements
"$HIMS we have decided 🤣 $HIMS we have decided 🤣 $HIMS"
[X Link](https://x.com/AponiaAnalytics/status/2020276390478975451) 2026-02-07T23:20Z [----] followers, [---] engagements
"$HIMS $NVO 🦉 Hims & Hers halts $49 Wegovy copycat pill after FDA threatened action. The telehealth firm reversed course days after launching the semaglutide offering as regulators warned of safety and legal risks"
[X Link](https://x.com/AponiaAnalytics/status/2020279624400240741) 2026-02-07T23:32Z [----] followers, [---] engagements
"$HIMS $NVO 🚨 NOVO NORDISK vs. $HIMS & HERS The lawsuit is [---] pages Filed in the US District Court for the District of Delaware It is a patent-only lawsuit; Novo is NOT suing for trademark or advertising issues The patent at issue is U.S. Patent No. [-------] ('343 patent) -- Novo's https://t.co/a4cszxRkcz 🚨 NOVO NORDISK vs. $HIMS & HERS The lawsuit is [---] pages Filed in the US District Court for the District of Delaware It is a patent-only lawsuit; Novo is NOT suing for trademark or advertising issues The patent at issue is U.S. Patent No. [-------] ('343 patent) -- Novo's"
[X Link](https://x.com/AponiaAnalytics/status/2020992956304695489) 2026-02-09T22:47Z [----] followers, [---] engagements
"$HIMS $HIMS Adjustment on Growth toward 2030🧵 Not Financial Advice FY2025: Revenue: $2.35B or 58% YoY (weightloss $740) Core $1.61B FY2026: Revenue $3.2B(36%) where weightloss may be down by 10-15% or flat. FY2027: Revenue $4.16B(30%) FY2028: Revenue: $5.2B(25%) FY2029 https://t.co/1vwVhdRONz $HIMS Adjustment on Growth toward 2030🧵 Not Financial Advice FY2025: Revenue: $2.35B or 58% YoY (weightloss $740) Core $1.61B FY2026: Revenue $3.2B(36%) where weightloss may be down by 10-15% or flat. FY2027: Revenue $4.16B(30%) FY2028: Revenue: $5.2B(25%) FY2029 https://t.co/1vwVhdRONz"
[X Link](https://x.com/AponiaAnalytics/status/2020993418776719871) 2026-02-09T22:49Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS partner sues Eli Lilly and Novo Nordisk. DAMNING for Big Pharma $LLY and $NVO. The time is now. Today is the day we start to apply MAXIMUM pressure to our congressmen and women in a stern but THOUGHTFUL manner. I will posst more information in a bit after I get off a few https://t.co/ksRz62lB2a $HIMS partner sues Eli Lilly and Novo Nordisk. DAMNING for Big Pharma $LLY and $NVO. The time is now. Today is the day we start to apply MAXIMUM pressure to our congressmen and women in a stern but THOUGHTFUL manner. I will posst more information in a bit after I get off a few"
[X Link](https://x.com/AponiaAnalytics/status/2020993546803658840) 2026-02-09T22:49Z [----] followers, [---] engagements
"$HIMS $NVO $HIMS extends losses to 22% after $NVO said it is suing over knockoff obesity drugs. This comes as the FDA signals full enforcement on compounded GLP 1s and the company exits compounded semaglutide. https://t.co/1WKROCRbtU $HIMS extends losses to 22% after $NVO said it is suing over knockoff obesity drugs. This comes as the FDA signals full enforcement on compounded GLP 1s and the company exits compounded semaglutide. https://t.co/1WKROCRbtU"
[X Link](https://x.com/AponiaAnalytics/status/2020993630568141282) 2026-02-09T22:50Z [----] followers, [---] engagements
"$LLY Eli Lilly $LLY to buy Orna Therapeutics (private) for $2.4 billion. Circular RNA CAR-T therapies. https://t.co/6iPghcwUuM via @matthewherper Eli Lilly $LLY to buy Orna Therapeutics (private) for $2.4 billion. Circular RNA CAR-T therapies. https://t.co/6iPghcwUuM via @matthewherper"
[X Link](https://x.com/AponiaAnalytics/status/2020993743634284777) 2026-02-09T22:50Z [----] followers, [--] engagements
"$HIMS @AndrewDudum This is EXACTLY the opposite of what you wanted to see from $HIMS management this morning I am beginning to think that @AndrewDudum has some sort of main-character narcissism flaw. I expected the ORAL PILL take-down to be a sign of them trying to make a mea culpa but this is https://t.co/67at1JNg8E This is EXACTLY the opposite of what you wanted to see from $HIMS management this morning I am beginning to think that @AndrewDudum has some sort of main-character narcissism flaw. I expected the ORAL PILL take-down to be a sign of them trying to make a mea culpa but this is"
[X Link](https://x.com/AponiaAnalytics/status/2020993947183497460) 2026-02-09T22:51Z [----] followers, [---] engagements
"$HIMS $HIMS When the Dept of treasury increases count of stocks by 50% within one quarter (Q4 13F) then you can imagine how confident are they in the company. HIMS is their top [--] investment now in terms of dollar value with avg cost $36 https://t.co/S8LhuqN118 $HIMS When the Dept of treasury increases count of stocks by 50% within one quarter (Q4 13F) then you can imagine how confident are they in the company. HIMS is their top [--] investment now in terms of dollar value with avg cost $36 https://t.co/S8LhuqN118"
[X Link](https://x.com/AponiaAnalytics/status/2020994094810403318) 2026-02-09T22:51Z [----] followers, [---] engagements
"$HIMS $HIMS & : BTIG reiterates maintains $ Analyst weighs in on semaglutide pill withdrawal cites regulatory risk as FDA ramps up GLP-1 compounding enforcement. https://t.co/F4jTHGtuIa $HIMS & : BTIG reiterates maintains $ Analyst weighs in on semaglutide pill withdrawal cites regulatory risk as FDA ramps up GLP-1 compounding enforcement. https://t.co/F4jTHGtuIa"
[X Link](https://x.com/AponiaAnalytics/status/2020994231100391557) 2026-02-09T22:52Z [----] followers, [---] engagements
"$HIMS $HIMS https://t.co/kn4ItGeV2m $HIMS https://t.co/kn4ItGeV2m"
[X Link](https://x.com/AponiaAnalytics/status/2020994287886885177) 2026-02-09T22:52Z [----] followers, [---] engagements
"$HIMS #App $HIMS App downloads are surging post superbowl ad. jumped to #5 most downloaded on the App Store. It was #22 yesterday. This is huge. https://t.co/hexPfKxEj5 $HIMS App downloads are surging post superbowl ad. jumped to #5 most downloaded on the App Store. It was #22 yesterday. This is huge. https://t.co/hexPfKxEj5"
[X Link](https://x.com/AponiaAnalytics/status/2020994581664252341) 2026-02-09T22:53Z [----] followers, [---] engagements
"$HIMS #GLP1s 🚨 BREAKING: $HIMS IS NOW OFFERING 20% OFF ON ORDERS OF $500+ Promo *includes* GLP-1s which brings price to $159/mo - the lowest we've seen in a while maybe ever Hims just kicked off this text message campaign with GLP-1 photo: https://t.co/AB1CQOXqzR 🚨 BREAKING: $HIMS IS NOW OFFERING 20% OFF ON ORDERS OF $500+ Promo *includes* GLP-1s which brings price to $159/mo - the lowest we've seen in a while maybe ever Hims just kicked off this text message campaign with GLP-1 photo: https://t.co/AB1CQOXqzR"
[X Link](https://x.com/AponiaAnalytics/status/2020994842164416895) 2026-02-09T22:54Z [----] followers, [---] engagements
"$HIMS Jeff Bezos says that if you have a 10% chance of making a 100x you should take that bet every single time. This is the case with $HIMS. Down 75% from its highs $4B market cap and a P/S ratio below [--]. $HIMS trades as if its destined to fail all the pessimism is already https://t.co/U7eCnL3Dpb Jeff Bezos says that if you have a 10% chance of making a 100x you should take that bet every single time. This is the case with $HIMS. Down 75% from its highs $4B market cap and a P/S ratio below [--]. $HIMS trades as if its destined to fail all the pessimism is already https://t.co/U7eCnL3Dpb"
[X Link](https://x.com/AponiaAnalytics/status/2020994921625264263) 2026-02-09T22:55Z [----] followers, [---] engagements
"$NVO 🚨BREAKING: $NVO THEY ACTUALLY DID IT. Novo Nordisk is asking the court to permanently ban $HIMS from selling unapproved compounded drugs that infringe our patents and is seeking to recover damages https://t.co/gvDJsOx1OT 🚨BREAKING: $NVO THEY ACTUALLY DID IT. Novo Nordisk is asking the court to permanently ban $HIMS from selling unapproved compounded drugs that infringe our patents and is seeking to recover damages https://t.co/gvDJsOx1OT"
[X Link](https://x.com/AponiaAnalytics/status/2020995002638221410) 2026-02-09T22:55Z [----] followers, [--] engagements
"$NVO $HIMS BREAKING: Novo Nordisk $NVO sues Hims & Hers $HIMS for infringing on a key Wegovy patent https://t.co/44Ndx293d4 via @pharmalot BREAKING: Novo Nordisk $NVO sues Hims & Hers $HIMS for infringing on a key Wegovy patent https://t.co/44Ndx293d4 via @pharmalot"
[X Link](https://x.com/AponiaAnalytics/status/2020995285829193759) 2026-02-09T22:56Z [----] followers, [---] engagements
"$NVO $HIMS $NVO sues $HIMS over cheaper copycat versions of Wegovy pill injections - CNBC. Stock down 20% pre-market. $18.42 - The same price as it was back in [----]. https://t.co/MuGyasfd2T $NVO sues $HIMS over cheaper copycat versions of Wegovy pill injections - CNBC. Stock down 20% pre-market. $18.42 - The same price as it was back in [----]. https://t.co/MuGyasfd2T"
[X Link](https://x.com/AponiaAnalytics/status/2020995387071324593) 2026-02-09T22:57Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: $HIMS RESPONDS TO NOVO LAWSUIT "Big Pharma is weaponizing the US judicial system to limit consumer choice" "This lawsuit attacks more than just one medication or company it directly assaults a well-established vital component of US pharmacy practice" https://t.co/NQThXxLVJi 🚨 BREAKING: $HIMS RESPONDS TO NOVO LAWSUIT "Big Pharma is weaponizing the US judicial system to limit consumer choice" "This lawsuit attacks more than just one medication or company it directly assaults a well-established vital component of US pharmacy practice" https://t.co/NQThXxLVJi"
[X Link](https://x.com/AponiaAnalytics/status/2020995862537568495) 2026-02-09T22:58Z [----] followers, [---] engagements
"$HIMS $HIMS buy companies that look like this https://t.co/KB6bQn6QrX $HIMS buy companies that look like this https://t.co/KB6bQn6QrX"
[X Link](https://x.com/AponiaAnalytics/status/2020996046948540692) 2026-02-09T22:59Z [----] followers, [---] engagements
"$NVO #FDA 🚨BREAKING - $NVO. The FDA flags Novo Nordisk for misleading Wegovy ad The FDA says that the ad misbrands Wegovy Semaglutide tablets and violates the Federal Food Drug and Cosmetic Act The FDA is really busy 😄 https://t.co/amH7Nko5Uq 🚨BREAKING - $NVO. The FDA flags Novo Nordisk for misleading Wegovy ad The FDA says that the ad misbrands Wegovy Semaglutide tablets and violates the Federal Food Drug and Cosmetic Act The FDA is really busy 😄 https://t.co/amH7Nko5Uq"
[X Link](https://x.com/AponiaAnalytics/status/2020996610398753180) 2026-02-09T23:01Z [----] followers, [---] engagements
"$NVO $HIMS 🚨 NOVO NORDISK HAS SUED $HIMS FOR INFRINGING ON U.S. PATENT [-------] The '343 patent is Novo's "crown jewel" patent This patent has already withstood an IRP patent challenge by Mylan Pharmaceuticals in [----] Novo is seeking both a permanent ban AND damages If a court 🚨 NOVO NORDISK HAS SUED $HIMS FOR INFRINGING ON U.S. PATENT [-------] The '343 patent is Novo's "crown jewel" patent This patent has already withstood an IRP patent challenge by Mylan Pharmaceuticals in [----] Novo is seeking both a permanent ban AND damages If a court"
[X Link](https://x.com/AponiaAnalytics/status/2020996753147728226) 2026-02-09T23:02Z [----] followers, [---] engagements
"$HIMS Once again misleading his followers. In the first half of [----] alone $HIMS generated $420M in GLP-1 revenue. We dont know the Q3 number because the company stopped reporting it but the vast majority of weight-loss revenue does come from GLP-1s. Source: Q2 10-Q filing https://t.co/ccli69DGT3 Once again misleading his followers. In the first half of [----] alone $HIMS generated $420M in GLP-1 revenue. We dont know the Q3 number because the company stopped reporting it but the vast majority of weight-loss revenue does come from GLP-1s. Source: Q2 10-Q filing https://t.co/ccli69DGT3"
[X Link](https://x.com/AponiaAnalytics/status/2020996872068837879) 2026-02-09T23:02Z [----] followers, [---] engagements
"$HIMS Interesting $HIMS https://t.co/Rixi46jzp5 Interesting $HIMS https://t.co/Rixi46jzp5"
[X Link](https://x.com/AponiaAnalytics/status/2020997088201322842) 2026-02-09T23:03Z [----] followers, [---] engagements
"$NVO $HIMS Former FDA Commissioner Scott Gottlieb on CNBC was blunt about the $NVO vs. $HIMS fight: Mass compounding of GLP-1s was meant as a temporary workaround for shortages not a permanent business model. He warned that using compounding to copy patented drugs undermines FDA Former FDA Commissioner Scott Gottlieb on CNBC was blunt about the $NVO vs. $HIMS fight: Mass compounding of GLP-1s was meant as a temporary workaround for shortages not a permanent business model. He warned that using compounding to copy patented drugs undermines FDA"
[X Link](https://x.com/AponiaAnalytics/status/2020997408667193488) 2026-02-09T23:05Z [----] followers, [---] engagements
"$HIMS IMO $HIMS entire GLP-1 operation is about to come down. $HIMS may backing off of the GLP-1 pill now but they opened Pandoras Box here coaxing the FDA into ***FINALLY*** cracking down on the overall GLP-1 mass compounding scam that $HIMS has been conducting/profiting from. https://t.co/QQKZm4Fslk IMO $HIMS entire GLP-1 operation is about to come down. $HIMS may backing off of the GLP-1 pill now but they opened Pandoras Box here coaxing the FDA into ***FINALLY*** cracking down on the overall GLP-1 mass compounding scam that $HIMS has been conducting/profiting from. https://t.co/QQKZm4Fslk"
[X Link](https://x.com/AponiaAnalytics/status/2020997703392481358) 2026-02-09T23:06Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: FDA WARNED $HIMS 503B FACILITY MEDISOURCERX AFTER FINDING BUGS AND FAILING TO REPORT ADVERSE EVENT - Warning issued late [----] - In Jan [----] patient reported "severe" stomach issues from GLP-1 spent [--] nights in a hospital - Event not reported to the FDA w/in [--] https://t.co/yR8YhJlpBH 🚨 BREAKING: FDA WARNED $HIMS 503B FACILITY MEDISOURCERX AFTER FINDING BUGS AND FAILING TO REPORT ADVERSE EVENT - Warning issued late [----] - In Jan [----] patient reported "severe" stomach issues from GLP-1 spent [--] nights in a hospital - Event not reported to the FDA w/in 15"
[X Link](https://x.com/AponiaAnalytics/status/2021009746921390501) 2026-02-09T23:54Z [----] followers, [---] engagements
"$NVO $NVO - Details on the share repurchase program. Novo wil repurchase up to 3.8B DKK (about 500M) shares in the period between the 4th of February and the 4th of March. This is part of the 15B DKK program (about 1% of total market cap and worth about 2B) that will be https://t.co/oqVC8ZMrFY $NVO - Details on the share repurchase program. Novo wil repurchase up to 3.8B DKK (about 500M) shares in the period between the 4th of February and the 4th of March. This is part of the 15B DKK program (about 1% of total market cap and worth about 2B) that will be https://t.co/oqVC8ZMrFY"
[X Link](https://x.com/AponiaAnalytics/status/2021010173544808468) 2026-02-09T23:55Z [----] followers, [---] engagements
"$HIMS Caesar Capital increased its position in Hims & Hers Health $HIMS today at $17.04 per share 🏛 New average cost basis: $25.77 (down from $26.10) https://t.co/JFQlQwV4ig Caesar Capital increased its position in Hims & Hers Health $HIMS today at $17.04 per share 🏛 New average cost basis: $25.77 (down from $26.10) https://t.co/JFQlQwV4ig"
[X Link](https://x.com/AponiaAnalytics/status/2021010277949636841) 2026-02-09T23:56Z [----] followers, [---] engagements
"$OSCR 🦉 Oscar put in place a $475M secured revolver maturing in [----]. The facility carries SOFR-linked pricing and quarterly covenants tied to premiums EBITDA liquidity and leverage. #form_8K"
[X Link](https://x.com/AponiaAnalytics/status/2021377344804430315) 2026-02-11T00:14Z [----] followers, [---] engagements
"$BNTC 🦉 Benitec Biopharma priced a $100M stock offering at $13.50 per share including a direct sale to Suvretta Capital. Funds will advance its ddRNAi gene therapy programs and strengthen liquidity. #pressrelease https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering"
[X Link](https://x.com/AponiaAnalytics/status/1986530953460658684) 2025-11-06T20:27Z [----] followers, [---] engagements
"$BNTC 🦉 Director Sharon Mates filed Form [--] on Nov [--] [----] disclosing no beneficial ownership in Benitec Biopharma following her appointment dated Nov [--] [----]. #form3 https://d1io3yog0oux5.cloudfront.net/benitec/sec/0001012975-25-000717/0001012975-25-000717.pdf https://d1io3yog0oux5.cloudfront.net/benitec/sec/0001012975-25-000717/0001012975-25-000717.pdf"
[X Link](https://x.com/AponiaAnalytics/status/1987220430856298720) 2025-11-08T18:07Z [----] followers, [---] engagements
"$BNTC 🦉 BB-301 didnt fade with time: the first OPMD patient kept improving two years after dosing. All four Cohort [--] patients still cleared responder bars at [--] months pointing to durable effect. https://www.benitec.com/for-investors/news-events/press-releases/detail/141/benitec-biopharma-provides-positive-long-term-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-demonstrating-robust-efficacy-and-continued-durability-of-response"
[X Link](https://x.com/AponiaAnalytics/status/2010395979431002596) 2026-01-11T16:58Z [----] followers, [---] engagements
"$BNTC 🦉 Four of four BB-301 patients met responder criteria at [--] months with one showing deeper benefit at [--] months as Benitec plans an FDA meeting to set a pivotal study mid-2026. The program remains early-stage Cohort [--] data due mid-2026. https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update"
[X Link](https://x.com/AponiaAnalytics/status/2022048153999224895) 2026-02-12T20:40Z [----] followers, [---] engagements
"$NVS $TRML 🦉 Novartis $48 per share tender offer for Tourmaline Bio expired Oct [--] with 92.94% shares tendered. Transaction expected to close Oct [--] following acceptance. #newsrelease"
[X Link](https://x.com/AponiaAnalytics/status/1983208319960359211) 2025-10-28T16:24Z [----] followers, [---] engagements
"$NUVL 🦉 Officer Alexandra Balcom plans to sell [-----] shares via cashless exercise through J.P. Morgan on Nov [--] [----]. Previous sales include [----] shares on Sep [--] and [-----] shares on Sep [--] and Oct [--] each. #form_144 https://app.quotemedia.com/data/downloadFilingwebmasterId=101533&ref=319588239&type=HTML&symbol=NUVL&cdn=9d1424dad837ebcf7218d09df88e8090&companyName=Nuvalent+Inc.&formType=144&dateFiled=2025-11-17"
[X Link](https://x.com/AponiaAnalytics/status/1990536823106568372) 2025-11-17T21:45Z [----] followers, [---] engagements
"$KURA 🚀🚨 BIOPHARM CATALYST ALERT 📆 $KURA Kura Oncology will present Phase [--] Acute Myeloid Leukemia Data for Ziftomenib (MEN1 Inhibitor - Small Molecule) tomorrow 👀 🚀🚨 BIOPHARM CATALYST ALERT 📆 $KURA Kura Oncology will present Phase [--] Acute Myeloid Leukemia Data for Ziftomenib (MEN1 Inhibitor - Small Molecule) tomorrow 👀"
[X Link](https://x.com/AponiaAnalytics/status/1997694121327444468) 2025-12-07T15:46Z [----] followers, [---] engagements
"$PCVX 🦉 Officer Elvia Cowan filed a Form [---] to sell [-----] shares about $557k via Morgan Stanley. Stock stems from RSUs and option exercises with sale slated for Dec. [--]. #form_144"
[X Link](https://x.com/AponiaAnalytics/status/2003954342592967063) 2025-12-24T22:22Z [----] followers, [---] engagements
"$GMAB #portfolio #update 🦉 Genmab is pulling the plug on acasunlimab after a portfolio reset despite encouraging data. Capital shifts to EPKINLY petosemtamab and Rina-S with [----] guidance left untouched. https://ml-eu.globenewswire.com/Resource/Download/d61a4b07-4b51-43bb-a463-e1911f63e6e9 https://ml-eu.globenewswire.com/Resource/Download/d61a4b07-4b51-43bb-a463-e1911f63e6e9"
[X Link](https://x.com/AponiaAnalytics/status/2005695742791540767) 2025-12-29T17:41Z [----] followers, [---] engagements
"$NMRA Small signal-seeking Phase 1b shows a modest overall effect on CMAI with a moderate signal only in an anxiety-enriched subgroup. $NMRA Clean safety and no sedation are positives but subgroup-dependence subjective endpoints and an outlier-exclusion in placebo are the bear Small signal-seeking Phase 1b shows a modest overall effect on CMAI with a moderate signal only in an anxiety-enriched subgroup. $NMRA Clean safety and no sedation are positives but subgroup-dependence subjective endpoints and an outlier-exclusion in placebo are the bear"
[X Link](https://x.com/AponiaAnalytics/status/2008190656305574181) 2026-01-05T14:55Z [----] followers, [---] engagements
"$NMRA $NMRA Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimers Disease Agitation https://t.co/FdvzZI1pUU $NMRA Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimers Disease Agitation https://t.co/FdvzZI1pUU"
[X Link](https://x.com/AponiaAnalytics/status/2008197278780334471) 2026-01-05T15:21Z [----] followers, [---] engagements
"$INCY Control in $INCY Frontmind (1st-line DLBCL) is R-Chop not Revlimid + R-Chop. So how do we know the (modest) PFS benefit toplined today is due to $INCY Monjuvi and not to Revlimid https://t.co/Swc41ElHFr Control in $INCY Frontmind (1st-line DLBCL) is R-Chop not Revlimid + R-Chop. So how do we know the (modest) PFS benefit toplined today is due to $INCY Monjuvi and not to Revlimid https://t.co/Swc41ElHFr"
[X Link](https://x.com/AponiaAnalytics/status/2008216154859270602) 2026-01-05T16:36Z [----] followers, [---] engagements
"$NBP $NBP (formerly called I-Mab) announced positive updated results from the Phase 1b combination study of givastomig a Claudin [----] (CLDN18.2) x 4-1BB bispecific antibody in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative first line (1L) https://t.co/Pr9lOoUqIe $NBP (formerly called I-Mab) announced positive updated results from the Phase 1b combination study of givastomig a Claudin [----] (CLDN18.2) x 4-1BB bispecific antibody in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative first line (1L) https://t.co/Pr9lOoUqIe"
[X Link](https://x.com/AponiaAnalytics/status/2008965042696556567) 2026-01-07T18:12Z [----] followers, [--] engagements
"$OMDA JUST IN: $OMDA announces preliminary Q4 results. Revenue of $72-74M vs. $69M est. 🟢 Total members at 886k up 55% YoY Both metrics accelerated further from Q3 exactly as I predicted in my recent article. The company expects to report final results on March [--] after market https://t.co/aEAMtPBa14 JUST IN: $OMDA announces preliminary Q4 results. Revenue of $72-74M vs. $69M est. 🟢 Total members at 886k up 55% YoY Both metrics accelerated further from Q3 exactly as I predicted in my recent article. The company expects to report final results on March [--] after market https://t.co/aEAMtPBa14"
[X Link](https://x.com/AponiaAnalytics/status/2010805304360124923) 2026-01-12T20:05Z [----] followers, [---] engagements
"$ABVX 🦉 Sofinnova cut its Abivax stake to 7.7% voting power after selling 684k ADS across Jan [----] at $118142. The group still holds 3.33M shares and 6.4M voting rights post-sale. #form_13D https://ir.abivax.com/static-files/0319d5cf-bd14-4c7f-93b3-b04887bc8bb3 https://ir.abivax.com/static-files/0319d5cf-bd14-4c7f-93b3-b04887bc8bb3"
[X Link](https://x.com/AponiaAnalytics/status/2011564321638330667) 2026-01-14T22:21Z [----] followers, [---] engagements
"#Sarepta $SRPT 🦉 Three years after a single dose kids with Duchenne treated with ELEVIDYS were still walking better than expected. The usual decline slowedby about 70%. That gap kept widening with time. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results"
[X Link](https://x.com/AponiaAnalytics/status/2015879288306671899) 2026-01-26T20:07Z [----] followers, [---] engagements
"#Sarepta $SRPT 🦉 At age nine when Duchenne typically speeds up boys in the EMBARK study stayed above their starting strength. Controls slipped. Gene therapy changed the curve not just the score. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results"
[X Link](https://x.com/AponiaAnalytics/status/2015879450429104592) 2026-01-26T20:08Z [----] followers, [---] engagements
"#Sarepta $SRPT"
[X Link](https://x.com/AponiaAnalytics/status/2015882152743764134) 2026-01-26T20:18Z [----] followers, [---] engagements
"$SRPT #Sarepta 🦉 Sarepta Therapeutics was upgraded to Zacks Rank #2 after earnings estimates rose 24.6% in three months. FY2025 EPS is still seen at $2.31 unchanged year over year. https://finance.yahoo.com/news/sarepta-therapeutics-srpt-upgraded-buy-170004126.html https://finance.yahoo.com/news/sarepta-therapeutics-srpt-upgraded-buy-170004126.html"
[X Link](https://x.com/AponiaAnalytics/status/2015884461989134757) 2026-01-26T20:28Z [----] followers, [---] engagements
"$RGNX #FDA 🦉 FDA placed clinical holds on RGX-111 and RGX-121 after a CNS tumor was detected in one RGX-111 patient. Causality is unestablished; both MPS programs are paused pending FDA review. #form_8K https://ir.regenxbio.com/static-files/58f6ab0b-debc-423f-9732-aed286f252a8 https://ir.regenxbio.com/static-files/58f6ab0b-debc-423f-9732-aed286f252a8"
[X Link](https://x.com/AponiaAnalytics/status/2016576535512166661) 2026-01-28T18:18Z [----] followers, [---] engagements
"$QURE #uniQure 🦉 Aberdeen Group and abrdn report [-------] uniQure shares a 5.91% stake. Voting and dispositive power are shared across the position. #form_13G https://uniqure.gcs-web.com/static-files/9b64fb3c-5db0-434b-beb2-ff5b78205abc https://uniqure.gcs-web.com/static-files/9b64fb3c-5db0-434b-beb2-ff5b78205abc"
[X Link](https://x.com/AponiaAnalytics/status/2016997697769631934) 2026-01-29T22:11Z [----] followers, [---] engagements
"$SRPT 🦉 Director Kathleen Behrens exercised [-----] options at $13.71 on Jan.27. She disposed [----] shares at $22.17 for taxes; holds [------] direct. #form_4 https://investorrelations.sarepta.com/static-files/497700f3-1eb7-42bc-8960-c895b3c011aa https://investorrelations.sarepta.com/static-files/497700f3-1eb7-42bc-8960-c895b3c011aa"
[X Link](https://x.com/AponiaAnalytics/status/2017255458956881978) 2026-01-30T15:15Z [----] followers, [---] engagements
"$PCVX 🦉Priced 11M shares at $50 for $550M gross Jan 29; grants 30-day option for 1.65M more; deal set to close Feb [--]. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-pricing-550-million-public-offering https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-pricing-550-million-public-offering"
[X Link](https://x.com/AponiaAnalytics/status/2017260317890294016) 2026-01-30T15:35Z [----] followers, [--] engagements
"$SRPT 🦉 Claude Nicaise exercised [-----] options at $13.71 Jan.29. [----] shares were withheld at $21.23 for taxes; [-----] shares remain direct. #form_4 https://investorrelations.sarepta.com/static-files/75649577-ec3e-40e1-8354-727e26eb03ff https://investorrelations.sarepta.com/static-files/75649577-ec3e-40e1-8354-727e26eb03ff"
[X Link](https://x.com/AponiaAnalytics/status/2017262176235368471) 2026-01-30T15:42Z [----] followers, [---] engagements
"$REGN 🦉 Regeneron Reports Fourth Quarter and Full Year [----] Financial and Operating Results Q4 revenue rose 3% to $3.9B; FY up 1% to $14.3B. Dupixent sales jumped 34% to $4.9B while total U.S. EYLEA franchise sales fell 28%. https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial"
[X Link](https://x.com/AponiaAnalytics/status/2017279323976175657) 2026-01-30T16:50Z [----] followers, [--] engagements
"$OKUR 🦉 Vanguard reports [------] OnKure shares equal to a 4.87% stake. Disposition power is shared across the position with only limited shared voting rights. #form_13G https://onkuretherapeutics.gcs-web.com/static-files/092b89f7-0253-466e-afe0-da0b1f6205fe https://onkuretherapeutics.gcs-web.com/static-files/092b89f7-0253-466e-afe0-da0b1f6205fe"
[X Link](https://x.com/AponiaAnalytics/status/2017327173162402161) 2026-01-30T20:00Z [----] followers, [--] engagements
"$SRPT #Sarepta"
[X Link](https://x.com/AponiaAnalytics/status/2019557513041957236) 2026-02-05T23:43Z [----] followers, [---] engagements
"$QURE 🦉 "uniQure paused mid- and high-dose AMT-191 dosing after an independent committee classified Grade [--] liver enzyme elevations as dose-limiting toxicity" https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-updated-preliminary-amt-191-phase-iiia-data https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-updated-preliminary-amt-191-phase-iiia-data"
[X Link](https://x.com/AponiaAnalytics/status/2019878078613524647) 2026-02-06T20:57Z [----] followers, [---] engagements
"$BNTX #FixVac $BMY #GVAX $NWBO #DCVax 🧬 THREE WAYS TO TEACH THE IMMUNE SYSTEM TO FIGHT CANCER AND WHY DENDRITIC CELLS DECIDE THE OUTCOME $BNTX #FixVac $BMY #GVAX and $NWBO #DCVax are a clean comparison because they sit on the same axis: all three depend on dendritic cells but they place the teaching job in 🧬 THREE WAYS TO TEACH THE IMMUNE SYSTEM TO FIGHT CANCER AND WHY DENDRITIC CELLS DECIDE THE OUTCOME $BNTX #FixVac $BMY #GVAX and $NWBO #DCVax are a clean comparison because they sit on the same axis: all three depend on dendritic cells but they place the teaching job in"
[X Link](https://x.com/AponiaAnalytics/status/2019887292928639324) 2026-02-06T21:33Z [----] followers, [---] engagements
"$IBRX #ANKTIVA In this JAMA study of over [-----] Americans a clear demonstration of survival related to lymphocyte levels is seen in this graph. When lymphocyte levels fall between [---] to [---] the survival rate plummets. ALC matters https://t.co/1o0eaQ4K7M https://t.co/hMuiuUrVyc In this JAMA study of over [-----] Americans a clear demonstration of survival related to lymphocyte levels is seen in this graph. When lymphocyte levels fall between [---] to [---] the survival rate plummets. ALC matters https://t.co/1o0eaQ4K7M https://t.co/hMuiuUrVyc"
[X Link](https://x.com/AponiaAnalytics/status/2019893726357688573) 2026-02-06T21:59Z [----] followers, [----] engagements
"$QURE $SGMO $SNY $IDEA [--] week [--] #Fabry headlines from #worldsymposium $SNY Fabry #fails to meet expectations $IDEA no renal benefit in Fabry $QURE Fabry #stops dosing on #tox do not report eGFR #high variability path forwar #unclear. $SGMO cures Fabry and stabilizes cardiac functions https://t.co/MiDhbP8tDx [--] week [--] #Fabry headlines from #worldsymposium $SNY Fabry #fails to meet expectations $IDEA no renal benefit in Fabry $QURE Fabry #stops dosing on #tox do not report eGFR #high variability path forwar #unclear. $SGMO cures Fabry and stabilizes cardiac functions https://t.co/MiDhbP8tDx"
[X Link](https://x.com/AponiaAnalytics/status/2020228171715788966) 2026-02-07T20:08Z [----] followers, [---] engagements
"$IBRX #ImmunityBio"
[X Link](https://x.com/AponiaAnalytics/status/2020996257116807645) 2026-02-09T23:00Z [----] followers, [---] engagements
"$IBRX $IBRX REMINDER - ImmunityBio will participate in the three-day [----] ASCO Genitourinary Cancers Symposium on February [--] - [--] at the Moscone West in San Francisco California. Held annually the event focuses on the latest research and treatments for cancers including prostate $IBRX REMINDER - ImmunityBio will participate in the three-day [----] ASCO Genitourinary Cancers Symposium on February [--] - [--] at the Moscone West in San Francisco California. Held annually the event focuses on the latest research and treatments for cancers including prostate"
[X Link](https://x.com/AponiaAnalytics/status/2021348257553842242) 2026-02-10T22:19Z [----] followers, [---] engagements
"$IBRX $IBRX right now you can buy this company that will be worth over a trillion dollars soon (within [--] years) for only $6.83B. Knowing full well how massive GLP-1s have been for obesity treatment I firmly believe that $IBRX's IL-15s broad spectrum anti-cancer peptide will become a https://t.co/ReOLBADeyG $IBRX right now you can buy this company that will be worth over a trillion dollars soon (within [--] years) for only $6.83B. Knowing full well how massive GLP-1s have been for obesity treatment I firmly believe that $IBRX's IL-15s broad spectrum anti-cancer peptide will become a"
[X Link](https://x.com/AponiaAnalytics/status/2021353653349777567) 2026-02-10T22:40Z [----] followers, [---] engagements
"$UNH $UNH Superinvestors should file remaining 13Fs by Monday 16th. I expect to see some large buys in UnitedHealth Group last quarter especially from Berkshire Hathaway-Warren Buffett. This is the same group of buyers that helped push the stock up more than 15% in Q3 after https://t.co/uh33Wr2MJZ $UNH Superinvestors should file remaining 13Fs by Monday 16th. I expect to see some large buys in UnitedHealth Group last quarter especially from Berkshire Hathaway-Warren Buffett. This is the same group of buyers that helped push the stock up more than 15% in Q3 after https://t.co/uh33Wr2MJZ"
[X Link](https://x.com/AponiaAnalytics/status/2021372195625459973) 2026-02-10T23:54Z [----] followers, [---] engagements
"$OSCR This $OSCR Guidance is INSANE 📈 - $19B Revenues +48% above estimates - $250-450M EBIT vs $5M estimate 50-100x Mark Bertolini is making a huge promise but most don't trust him. Those who do could be rewarded https://t.co/VWcnaj0Dhd This $OSCR Guidance is INSANE 📈 - $19B Revenues +48% above estimates - $250-450M EBIT vs $5M estimate 50-100x Mark Bertolini is making a huge promise but most don't trust him. Those who do could be rewarded https://t.co/VWcnaj0Dhd"
[X Link](https://x.com/AponiaAnalytics/status/2021372285102567575) 2026-02-10T23:54Z [----] followers, [---] engagements
"$IBRX @DrPatrick How does $IBRX benefit from the Saudi FDA approval of Anktiva What say the fanboys/girls of @DrPatrick on this question I'm not talking about the stock price so spare me that reply. What material benefit will ImmunityBio gain from focusing on Saudi Arabia How does $IBRX benefit from the Saudi FDA approval of Anktiva What say the fanboys/girls of @DrPatrick on this question I'm not talking about the stock price so spare me that reply. What material benefit will ImmunityBio gain from focusing on Saudi Arabia"
[X Link](https://x.com/AponiaAnalytics/status/2021635425241096441) 2026-02-11T17:20Z [----] followers, [---] engagements
"$UNH Hedge funds are heavily overweight healthcare stocks. For reference $UNH was the most bought stock by hedge funds in Q3 [----]. The sector is now valued at just 18x forward earnings against 22x of S&P [---]. Long healthcare. $UNH $OSCR $CNC $CI $MOH $ELV https://t.co/R16TYkEpiM Hedge funds are heavily overweight healthcare stocks. For reference $UNH was the most bought stock by hedge funds in Q3 [----]. The sector is now valued at just 18x forward earnings against 22x of S&P [---]. Long healthcare. $UNH $OSCR $CNC $CI $MOH $ELV https://t.co/R16TYkEpiM"
[X Link](https://x.com/AponiaAnalytics/status/2021643248314253598) 2026-02-11T17:51Z [----] followers, [---] engagements
"$IBRX $IBRX 🚨🤯🚨 OMG Everyone must see this Current free float is [---] million shares short interest is [---] million shares That means over the stock run up shorts have increased their shorting and right now there's more shorts than shares in free float We are set up for most https://t.co/2YYApSmBNe $IBRX 🚨🤯🚨 OMG Everyone must see this Current free float is [---] million shares short interest is [---] million shares That means over the stock run up shorts have increased their shorting and right now there's more shorts than shares in free float We are set up for most https://t.co/2YYApSmBNe"
[X Link](https://x.com/AponiaAnalytics/status/2021643494750834843) 2026-02-11T17:52Z [----] followers, [---] engagements
"$NVO $LLY Motley Fool says there are [--] healthcare stocks to buy on the dip and $NVO is one of them. Their take: Novo is now second fiddle to $LLY. Lillys Mounjaro +99% sales growth Zepbound +175% Novos obesity portfolio +31% They argue pricing pressure in the U.S. will Motley Fool says there are [--] healthcare stocks to buy on the dip and $NVO is one of them. Their take: Novo is now second fiddle to $LLY. Lillys Mounjaro +99% sales growth Zepbound +175% Novos obesity portfolio +31% They argue pricing pressure in the U.S. will"
[X Link](https://x.com/AponiaAnalytics/status/2021644019949064593) 2026-02-11T17:54Z [----] followers, [---] engagements
"$OSCR $OSCR guided for [---] million members but 400K of those are expected to drop off by end of Q1. They were $0 premium enrollees who got passively renewed into plans that now cost actual money. They're in a grace period through March. If they don't pay they're off the books. So https://t.co/SLkYw0Qp3L $OSCR guided for [---] million members but 400K of those are expected to drop off by end of Q1. They were $0 premium enrollees who got passively renewed into plans that now cost actual money. They're in a grace period through March. If they don't pay they're off the books. So"
[X Link](https://x.com/AponiaAnalytics/status/2021644123988537629) 2026-02-11T17:54Z [----] followers, [---] engagements
"$OSCR #Oscar Here are a few highlights from Oscars latest earnings call as reported this week. 👉 FY25 revenue: Increased to approximately $11.7B up 28% year-over-year 👉 FY25 SG&A expense ratio: 17.5% improved approximately [---] basis points year-over-year In addition as of February https://t.co/Ut5QTUpGqy Here are a few highlights from Oscars latest earnings call as reported this week. 👉 FY25 revenue: Increased to approximately $11.7B up 28% year-over-year 👉 FY25 SG&A expense ratio: 17.5% improved approximately [---] basis points year-over-year In addition as of February"
[X Link](https://x.com/AponiaAnalytics/status/2021645013281800586) 2026-02-11T17:58Z [----] followers, [---] engagements
"$UNH $UNH UnitedHealth Group is going to do very well on earnings this year which should shock the market at a $250 Billion MC Exactly what $META MC was at when it was trading near the $90s. MA Increase % this year is nearly 7.5% including all factors which is huge. Deep Value. https://t.co/1CGvz31jhl $UNH UnitedHealth Group is going to do very well on earnings this year which should shock the market at a $250 Billion MC Exactly what $META MC was at when it was trading near the $90s. MA Increase % this year is nearly 7.5% including all factors which is huge. Deep Value. https://t.co/1CGvz31jhl"
[X Link](https://x.com/AponiaAnalytics/status/2022024828920975630) 2026-02-12T19:07Z [----] followers, [---] engagements
"$UNH Mizuho cut its price recommendation on $UNH to $350 from $430 but kept an Outperform rating on the stock. The revision came after the companys Q4 results with the firm pointing to a slower-than-expected earnings recovery as the main reason for the https://t.co/ooKxI9ImgP Mizuho cut its price recommendation on $UNH to $350 from $430 but kept an Outperform rating on the stock. The revision came after the companys Q4 results with the firm pointing to a slower-than-expected earnings recovery as the main reason for the https://t.co/ooKxI9ImgP"
[X Link](https://x.com/AponiaAnalytics/status/2022024922797908412) 2026-02-12T19:08Z [----] followers, [---] engagements
"$IBRX @DrPatrick @ImmunityBio #ImmunityBio doesn't just deliver a drug; it utilizes second-generation adenovirus (hAd5) vector technology to transform our bodies into a "special forces unit" for hunting viruses. The company uses adenoviruses genetically modified to be harmless to humans as a type of #ImmunityBio doesn't just deliver a drug; it utilizes second-generation adenovirus (hAd5) vector technology to transform our bodies into a "special forces unit" for hunting viruses. The company uses adenoviruses genetically modified to be harmless to humans as a type of"
[X Link](https://x.com/AponiaAnalytics/status/2022025435996152145) 2026-02-12T19:10Z [----] followers, [---] engagements
"$NVO $HIMS $NVO CEO Mike Doustdar to compounders: time to partner not copy. Despite suing 130+ copycat sellers (incl. $HIMS) he says many built patient access Novo couldnt reach. Example: Ro now sells the branded drug and became a very good partner. But nothing in his comments $NVO CEO Mike Doustdar to compounders: time to partner not copy. Despite suing 130+ copycat sellers (incl. $HIMS) he says many built patient access Novo couldnt reach. Example: Ro now sells the branded drug and became a very good partner. But nothing in his comments"
[X Link](https://x.com/AponiaAnalytics/status/2022025682658992226) 2026-02-12T19:11Z [----] followers, [---] engagements
"$OSCR #Oscar As we shared with our full-year [----] results and [----] outlook Oscars vision remains clear: were leading the individual market with a consumer-first experience member-focused tools powered by AI and a clear path back to profitability. Read our full earnings release here: https://t.co/Ev1o5QtLFD As we shared with our full-year [----] results and [----] outlook Oscars vision remains clear: were leading the individual market with a consumer-first experience member-focused tools powered by AI and a clear path back to profitability. Read our full earnings release here:"
[X Link](https://x.com/AponiaAnalytics/status/2022026024125669839) 2026-02-12T19:12Z [----] followers, [---] engagements
"$IBRX $IBRX is actively advancing clinical research in glioblastoma an aggressive Grade [--] brain tumor with limited treatment options and median survival typically just over one year post-diagnosis. Full focus on Innovative immunotherapy combinations in ongoing Ph [--] trial $IBRX is actively advancing clinical research in glioblastoma an aggressive Grade [--] brain tumor with limited treatment options and median survival typically just over one year post-diagnosis. Full focus on Innovative immunotherapy combinations in ongoing Ph [--] trial"
[X Link](https://x.com/AponiaAnalytics/status/2022029979291361463) 2026-02-12T19:28Z [----] followers, [---] engagements
"$VKTX $VKTX Huge news for shareholders- Boom Oral drug moving to Ph3 guys https://t.co/DHczsATn4F $VKTX Huge news for shareholders- Boom Oral drug moving to Ph3 guys https://t.co/DHczsATn4F"
[X Link](https://x.com/AponiaAnalytics/status/2022030616016171242) 2026-02-12T19:30Z [----] followers, [---] engagements
"$NVO #Wegovy $NVO oral version of Wegovy (semaglutide) launched in January has seen significant uptake with approximately 36% of users being new to GLP-1 therapies. A study by Truveta reveals that 21% of users transitioned from the injectable Wegovy while 16% came from $LLY Zepbound https://t.co/VIP0XF8vj8 $NVO oral version of Wegovy (semaglutide) launched in January has seen significant uptake with approximately 36% of users being new to GLP-1 therapies. A study by Truveta reveals that 21% of users transitioned from the injectable Wegovy while 16% came from $LLY Zepbound"
[X Link](https://x.com/AponiaAnalytics/status/2022030727651655904) 2026-02-12T19:31Z [----] followers, [---] engagements
"$VKTX $VKTX new slides & nice pic from piper that sums it up well on catalysts https://t.co/DmzAtMVv8P https://t.co/79HABADM4h $VKTX new slides & nice pic from piper that sums it up well on catalysts https://t.co/DmzAtMVv8P https://t.co/79HABADM4h"
[X Link](https://x.com/AponiaAnalytics/status/2022031837800059154) 2026-02-12T19:35Z [----] followers, [---] engagements
"$AGIO 🦉 Agios posted a $108M Q4 net loss as cash fell to $1.2B while PYRUKYND and newly launched AQVESME drove $20M in quarterly sales. The company heads into a pre-sNDA FDA meeting for mitapivat in sickle cell after reporting $54M full-year revenue. https://investor.agios.com/news-releases/news-release-details/agios-reports-fourth-quarter-and-full-year-2025-financial https://investor.agios.com/news-releases/news-release-details/agios-reports-fourth-quarter-and-full-year-2025-financial"
[X Link](https://x.com/AponiaAnalytics/status/2022034105299611765) 2026-02-12T19:44Z [----] followers, [--] engagements
"$ZYME 🦉 Zymeworks will report Q4 and full-year [----] results pre-market March [--] with a call at 8:30 a.m. ET. The company has yet to publish year-end figures leaving updated cash revenue and pipeline data pending. https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-report-fourth-quarter-and-full-year-2025-financial https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-report-fourth-quarter-and-full-year-2025-financial"
[X Link](https://x.com/AponiaAnalytics/status/2022034728485105939) 2026-02-12T19:47Z [----] followers, [--] engagements
"$CGEN 🦉 Compugen appointed Michele Holcomb to its board as an independent director effective Feb. [--]. The addition comes as the company remains clinical-stage reliant on partnered programs and without approved products generating revenue. https://cgen.com/investors-and-media/press-releases/news-details/2026/Compugen-Announces-the-Appointment-of-Michele-Holcomb-Ph-D--to-its-Board-of-Directors/default.aspx https://cgen.com/investors-and-media/press-releases/news-details/2026/Compugen-Announces-the-Appointment-of-Michele-Holcomb-Ph-D--to-its-Board-of-Directors/default.aspx"
[X Link](https://x.com/AponiaAnalytics/status/2022037127115268525) 2026-02-12T19:56Z [----] followers, [--] engagements
"$BBIO 🦉 BBIO said Phase [--] PROPEL [--] met its goal; infigratinib added +1.74 cm/year vs placebo and was first to show significant body proportionality gains. No oral FGFR3 drug has done this; FDA filing talks set for 2H26."
[X Link](https://x.com/AponiaAnalytics/status/2022043579380851146) 2026-02-12T20:22Z [----] followers, [---] engagements
"$BBIO $BMRN BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase [--] success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase [--] success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde"
[X Link](https://x.com/AponiaAnalytics/status/2022043789213479237) 2026-02-12T20:23Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS $LLY $NVO 🚨 FOUNDER & CEO OF MOCHI HEALTH: EXPECT "WAY HIGHER" CHURN ON NOVO'S GLP-1 PILL " The orals just don't work very well. Rybelsus has been on the market for years. And nobody takes it" " I think the pill is a great on-ramp but it also just doesn't really https://t.co/wVjd6ByJIX $HIMS $LLY $NVO 🚨 FOUNDER & CEO OF MOCHI HEALTH: EXPECT "WAY HIGHER" CHURN ON NOVO'S GLP-1 PILL " The orals just don't work very well. Rybelsus has been on the market for years. And nobody takes it" " I think the pill is a great on-ramp but it also just doesn't really"
[X Link](https://x.com/AponiaAnalytics/status/2022043878174732359) 2026-02-12T20:23Z [----] followers, [---] engagements
"$SPRB 🦉Spruce Biosciences posted a Q3 [----] net loss of $8.2M as R&D spending fell to $5M after ending tildacerfont work. Cash totaled $10.7M extended to 4Q26 with $50M financing. #pressrelease #Q3 #report https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-reports-third-quarter-2025-financial-results https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-reports-third-quarter-2025-financial-results"
[X Link](https://x.com/AponiaAnalytics/status/1987991517126910425) 2025-11-10T21:11Z [----] followers, [---] engagements
"$CNTA 🦉 Centessa names Mario Accardi CEO as it pivots fully to its orexin franchise effective Jan. [--] [----]. Outgoing chief Saurabh Saha becomes advisor while ORX750 heads toward a Q1 [----] registrational start. https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-ceo-transition-company https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-ceo-transition-company"
[X Link](https://x.com/AponiaAnalytics/status/1999195833317683523) 2025-12-11T19:13Z [----] followers, [---] engagements
"$CNTA #Centessa 🦉 Centessa showed preclinical data at ACNP where OX2R activation cut depressive-like behavior and boosted wakefulness in animal models. The results support expanding its orexin pipeline beyond hypersomnia into neuropsychiatric disease. https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-poster-presentation-new https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-poster-presentation-new"
[X Link](https://x.com/AponiaAnalytics/status/2011870093538705881) 2026-01-15T18:36Z [----] followers, [---] engagements
"$ROG $RHHBY 🦉 Roche booked CHF61.5B in [----] sales up 7% CER with Phesgo Ocrevus and Vabysmo carrying growth. Core profit rose 13% and the board put up a CHF9.80 dividend while guiding [----] to mid-single-digit CER gains. https://www.roche.com/investors/updates/inv-update-2026-01-29 https://www.roche.com/investors/updates/inv-update-2026-01-29"
[X Link](https://x.com/AponiaAnalytics/status/2016942875330687203) 2026-01-29T18:33Z [----] followers, [--] engagements
"$UNCY @FDA 🦉 Jan [--] 2026: FDA accepted OLC NDA resubmission; set PDUFA June [--] [----]. Agency classified as Class II CRL; six-month review. Company reported $41.3M cash at [----] end runway into [----]. https://ir.unicycive.com/news/detail/117/unicycive-therapeutics-announces-fda-acceptance-of https://ir.unicycive.com/news/detail/117/unicycive-therapeutics-announces-fda-acceptance-of"
[X Link](https://x.com/AponiaAnalytics/status/2016945597010284843) 2026-01-29T18:44Z [----] followers, [--] engagements
"$UNCY 🦉 Jan [--] 2026: Unicycive Therapeutics said U.S. Food and Drug Administration accepted its OLC NDA resubmission and set a June [--] [----] PDUFA date. Filing marked Class II with six-month review. Company reported $41.3M cash at [----] end. https://ir.unicycive.com/news/detail/118/update---unicycive-therapeutics-announces-fda-acceptance-of https://ir.unicycive.com/news/detail/118/update---unicycive-therapeutics-announces-fda-acceptance-of"
[X Link](https://x.com/AponiaAnalytics/status/2016949013627408884) 2026-01-29T18:58Z [----] followers, [--] engagements
"$PALI 🦉 Franklin Resources and affiliated entities reported a combined [-------] shares (6.0% of class) beneficially owned in Palisade Bio as of Dec [--] [----] under a Schedule 13G. Ownership includes warrants exercisable for [-------] shares. #form_13G https://s3.amazonaws.com/sec.irpass.cc/2827/0000038777-26-000014.htm https://s3.amazonaws.com/sec.irpass.cc/2827/0000038777-26-000014.htm"
[X Link](https://x.com/AponiaAnalytics/status/2016951052033986594) 2026-01-29T19:06Z [----] followers, [---] engagements
"$BNTC 🦉 Franklin Resources reported [-------] Benitec shares a 10.6% stake including [-------] warrant shares. Voting and dispositive power sit with Franklin Advisers as investment manager. #form_13G https://d1io3yog0oux5.cloudfront.net/benitec/sec/0000038777-26-000024/0000038777-26-000024.pdf https://d1io3yog0oux5.cloudfront.net/benitec/sec/0000038777-26-000024/0000038777-26-000024.pdf"
[X Link](https://x.com/AponiaAnalytics/status/2016953034283126902) 2026-01-29T19:14Z [----] followers, [--] engagements
"$HIMS #GLP1 In an emergency Hims House episode Crmieux joined Jonathan Stern to discuss all things $HIMS GLP-1s and the legalities of everything that unfolded today between Hims Novo Nordisk and the FDA. This clip summarizes their conversation. https://t.co/LscFxvpA0m In an emergency Hims House episode Crmieux joined Jonathan Stern to discuss all things $HIMS GLP-1s and the legalities of everything that unfolded today between Hims Novo Nordisk and the FDA. This clip summarizes their conversation. https://t.co/LscFxvpA0m"
[X Link](https://x.com/AponiaAnalytics/status/2019763243753841014) 2026-02-06T13:20Z [----] followers, [---] engagements
"$IBRX 🚀 $IBRX [----] Catalyst Rocket: FDA Resub INCOMING ASCO GU Buzz Saudi Rollout Heating Up Earnings Beat Potential Major BLA Path & Global Expansion This Dip Is Pure Setup for Explosive Leg Up 💥 Todays dip stings after that breakout pure profit-taking + volatility no https://t.co/3w7ouusihX 🚀 $IBRX [----] Catalyst Rocket: FDA Resub INCOMING ASCO GU Buzz Saudi Rollout Heating Up Earnings Beat Potential Major BLA Path & Global Expansion This Dip Is Pure Setup for Explosive Leg Up 💥 Todays dip stings after that breakout pure profit-taking + volatility no https://t.co/3w7ouusihX"
[X Link](https://x.com/AponiaAnalytics/status/2021644214006620498) 2026-02-11T17:55Z [----] followers, [---] engagements
"$IBRX @ImmunityBio"
[X Link](https://x.com/AponiaAnalytics/status/2022023430875546027) 2026-02-12T19:02Z [----] followers, [---] engagements
"$IBRX $IBRX - Feb 11th [----] Short Data Analysis based on real data . 1- Utilization is now 100%. What does that mean What Does "100% Utilization" Mean Think of the stock market like a car rental lot. 100% Utilization means every single car (share) available for rent (shorting) https://t.co/Gj6iCRwccP $IBRX - Feb 11th [----] Short Data Analysis based on real data . 1- Utilization is now 100%. What does that mean What Does "100% Utilization" Mean Think of the stock market like a car rental lot. 100% Utilization means every single car (share) available for rent (shorting) https://t.co/Gj6iCRwccP"
[X Link](https://x.com/AponiaAnalytics/status/2022023713214861720) 2026-02-12T19:03Z [----] followers, [---] engagements
"$PEPG #PepGen $pepg up 50% in [--] trading days. Data ANY day now. https://t.co/gh6IgYfpPa $pepg up 50% in [--] trading days. Data ANY day now. https://t.co/gh6IgYfpPa"
[X Link](https://x.com/AponiaAnalytics/status/2022023995877654837) 2026-02-12T19:04Z [----] followers, [--] engagements
"$IBRX #Anktiva $MRK FDA encouraged Merck to proceed based on breakthrough therapy designation. Anktiva has Breakthrough Therapy Designation (BTD). Priority review was denied in [----] when BLA was filed despite BTD. Now Anktiva has RMAT status and Expanded Access Authorization across multiple tumor https://t.co/YgYY5nsx3r FDA encouraged Merck to proceed based on breakthrough therapy designation. Anktiva has Breakthrough Therapy Designation (BTD). Priority review was denied in [----] when BLA was filed despite BTD. Now Anktiva has RMAT status and Expanded Access Authorization across multiple tumor"
[X Link](https://x.com/AponiaAnalytics/status/2022024651371950158) 2026-02-12T19:06Z [----] followers, [---] engagements
"$IBRX $IBRX Call volume 📈 "Financial giants have made a bullish move on ImmunityBio. Our analysis of options history reveal 57% of traders were bullish while 26% showed bearish tendencies." - @Benzinga Trades spotted: [--] puts valued at $71500 [--] calls valued at $1230478 https://t.co/7hnFH8nCXK $IBRX Call volume 📈 "Financial giants have made a bullish move on ImmunityBio. Our analysis of options history reveal 57% of traders were bullish while 26% showed bearish tendencies." - @Benzinga Trades spotted: [--] puts valued at $71500 [--] calls valued at $1230478 https://t.co/7hnFH8nCXK"
[X Link](https://x.com/AponiaAnalytics/status/2022025001256489391) 2026-02-12T19:08Z [----] followers, [---] engagements
"$VKTX $VKTX excellent execution i I take $VKTX CEO any day his execution has been spectacular in getting these trials up and running and FDA blessings done VANQUISH-1: Enrollment complete [----] patients (exceeded target) - VANQUISH-2: Nearing full enrollment in 1Q26 - Oral VK2735: $VKTX excellent execution i I take $VKTX CEO any day his execution has been spectacular in getting these trials up and running and FDA blessings done VANQUISH-1: Enrollment complete [----] patients (exceeded target) - VANQUISH-2: Nearing full enrollment in 1Q26 - Oral VK2735:"
[X Link](https://x.com/AponiaAnalytics/status/2022026196050227358) 2026-02-12T19:13Z [----] followers, [---] engagements
"$SNY $XBI 🚨WOW @Sanofi's CEO was just ousted The companys board of directors met on February [--] [----] and decided not to renew the Director mandate of Paul Hudson As a result Paul Hudsons last day as $SNY CEO will be on February [--] [----] at the end of business. The board has https://t.co/blC4H7PjhG 🚨WOW @Sanofi's CEO was just ousted The companys board of directors met on February [--] [----] and decided not to renew the Director mandate of Paul Hudson As a result Paul Hudsons last day as $SNY CEO will be on February [--] [----] at the end of business. The board has https://t.co/blC4H7PjhG"
[X Link](https://x.com/AponiaAnalytics/status/2022029830485946500) 2026-02-12T19:27Z [----] followers, [---] engagements
"$IBRX #ImmunityBio $MRK #ANKTIVA #ImmunityBio has saved patients who had failed even Keytruda the world's number one cancer drug. In recently released lung cancer data patients achieved a median overall survival of [----] monthsstretching up to [----] monthswhich is more than double the [--] to [--] months seen with #ImmunityBio has saved patients who had failed even Keytruda the world's number one cancer drug. In recently released lung cancer data patients achieved a median overall survival of [----] monthsstretching up to [----] monthswhich is more than double the [--] to [--] months seen with"
[X Link](https://x.com/AponiaAnalytics/status/2022030438911644121) 2026-02-12T19:29Z [----] followers, [---] engagements
"Welcome to @AponiaAnalytics 🦉🦉🦉 Curious about how emerging diseases and breakthrough innovations shape tomorrows healthcare worldwide Follow along for the latest news real-time trends and unbiased analysis. 🦉📈💊⚕ Your provider of holistic intelligence in healthcare and biotech. We cover: - #BreakingNews in biotech medtech and healthcare. - Health threat reports emerging #diseases #outbreaks #epidemiology. - #MarketAnalysis - Trending companies and #startups. Follow us @aponia_analytics team 🦉🦉🦉"
[X Link](https://x.com/anyuser/status/1870209619269656715) 2024-12-20T20:48Z [----] followers, 30.4K engagements
"$IBRX $IBRX Blackrock ImmunityBio Second Largest Institutional Holder Increases Its Stake By 5.8mil Shares In 4Q25 ie +29% Reaching Up 25.6mil Shares Overall. https://t.co/cLFTH7p6J3 $IBRX Blackrock ImmunityBio Second Largest Institutional Holder Increases Its Stake By 5.8mil Shares In 4Q25 ie +29% Reaching Up 25.6mil Shares Overall. https://t.co/cLFTH7p6J3"
[X Link](https://x.com/AponiaAnalytics/status/2022338343942709752) 2026-02-13T15:53Z [----] followers, [---] engagements
"$NVO #Wegovy 🚨BREAKING - Wegovy Pill sales are up 34% $NVO TRx came in at [------] in the 5th week after launch. Up from TRx [-----] last week. This is the IQVIA data which is widely regarded as the most trustworthy and accurate Remember this still without the effect of the Superbowl https://t.co/ewCLNIS0xG 🚨BREAKING - Wegovy Pill sales are up 34% $NVO TRx came in at [------] in the 5th week after launch. Up from TRx [-----] last week. This is the IQVIA data which is widely regarded as the most trustworthy and accurate Remember this still without the effect of the Superbowl https://t.co/ewCLNIS0xG"
[X Link](https://x.com/AponiaAnalytics/status/2022338613611278430) 2026-02-13T15:54Z [----] followers, [---] engagements
"$HIMS Wild to see that $HIMS is down 30% over the past five years https://t.co/dG3Ur6LVzD Wild to see that $HIMS is down 30% over the past five years https://t.co/dG3Ur6LVzD"
[X Link](https://x.com/AponiaAnalytics/status/2022338754976072071) 2026-02-13T15:55Z [----] followers, [---] engagements
"$LLY $NVO $VKTX $LLY builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision. $NVO $VKTX https://t.co/7PyoEtEw5D $LLY builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision. $NVO $VKTX https://t.co/7PyoEtEw5D"
[X Link](https://x.com/AponiaAnalytics/status/2022339682122785064) 2026-02-13T15:58Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS $LLY $NVO 🚨 SABINA HEMMI (@LAWLIEPOP) ON THE FDA's GLP-1 ANNOUNCEMENT LAST FRIDAY: "It's clearly been sparked by Hims's actions." "While the most concerning part of the FDA statement is its mention of API's it seems to primarily be focused on marketing. They directly https://t.co/VJ0ufiWvNR $HIMS $LLY $NVO 🚨 SABINA HEMMI (@LAWLIEPOP) ON THE FDA's GLP-1 ANNOUNCEMENT LAST FRIDAY: "It's clearly been sparked by Hims's actions." "While the most concerning part of the FDA statement is its mention of API's it seems to primarily be focused on marketing. They directly"
[X Link](https://x.com/AponiaAnalytics/status/2022049163924631903) 2026-02-12T20:44Z [----] followers, [---] engagements
"$VKTX $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY"
[X Link](https://x.com/anyuser/status/2022049290101960802) 2026-02-12T20:44Z [----] followers, [---] engagements
"$CRBU 🦉 Caribou Biosciences will speak at Citi and Leerink investor events; no clinical data no FDA update no capital raise disclosed. The stock had no fresh catalyst after prior CAR-T updates. https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-participate-upcoming-investor-conferences-12 https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-participate-upcoming-investor-conferences-12"
[X Link](https://x.com/AponiaAnalytics/status/2022061013844246679) 2026-02-12T21:31Z [----] followers, [---] engagements
"$NWBO #DCVax 🧬 Why the New Nature #mRNA Study Quietly Proves the Superiority of $NWBO #DCVax And Why mRNA Cancer Vaccines Cannot Match Dendritic-Cell Immunotherapy. and why the #FDA is correct. 🔗https://t.co/v451mF4xqH https://t.co/bxycWLb7Hs 🧬 Why the New Nature #mRNA Study Quietly Proves the Superiority of $NWBO #DCVax And Why mRNA Cancer Vaccines Cannot Match Dendritic-Cell Immunotherapy. and why the #FDA is correct. 🔗https://t.co/v451mF4xqH https://t.co/bxycWLb7Hs"
[X Link](https://x.com/AponiaAnalytics/status/2022338219552186572) 2026-02-13T15:52Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@AponiaAnalytics aponia_analytics
Several biotech companies have recently made significant announcements. TG Therapeutics reported a strong Q3 revenue of $161.7m, driven by Briumvi sales, and raised its [----] guidance. Regeneron also posted a 13% increase in Q3 revenue to $3.68b, driven by Dupixent and Eylea HD. Additionally, Pfizer reported solid Q3 results, with a revenue of $16.7b and raised its [----] EPS guidance.
Engagements: [-----] #
- [--] Week [-------] +1,546%
- [--] Month [-------] +30%
- [--] Months [---------] +36%
- [--] Year [---------] +1,121%
Mentions: [--] #
- [--] Month [---] -59%
- [--] Months [-----] +28%
- [--] Year [------] +707%
Followers: [-----] #
- [--] Week [-----] +0.63%
- [--] Month [-----] +0.77%
- [--] Months [-----] -0.27%
- [--] Year [-----] +72%
CreatorRank: [-------] #
Social Influence
Social category influence stocks 73.58% finance 17.92% cryptocurrencies 2.36% financial services #998 technology brands 0.94% countries 0.94% celebrities 0.94% currencies 0.94% exchanges 0.47% travel destinations 0.47%
Social topic influence $hims #98, $nvo #123, $ibrx #13, $nwbo #5, novo #3041, $lly #85, in the 4.72%, $unh #253, $vktx #56, ceo 3.3%
Top accounts mentioned or mentioned by @fda @drpatrick @andrewdudum @immunitybio @saiseiinvesting @againstheliars @jfais20 @abalakum @cremieuxrecueil @thekiwikapital @matthewherper @pharmalot @damiangarde @benzinga @sanofis @lawliepop @michaeljburry @theroaringkitty @investinc_intel
Top assets mentioned Hims & Hers Health, Inc. (HIMS) Novo-Nordisk (NVO) ImmunityBio, Inc. Common Stock (IBRX) Eli Lilly and Company (LLY) UnitedHealth Group (UNH) Viking Therapeutics, Inc (VKTX) Oscar Health, Inc. (OSCR) Sarepta Therapeutics, Inc. (SRPT) Unicycive Therapeutics, Inc. (UNCY) Merck & Co., Inc. (MRK) uniQure N.V. (QURE) Royalty Pharma plc (RPRX) Pfizer, Inc. (PFE) Regeneron Pharmaceuticals Inc (REGN) Synthetify (SNY) Morgan Stanley (MS) Denali Therapeutics Inc. Common Stock (DNLI) OnKure Therapeutics, Inc. (OKUR) Bristol-Myers Squibb Co (BMY) Fractyl Health, Inc. (GUTS) Abivax SA (ABVX) Revolution Medicines, Inc. (RVMD) Amgen, Inc. (AMGN) Gilead Sciences, Inc. (GILD) The 99% Community (99) Vaxcyte, Inc. (PCVX) Neumora Therapeutics, Inc. (NMRA) BridgeBio Pharma, Inc. Common Stock (BBIO) Centessa Pharmaceuticals plc (CNTA) Schrodinger, Inc. (SDGR) Edgewise Therapeutics, Inc. (EWTX) Cytokinetics Inc. (CYTK) Janux Therapeutics, Inc. (JANX) HSBC Holdings PLC (HSBC) Liquidia Corporation Common Stock (LQDA) Dana Incorporated (DAN) Wave Life Sciences Ltd. Ordinary Shares (WVE)
Top Social Posts
Top posts by engagements in the last [--] hours
"$IBRX @DrPatrick Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): Its fully approved in the US for one rare form of bladder cancer but not for the common form most patients have. So even though the same drug is already FDA-approved and https://t.co/jb46zpPbPL Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): Its fully approved in the US for one rare form of bladder cancer but not for the common form most patients have. So even though the same drug is already FDA-approved and"
X Link 2026-02-12T19:01Z [----] followers, [---] engagements
"$IBRX $IBRX shorts got PLAYED. They piled in heavy on insider FDA dirtbetting on papillary rejection/delays thinking ANKTIVA was dead in the water. Then Dr. Pat drops the HAMMER: Saudi FDA slams accelerated approvals for ANKTIVA in BLADDER AND NSCLC first worldwide subQ IL-15 wins $IBRX shorts got PLAYED. They piled in heavy on insider FDA dirtbetting on papillary rejection/delays thinking ANKTIVA was dead in the water. Then Dr. Pat drops the HAMMER: Saudi FDA slams accelerated approvals for ANKTIVA in BLADDER AND NSCLC first worldwide subQ IL-15 wins"
X Link 2026-02-12T19:07Z [----] followers, [---] engagements
"$VKTX $VKTX Stifel $VKTX remains undeterred by expanding competition in the obesity landscape. Notably VKTX is aligning its programs with next- generation profiles that not only address tolerability but issues with treatment duration exploring both weeklymonthly and weeklyoral $VKTX Stifel $VKTX remains undeterred by expanding competition in the obesity landscape. Notably VKTX is aligning its programs with next- generation profiles that not only address tolerability but issues with treatment duration exploring both weeklymonthly and weeklyoral"
X Link 2026-02-12T19:37Z [----] followers, [---] engagements
"$AKBA $QTTB $AKBA $QTTB Akebia Announces Establishment of Rare Kidney Disease Pipeline - QTTB BioPharmCatalyst https://t.co/L22GgQEWAC $AKBA $QTTB Akebia Announces Establishment of Rare Kidney Disease Pipeline - QTTB BioPharmCatalyst https://t.co/L22GgQEWAC"
X Link 2025-12-01T20:22Z [----] followers, [---] engagements
"$RPRX $DNLI $RPRX $DNLI Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement BioPharmCatalyst https://t.co/wGUQ4rSYTI $RPRX $DNLI Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement BioPharmCatalyst https://t.co/wGUQ4rSYTI"
X Link 2025-12-04T17:33Z [----] followers, [---] engagements
"$DNLI $RPRX $DNLI and $RPRX Announce $275 Million Royalty Funding Agreement https://t.co/IsG6su0xFN $DNLI and $RPRX Announce $275 Million Royalty Funding Agreement https://t.co/IsG6su0xFN"
X Link 2025-12-04T17:39Z [----] followers, [---] engagements
"$SDGR 🦉Schrdinger granted RSUs covering [----] shares to six new hires on Dec. [--] under its [----] inducement plan. Awards vest over four years starting with 25% after year one. https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4-ff9b7e0d0/default.aspx https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4-ff9b7e0d0/default.aspx"
X Link 2025-12-17T18:48Z [----] followers, [---] engagements
"$OKUR 🦉 CEO Nicholas Saccomano sold [--] shares at $2.97 to cover RSU tax withholding. Post-transaction ownership totals [----] shares per filing. #form_4 https://onkuretherapeutics.gcs-web.com/static-files/def41edf-4764-480a-b892-155b1032652a https://onkuretherapeutics.gcs-web.com/static-files/def41edf-4764-480a-b892-155b1032652a"
X Link 2025-12-24T21:23Z [----] followers, [---] engagements
"$UNCY $UNCY resubmits Oxylanthanum Carbonate (OLC) NDA $UNCY resubmits Oxylanthanum Carbonate (OLC) NDA"
X Link 2025-12-29T17:54Z [----] followers, [---] engagements
"$RPRX $RPRX Acquires Remaining Royalty Interest in Roches Evrysdi for $240M and Potential Milestones $RPRX Acquires Remaining Royalty Interest in Roches Evrysdi for $240M and Potential Milestones"
X Link 2025-12-30T15:44Z [----] followers, [---] engagements
"$CYTK $BMY $EWTX Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies added If successful it could open up aficamten in nHCM which Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies added If successful it could open up aficamten in nHCM which"
X Link 2026-01-09T15:58Z [----] followers, [---] engagements
"$JNXT 🦉 Janux Therapeutics names William Go ex-Kite and A2 Bio CMO effective Jan [--] replacing Zachariah McIver. Go led ZUMA-1 to Yescarta FDA/EMA approval and joins as JANX007 and JANX008 run Phase [--]. https://investors.januxrx.com/investor-media/news/news-details/2026/Janux-Therapeutics-Appoints-William-Go-M-D--Ph-D--as-Chief-Medical-Officer/default.aspx https://investors.januxrx.com/investor-media/news/news-details/2026/Janux-Therapeutics-Appoints-William-Go-M-D--Ph-D--as-Chief-Medical-Officer/default.aspx"
X Link 2026-01-26T19:36Z [----] followers, [--] engagements
"$NWBO $PFE $HSBC $NWBO rubbing shoulders now with some bigger names like $PFE $HSBC #AARC as they all join forces in a global think tank to advance the development of cancer vaccines in #immunotherapy. https://t.co/m6cDnOncoB $NWBO rubbing shoulders now with some bigger names like $PFE $HSBC #AARC as they all join forces in a global think tank to advance the development of cancer vaccines in #immunotherapy. https://t.co/m6cDnOncoB"
X Link 2026-01-28T17:09Z [----] followers, [---] engagements
"$LQDA 🦉 Chief Accounting Officer Dana Boyle sold [----] shares at $41.65 under a 10b5-1 plan to cover RSU tax withholding. Post-sale beneficial ownership stands at 178.8k shares largely unvested equity. #form_4 https://www.liquidia.com/static-files/f3ffc534-a174-4fd3-8638-e1c0858300af https://www.liquidia.com/static-files/f3ffc534-a174-4fd3-8638-e1c0858300af"
X Link 2026-01-28T21:39Z [----] followers, [---] engagements
"$GUTS $GUTS Anticipated Catalysts https://t.co/bGEXb7eL7b $GUTS Anticipated Catalysts https://t.co/bGEXb7eL7b"
X Link 2026-01-29T15:52Z [----] followers, [---] engagements
"$GUTS #FDA $GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo pathway in Q2 $GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo pathway in Q2"
X Link 2026-01-29T15:53Z [----] followers, [--] engagements
"$UNCY #FDA $UNCY FDA Accepts Oxylanthanum Carbonate (OLC) NDA Resubmission. PDUFA 06/27/26 $UNCY FDA Accepts Oxylanthanum Carbonate (OLC) NDA Resubmission. PDUFA 06/27/26"
X Link 2026-01-29T18:19Z [----] followers, [---] engagements
"$ABVX $ABVX hang this slide up in a museum https://t.co/ApagfLw0FM $ABVX hang this slide up in a museum https://t.co/ApagfLw0FM"
X Link 2026-01-29T18:20Z [----] followers, [---] engagements
"$RVMD $RVMD Doses First Patient in Clinical Trial Evaluating RMC-5127 a RAS(ON) G12V-Selective Inhibitor $RVMD Doses First Patient in Clinical Trial Evaluating RMC-5127 a RAS(ON) G12V-Selective Inhibitor"
X Link 2026-01-29T19:16Z [----] followers, [--] engagements
"$NVO $LLY $VKTX The data is in for the week that ended [--] January and the trend reversal is undeniable. $NVO New-to-Brand (NBRx) prescriptions for Wegovy just exploded +71.9% week-over-week. While the market was worried Novo just printed one of its strongest growth weeks in history. Lets https://t.co/fOhxgDMlzF The data is in for the week that ended [--] January and the trend reversal is undeniable. $NVO New-to-Brand (NBRx) prescriptions for Wegovy just exploded +71.9% week-over-week. While the market was worried Novo just printed one of its strongest growth weeks in history. Lets"
X Link 2026-01-29T19:20Z [----] followers, [---] engagements
"$UNCY $UNCY: The Class II designation and a tough day for the indexes $IWM explains todays volatility. FDA accepted the OLC resubmission as Class II with a PDUFA target 6/27/26a longer review window not a clinical negative. Cash was $41.3M at YE25 with stated runway into [----] $UNCY: The Class II designation and a tough day for the indexes $IWM explains todays volatility. FDA accepted the OLC resubmission as Class II with a PDUFA target 6/27/26a longer review window not a clinical negative. Cash was $41.3M at YE25 with stated runway into 2027"
X Link 2026-01-29T19:29Z [----] followers, [---] engagements
"$RVMD LIFESCI $RVMD Mgmt Discussion Takeaways: Incremental Color on RASolute [---] Dynamics Pipeline Execution and Early Clinical-Stage Assets January [--] [----] OUTPERFORM PRICE TARGET: $144.00 LIFESCI $RVMD Mgmt Discussion Takeaways: Incremental Color on RASolute [---] Dynamics Pipeline Execution and Early Clinical-Stage Assets January [--] [----] OUTPERFORM PRICE TARGET: $144.00"
X Link 2026-01-30T02:07Z [----] followers, [--] engagements
"$REGN $REGN on ox40 and the bar needed to compete with dupi $AMGN $SNY https://t.co/tUPGtYtB1c $REGN on ox40 and the bar needed to compete with dupi $AMGN $SNY https://t.co/tUPGtYtB1c"
X Link 2026-01-30T15:35Z [----] followers, [--] engagements
"$QURE 🦉 UniQure to meet with U.S. Food and Drug Administration on Huntingtons gene therapy after the agency changed its view on the trial; patients discussed petitions on STATs The Readout LOUD https://www.statnews.com/2026/01/29/readout-loud-podcast-huntingtons-patients-uniqure-gene-therapy/ https://www.statnews.com/2026/01/29/readout-loud-podcast-huntingtons-patients-uniqure-gene-therapy/"
X Link 2026-01-30T15:40Z [----] followers, [---] engagements
"$QURE @jfais20 One of the less understood things about HD is the very high suicide rate. During yesterday's podcast it was understated and the actual rate of suicide during "normal" times for HD community is 10-12 TIMES MORE likely than gen pop. FDA needs to give them hope now $QURE https://t.co/voZeRdlvYc @jfais20 One of the less understood things about HD is the very high suicide rate. During yesterday's podcast it was understated and the actual rate of suicide during "normal" times for HD community is 10-12 TIMES MORE likely than gen pop. FDA needs to give them hope now $QURE"
X Link 2026-01-30T16:40Z [----] followers, [---] engagements
"$IBRX #ANKTIVA $GILD $MRK ImmunityBio $IBRX Target Valuation & Market Cap Projections Current Valuation (Intrinsic Fair Value) Estimated Market Cap: $18B $25B Revenue Explosion: FY2025 net product revenue grew by 700% year-over-year to approximately $113M. This performance demonstrates the https://t.co/CylwZCjkQp ImmunityBio $IBRX Target Valuation & Market Cap Projections Current Valuation (Intrinsic Fair Value) Estimated Market Cap: $18B $25B Revenue Explosion: FY2025 net product revenue grew by 700% year-over-year to approximately $113M. This performance demonstrates the"
X Link 2026-01-30T17:02Z [----] followers, [---] engagements
"$UNH $UNH 🐳🚨 🚨Monster accumulation: 1.3M+ shares in [--] blocks within an hour and a half midday buyers paid premiums up to $1.01 over ask on blocks 164k400k. $373M notional scooped on💰 🐂For a $500B+ market cap name like UNH this kind of size on dips (post-earnings/guidance https://t.co/cvQPF3U3F2 $UNH 🐳🚨 🚨Monster accumulation: 1.3M+ shares in [--] blocks within an hour and a half midday buyers paid premiums up to $1.01 over ask on blocks 164k400k. $373M notional scooped on💰 🐂For a $500B+ market cap name like UNH this kind of size on dips (post-earnings/guidance https://t.co/cvQPF3U3F2"
X Link 2026-01-31T21:29Z [----] followers, [---] engagements
"$UNH Torray Funds added some more $UNH shares. Is $UNH going to be most bought stock [--] quarters in a row for superinvestors 🤯🤯 https://t.co/o61W0OovPW Torray Funds added some more $UNH shares. Is $UNH going to be most bought stock [--] quarters in a row for superinvestors 🤯🤯 https://t.co/o61W0OovPW"
X Link 2026-01-31T21:30Z [----] followers, [--] engagements
"$UNH UnitedHealth $UNH forms first Golden Cross since July [----] ✅📈👀 https://t.co/MceSrTl42N UnitedHealth $UNH forms first Golden Cross since July [----] ✅📈👀 https://t.co/MceSrTl42N"
X Link 2026-01-31T21:31Z [----] followers, [---] engagements
"$WVE This is the Grade [--] SAE version of "our partner doesn't like or want our drug so they gave it back." Wave Life Sciences $WVE announces plans to accelerate regulatory engagement with full control of WVE-006 for alpha-1 antitrypsin deficiency This is the Grade [--] SAE version of "our partner doesn't like or want our drug so they gave it back." Wave Life Sciences $WVE announces plans to accelerate regulatory engagement with full control of WVE-006 for alpha-1 antitrypsin deficiency"
X Link 2026-02-02T14:55Z [----] followers, [--] engagements
"$NWBO #MHRA $NWBO Anticipatory MHRA approval signs continue with new Job Posting https://t.co/coeCDJQQWp https://t.co/khJvvT1sVx $NWBO Anticipatory MHRA approval signs continue with new Job Posting https://t.co/coeCDJQQWp https://t.co/khJvvT1sVx"
X Link 2026-02-03T16:33Z [----] followers, [---] engagements
"$NWBO $NWBO The Pfizer guy was totally amazed by the results from DC vaccine trials on GBM breast cancer and melanoma. He probably didn't see the results from the DC vaccine trials on ovarian cancer. Otherwise he could have been amazed even more. LP mentioned that the collaboration https://t.co/16gpPn6CZ0 $NWBO The Pfizer guy was totally amazed by the results from DC vaccine trials on GBM breast cancer and melanoma. He probably didn't see the results from the DC vaccine trials on ovarian cancer. Otherwise he could have been amazed even more. LP mentioned that the collaboration"
X Link 2026-02-05T21:08Z [----] followers, [---] engagements
"$NWBO #DCVax"
X Link 2026-02-05T21:09Z [----] followers, [---] engagements
"$UNH Unfortunately when it rains it pours and there could be more bad news heading $UNH's way regarding Medicare. The Centers for Medicare & Medicaid Services (CMS) proposed increasing payments to private insurers by only 0.09% in [----]. If you're wondering how the market reacted https://t.co/CdlnHULNHY Unfortunately when it rains it pours and there could be more bad news heading $UNH's way regarding Medicare. The Centers for Medicare & Medicaid Services (CMS) proposed increasing payments to private insurers by only 0.09% in [----]. If you're wondering how the market reacted"
X Link 2026-02-05T21:09Z [----] followers, [---] engagements
"$NWBO $NWBO It seems like @abalakum was really impressed with the trial results from DC vaccines. He should know that Pfizer's Prevnar has been combined with DC vaccine in various trials conducted by Mayo Clinic which produced truly amazing results. I suppose he could bring his boss https://t.co/iybdW9KuFB $NWBO It seems like @abalakum was really impressed with the trial results from DC vaccines. He should know that Pfizer's Prevnar has been combined with DC vaccine in various trials conducted by Mayo Clinic which produced truly amazing results. I suppose he could bring his boss"
X Link 2026-02-05T21:13Z [----] followers, [---] engagements
"$NWBO #DCVax 🧬 Englands New Cancer Operating System: A Forensic Reading of the [----] National Cancer Plan and Where $NWBO #DCVax Fits #UnitedByUnique #WorldCancerDay TL;DR: Englands National Cancer Plan (February 2026) is a ten-year rebuild of cancer care as an engineered measurable https://t.co/SEiG2IoRGu 🧬 Englands New Cancer Operating System: A Forensic Reading of the [----] National Cancer Plan and Where $NWBO #DCVax Fits #UnitedByUnique #WorldCancerDay TL;DR: Englands National Cancer Plan (February 2026) is a ten-year rebuild of cancer care as an engineered measurable"
X Link 2026-02-05T21:22Z [----] followers, [---] engagements
"#DCVax $NWBO #UnitedByUnique #WorldCancerDay #CancerImmunotherapy #PersonalizedMedicine #DCVax $NWBO Cancer is not one enemy. It is a thousand disguises. Two patients can share the same diagnosis and still have different tumors different escape routes different immune histories and #UnitedByUnique #WorldCancerDay #CancerImmunotherapy #PersonalizedMedicine #DCVax $NWBO Cancer is not one enemy. It is a thousand disguises. Two patients can share the same diagnosis and still have different tumors different escape routes different immune histories and"
X Link 2026-02-05T21:48Z [----] followers, [---] engagements
"$NWBO $NWBO Dr. Keith Knutson from Mayo Clinic also attended the conference organized by Cancer Vaccine Coalition. I assume by now Arun Balakumaran may have read some publications by Keith Knutson and other researchers at Mayo Clinic. Mayo once conducted a trial on advanced ovarian https://t.co/wlObsVmLbN $NWBO Dr. Keith Knutson from Mayo Clinic also attended the conference organized by Cancer Vaccine Coalition. I assume by now Arun Balakumaran may have read some publications by Keith Knutson and other researchers at Mayo Clinic. Mayo once conducted a trial on advanced ovarian"
X Link 2026-02-05T21:49Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: $HIMS JUST ADDED THE "GLP-1 MICRODOSE" TAG TO THIS GRAPHIC ON ITS WEBSITE https://t.co/a1wGcJFTLK 🚨 BREAKING: $HIMS JUST ADDED THE "GLP-1 MICRODOSE" TAG TO THIS GRAPHIC ON ITS WEBSITE https://t.co/a1wGcJFTLK"
X Link 2026-02-05T21:49Z [----] followers, [---] engagements
"#dcvax $nwbo #dcvax $nwbo #gbm Interesting notes on Dr. Balakumaran's extensive background below:- "The "CAR T moment" for solid tumors is here. For decades we've watched survival curves drop like a staircase. But the latest signals from the CVC Think Tank and the data across GBM https://t.co/BXLVWWxulN #dcvax $nwbo #gbm Interesting notes on Dr. Balakumaran's extensive background below:- "The "CAR T moment" for solid tumors is here. For decades we've watched survival curves drop like a staircase. But the latest signals from the CVC Think Tank and the data across GBM https://t.co/BXLVWWxulN"
X Link 2026-02-05T21:50Z [----] followers, [---] engagements
"$NVO $HIMS Novo Nordisk $NVO accused Hims & Hers $HIMS of illegal mass compounding after the telehealth platform said it would offer a cheaper compounded version of the Wegovy pill - WSJ https://t.co/THw0ygs1Jh Novo Nordisk $NVO accused Hims & Hers $HIMS of illegal mass compounding after the telehealth platform said it would offer a cheaper compounded version of the Wegovy pill - WSJ https://t.co/THw0ygs1Jh"
X Link 2026-02-05T21:50Z [----] followers, [---] engagements
"$NVO $HIMS As expected $NVO just announced its taking legal and regulatory action against $HIMS. This is another example of $HIMS' historic behaviour of duping the American public with knock-off GLP-1 products and the FDA has previously warned them about their deceptive advertising of As expected $NVO just announced its taking legal and regulatory action against $HIMS. This is another example of $HIMS' historic behaviour of duping the American public with knock-off GLP-1 products and the FDA has previously warned them about their deceptive advertising of"
X Link 2026-02-05T21:51Z [----] followers, [---] engagements
"$NWBO $NWBO while investors wring their hands in frustration and fall for shorts tricks real work goes on in the important places. Follow science not charts. https://t.co/8p1VGVjg9L $NWBO while investors wring their hands in frustration and fall for shorts tricks real work goes on in the important places. Follow science not charts. https://t.co/8p1VGVjg9L"
X Link 2026-02-05T23:16Z [----] followers, [---] engagements
"$NWBO $NWBO The real meaning of Eikon Therapeutics' TLR7/8 agonist is about activating DCs which have tumor target proteins on their surface so that anti-tumor immune response can be boosted even more. https://t.co/OTowi66hzw $NWBO The real meaning of Eikon Therapeutics' TLR7/8 agonist is about activating DCs which have tumor target proteins on their surface so that anti-tumor immune response can be boosted even more. https://t.co/OTowi66hzw"
X Link 2026-02-05T23:17Z [----] followers, [---] engagements
"$HIMS $NVO Heres some additional context: $HIMS is allegedly not infringing $NVO's patent because it isnt using SNAC technology the mechanism that enables oral absorption of semaglutide. But without SNAC the drug shouldnt work. So what exactly are people paying $49/month for $HIMS Heres some additional context: $HIMS is allegedly not infringing $NVO's patent because it isnt using SNAC technology the mechanism that enables oral absorption of semaglutide. But without SNAC the drug shouldnt work. So what exactly are people paying $49/month for $HIMS"
X Link 2026-02-05T23:17Z [----] followers, [---] engagements
"$NVO $LLY $HIMS $HIMS is down 15% from the daily high. This is what you get when you literally scam your own patients. $NVO $LLY $HIMS https://t.co/r8Z14SGCKV $HIMS is down 15% from the daily high. This is what you get when you literally scam your own patients. $NVO $LLY $HIMS https://t.co/r8Z14SGCKV"
X Link 2026-02-05T23:17Z [----] followers, [---] engagements
"$HIMS $NVO 🚨 EMERGENCY POD $HIMS LAUNCHES GLP-1 PILL $NVO THREATENS LAWSUIT Thanks to @cremieuxrecueil for coming on the show 02:24 Initial reaction to the news 03:56 Science deep dive: liposomal delivery vs. SNAC 06:02 Legal implications and possible lawsuit 18:38 Future of the https://t.co/PtxWY4dyE8 🚨 EMERGENCY POD $HIMS LAUNCHES GLP-1 PILL $NVO THREATENS LAWSUIT Thanks to @cremieuxrecueil for coming on the show 02:24 Initial reaction to the news 03:56 Science deep dive: liposomal delivery vs. SNAC 06:02 Legal implications and possible lawsuit 18:38 Future of the https://t.co/PtxWY4dyE8"
X Link 2026-02-05T23:20Z [----] followers, [---] engagements
"$HIMS $LLY $NVO 🚨 BREAKING: JUDGE DISMISSES ELI LILLY'S LAWSUIT AGAINST WILLOW HEALTH $HIMS $LLY $NVO 🚨 BREAKING: JUDGE DISMISSES ELI LILLY'S LAWSUIT AGAINST WILLOW HEALTH $HIMS $LLY $NVO"
X Link 2026-02-05T23:21Z [----] followers, [---] engagements
"$NVO $HIMS $NVO calling $HIMS basically the corner store drug dealer lol https://t.co/hDPgukSvX3 $NVO calling $HIMS basically the corner store drug dealer lol https://t.co/hDPgukSvX3"
X Link 2026-02-05T23:25Z [----] followers, [---] engagements
"$HIMS 🦉 Feb [--] 2026: Hims & Hers said providers can prescribe compounded semaglutide pills. Intro price $49 for month one then $99. Product is not FDA-approved and differs from approved oral semaglutide. https://investors.hims.com/news/news-details/2026/Hims--Hers-Expands-Personalized-Weight-Loss-Portfolio-with-Access-to-Compounded-Semaglutide-Pills-Starting-at-49Month/default.aspx https://investors.hims.com/news/news-details/2026/Hims--Hers-Expands-Personalized-Weight-Loss-Portfolio-with-Access-to-Compounded-Semaglutide-Pills-Starting-at-49Month/default.aspx"
X Link 2026-02-05T23:32Z [----] followers, [---] engagements
"$NVO 🦉 Feb [--] 2026: Novo Nordisk said Hims & Hers plans to mass-market an unapproved compounded semaglutide pill are illegal. Novo said only its Wegovy pill is FDA-approved and warned compounded versions may have impurities. https://ml-eu.globenewswire.com/Resource/Download/300bdcca-d316-4e74-8d4c-8f6fcbb0dfec https://ml-eu.globenewswire.com/Resource/Download/300bdcca-d316-4e74-8d4c-8f6fcbb0dfec"
X Link 2026-02-05T23:34Z [----] followers, [---] engagements
"$NVO 🦉 Novo Nordisk insiders transferred thousands of shares on Feb [--] under long-term plans including CEO Doustdars [-----] shares and others at zero cost. CFO Knudsen moved [-----] shares; some execs sold stock on Nasdaq Copenhagen. https://ml-eu.globenewswire.com/Resource/Download/56263a8d-9be6-4a3a-98a4-8d4f30521f06 https://ml-eu.globenewswire.com/Resource/Download/56263a8d-9be6-4a3a-98a4-8d4f30521f06"
X Link 2026-02-05T23:39Z [----] followers, [---] engagements
"$HIMS $NVO 🚨 $HIMS LAUNCHES COPY OF WEGOVY PILL AT $49/MO - Price undercuts Novo brand by roughly $100 monthly - Monthly price rises to $99 after introductory offer - Novo is facing unprecedented pricing pressure from cash-pay market "We're excited to find ways to continue bringing 🚨 $HIMS LAUNCHES COPY OF WEGOVY PILL AT $49/MO - Price undercuts Novo brand by roughly $100 monthly - Monthly price rises to $99 after introductory offer - Novo is facing unprecedented pricing pressure from cash-pay market "We're excited to find ways to continue bringing"
X Link 2026-02-05T23:57Z [----] followers, [---] engagements
"$HIMS $NVO I can assure you $HIMS did their legal DD before going to market with this How is it that a $5 Billion Market Cap company like $HIMS can petrify these big pharmas like this Because they know their value now and identified it to the market $HIMs at the very least is a $50 https://t.co/n14gha058H I can assure you $HIMS did their legal DD before going to market with this How is it that a $5 Billion Market Cap company like $HIMS can petrify these big pharmas like this Because they know their value now and identified it to the market $HIMs at the very least is a $50"
X Link 2026-02-06T00:00Z [----] followers, [---] engagements
"$HIMS $HIMS SHARES AVAILABLE TO SHORT WENT FROM ZERO TO [---] MILLION JUST BEFORE MARKET OPEN LAST NIGHT WAS BELOW [--] MILLION FOR THE FIRST TIME IN A LONG TIME CRAZY ACTION FROM SHORTS RIGHT NOW h/t @thekiwikapital https://t.co/T5K4BnGzyH $HIMS SHARES AVAILABLE TO SHORT WENT FROM ZERO TO [---] MILLION JUST BEFORE MARKET OPEN LAST NIGHT WAS BELOW [--] MILLION FOR THE FIRST TIME IN A LONG TIME CRAZY ACTION FROM SHORTS RIGHT NOW h/t @thekiwikapital https://t.co/T5K4BnGzyH"
X Link 2026-02-06T00:00Z [----] followers, [---] engagements
"$HIMS $HIMS WEEKLY - WHAT A WEEK 😳 - GLP-1 pill launch ($49) - Liposomal delivery not SNAC - $NVO vows legal action 👿 - Makary pours gasoline on the fire - Stock craters to 52-week low - $LLY lawsuit vs. Willow dismissed - Oh and Hims launched cancer testing (link below) https://t.co/dKVqjF1Vb3 $HIMS WEEKLY - WHAT A WEEK 😳 - GLP-1 pill launch ($49) - Liposomal delivery not SNAC - $NVO vows legal action 👿 - Makary pours gasoline on the fire - Stock craters to 52-week low - $LLY lawsuit vs. Willow dismissed - Oh and Hims launched cancer testing (link below) https://t.co/dKVqjF1Vb3"
X Link 2026-02-06T12:54Z [----] followers, [---] engagements
"$HIMS $NVO #FDA 🚨 JUST IN: FDA Commissioner Dr. Marty Makary just issued a statement on the $HIMS x $NVO conflict. Oh boy. https://t.co/sU95BfjdSb 🚨 JUST IN: FDA Commissioner Dr. Marty Makary just issued a statement on the $HIMS x $NVO conflict. Oh boy. https://t.co/sU95BfjdSb"
X Link 2026-02-06T12:56Z [----] followers, [---] engagements
"#FDA $NVO $HIMS FDA will take swift action against companies mass-marketing illegal copycat drugs claiming they are similar to FDA-approved products. The FDA cannot verify the quality safety or effectiveness of non-approved drugs. FDA will take swift action against companies mass-marketing illegal copycat drugs claiming they are similar to FDA-approved products. The FDA cannot verify the quality safety or effectiveness of non-approved drugs"
X Link 2026-02-06T13:01Z [----] followers, [---] engagements
"$MRK $PFE $AMGN $REGN $NWBO 🧭 The Tail They Learned to Trust Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK $PFE $AMGN $REGN and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained 🧭 The Tail They Learned to Trust Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK $PFE $AMGN $REGN and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained"
X Link 2026-02-06T13:08Z [----] followers, [---] engagements
"$HIMS #FDA The current $HIMS panic reminds me of when I first went all in around September [----]. Read this: Please stop panicking. The recent post from the FDA about "not tollerating mass-compounding of illegal drugs classified" as "FDA approved" is just a scare tactic. ** $HIMS does https://t.co/nTsadDWRL1 The current $HIMS panic reminds me of when I first went all in around September [----]. Read this: Please stop panicking. The recent post from the FDA about "not tollerating mass-compounding of illegal drugs classified" as "FDA approved" is just a scare tactic. ** $HIMS does"
X Link 2026-02-06T13:10Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: LEERINK REITERATES $HIMS $41 PRICE TARGET - MARKET PERFORM RATING Leerink called the GLP-1 pill "an extremely logical new product offering" And noted that the current legal environment creates favorable conditions to expand its offerings to other weight loss 🚨 BREAKING: LEERINK REITERATES $HIMS $41 PRICE TARGET - MARKET PERFORM RATING Leerink called the GLP-1 pill "an extremely logical new product offering" And noted that the current legal environment creates favorable conditions to expand its offerings to other weight loss"
X Link 2026-02-06T13:10Z [----] followers, [---] engagements
"$HIMS The market is wrong about $HIMS. $HIMS is moving towards a $PLTR-style non-linear value creation even that brings the world's most valuable subscription service to the life. https://t.co/yg4HEow5YW The market is wrong about $HIMS. $HIMS is moving towards a $PLTR-style non-linear value creation even that brings the world's most valuable subscription service to the life. https://t.co/yg4HEow5YW"
X Link 2026-02-06T13:11Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: MORGAN STANLEY REITERATES $HIMS $40 PRICE TARGET - HOLD RATING 🚨 BREAKING: MORGAN STANLEY REITERATES $HIMS $40 PRICE TARGET - HOLD RATING"
X Link 2026-02-06T13:19Z [----] followers, [---] engagements
"$HIMS #GLP1 🚨 UBS SKEPTICAL OF $HIMS GLP-1 PILL EFFICACY https://t.co/3r6oFCIJbR 🚨 UBS SKEPTICAL OF $HIMS GLP-1 PILL EFFICACY https://t.co/3r6oFCIJbR"
X Link 2026-02-06T13:20Z [----] followers, [---] engagements
"$PFE #FDA 🦉 FDA granted Priority Review for marstacimab sBLA expanding hemophilia A and B use; PDUFA action date set for Q2 [----] https://investors.pfizer.com/Investors/News/news-details/2026/FDA-Grants-Priority-Review-for-HYMPAVZI-marstacimab-sBLA-for-the-Treatment-of-Two-Hemophilia-A-or-B-Patient-Populations-with-Significant-Medical-Need/default.aspx https://investors.pfizer.com/Investors/News/news-details/2026/FDA-Grants-Priority-Review-for-HYMPAVZI-marstacimab-sBLA-for-the-Treatment-of-Two-Hemophilia-A-or-B-Patient-Populations-with-Significant-Medical-Need/default.aspx"
X Link 2026-02-06T21:12Z [----] followers, [--] engagements
"$GILD @FDA 🦉 FDA removed the prior use limitation for Yescarta in relapsed or refractory primary CNS lymphoma. The CAR-T label now covers PCNSL patients previously excluded based on a small Phase [--] safety study showing frequent neurologic toxicity. https://investors.gilead.com/news/news-details/2026/FDA-Approves-Label-Update-for-Kites-Yescarta-for-RelapsedRefractory-Primary-Central-Nervous-System-Lymphoma/default.aspx https://investors.gilead.com/news/news-details/2026/FDA-Approves-Label-Update-for-Kites-Yescarta-for-RelapsedRefractory-Primary-Central-Nervous-System-Lymphoma/default.aspx"
X Link 2026-02-06T21:33Z [----] followers, [--] engagements
"$HIMS $NVO 🦉 FDA said its ready to act on illegal copycat drugs after Hims rolled out a $49 compounded Wegovy pill; Novo says a lawsuit is coming. Compounded GLP-1s had lived in a shortage loophole. That shelter looks thinner. https://ts2.tech/en/hims-hers-hims-stock-slips-again-as-49-wegovy-copy-draws-fda-heat-and-novo-legal-threat/ https://ts2.tech/en/hims-hers-hims-stock-slips-again-as-49-wegovy-copy-draws-fda-heat-and-novo-legal-threat/"
X Link 2026-02-06T22:13Z [----] followers, [---] engagements
"🦉 $HIMS @FDA #GLP1 FDA to restrict GLP-1 ingredients used in non-approved compounded drugs https://www.marketscreener.com/news/fda-to-restrict-glp-1-ingredients-used-in-non-approved-compounded-drugs-ce7e5ad9de8cf122 https://www.marketscreener.com/news/fda-to-restrict-glp-1-ingredients-used-in-non-approved-compounded-drugs-ce7e5ad9de8cf122"
X Link 2026-02-06T22:17Z [----] followers, [---] engagements
"🦉 $HIMS #investigation HHS general counsel Mike Stuart says based on review of applicable facts referred Hims to DOJ for investigation for potential violations"
X Link 2026-02-06T22:19Z [----] followers, [---] engagements
"$NVO $HIMS 🦉 NVO rebounded after an 8% drop tied to Hims $49 compounded Wegovy launch that pushed shares to post-2021 lows. https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-shares-rebound-fda-targets-illegal-drug-copies-2026-02-06/ https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-shares-rebound-fda-targets-illegal-drug-copies-2026-02-06/"
X Link 2026-02-06T22:27Z [----] followers, [---] engagements
"$OSCR [--] days before $OSCR earnings. I want to remember Bright Health. Same playbook. Tech-first ACA insurer IPO'd in [----] massive growth ambitions. Bright hit 103% MLR burned through hundreds of millions and is gone from the market. They rebranded sold off the pieces and went https://t.co/bk1F6dzdQz [--] days before $OSCR earnings. I want to remember Bright Health. Same playbook. Tech-first ACA insurer IPO'd in [----] massive growth ambitions. Bright hit 103% MLR burned through hundreds of millions and is gone from the market. They rebranded sold off the pieces and went https://t.co/bk1F6dzdQz"
X Link 2026-02-07T19:18Z [----] followers, [---] engagements
"@FDA #GLP1 $HIMS FDA says it will go after telehealth compounders and Hims and Hers specifically. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs https://t.co/jd5rs1Y9d8 FDA says it will go after telehealth compounders and Hims and Hers specifically. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs https://t.co/jd5rs1Y9d8"
X Link 2026-02-07T19:23Z [----] followers, [---] engagements
"$HIMS #GLP1 🚨 BREAKING: $HIMS STOPS OFFERING GLP-1 PILL LAUNCHED EARLIER THIS WEEK https://t.co/FbslxBzbZO 🚨 BREAKING: $HIMS STOPS OFFERING GLP-1 PILL LAUNCHED EARLIER THIS WEEK https://t.co/FbslxBzbZO"
X Link 2026-02-07T19:28Z [----] followers, [---] engagements
"$HIMS $NVO The Streisand Effect in action with $HIMS and $NVO 👇 The Streisand Effect occurs when an attempt to suppress censor or discredit information (or a product) backfires spectacularly drawing far more public attention to it than would have happened otherwise. Heres how its https://t.co/pgMd2wpLTa The Streisand Effect in action with $HIMS and $NVO 👇 The Streisand Effect occurs when an attempt to suppress censor or discredit information (or a product) backfires spectacularly drawing far more public attention to it than would have happened otherwise. Heres how its https://t.co/pgMd2wpLTa"
X Link 2026-02-07T19:35Z [----] followers, [---] engagements
"$MRK $NWBO #DCVax ❄PROJECT WINTERFELL $MRK Silent Manufacturing Network and the $NWBO #DCVax Immune Kit Platform PREFACE This is not a story about one building. It is a story about an ecosystem being assembled to function as a unit. Along a short corridor in Montgomery County Pennsylvania https://t.co/NXIqUpWfOe ❄PROJECT WINTERFELL $MRK Silent Manufacturing Network and the $NWBO #DCVax Immune Kit Platform PREFACE This is not a story about one building. It is a story about an ecosystem being assembled to function as a unit. Along a short corridor in Montgomery County Pennsylvania"
X Link 2026-02-07T19:38Z [----] followers, [---] engagements
"$HIMS $NVO $HIMS has more than 2X the performance of $NVO since going public in late [----]. $HIMS +132% $NVO +63% Hims is a health disruptor Novo Nordisk do not like it and continue to threaten to sue Hims because they are a clear threat. $HIMS isn't going anywhere and will continue https://t.co/d70OqdAUcs $HIMS has more than 2X the performance of $NVO since going public in late [----]. $HIMS +132% $NVO +63% Hims is a health disruptor Novo Nordisk do not like it and continue to threaten to sue Hims because they are a clear threat. $HIMS isn't going anywhere and will continue"
X Link 2026-02-07T19:57Z [----] followers, [---] engagements
"$HIMS #FDA $NVO Prediction: [--]. $HIMS turns quarrel with FDA and $NVO into massive marketing campaign with SuperBowl Ad. [--]. Ends in a fine. [--]. Business does fine long term. Prediction: [--]. $HIMS turns quarrel with FDA and $NVO into massive marketing campaign with SuperBowl Ad. [--]. Ends in a fine. [--]. Business does fine long term"
X Link 2026-02-07T20:01Z [----] followers, [---] engagements
"$NVO $LLY $HIMS $NVO $LLY $HIMS Reuters also wrote about the FDAs crackdown on compounded GLP-1 drugs The U.S. FDA said it plans to crack down on compounded weight-loss drugs citing safety quality and potential violations of federal law. The agency may restrict access to GLP-1 ingredients $NVO $LLY $HIMS Reuters also wrote about the FDAs crackdown on compounded GLP-1 drugs The U.S. FDA said it plans to crack down on compounded weight-loss drugs citing safety quality and potential violations of federal law. The agency may restrict access to GLP-1 ingredients"
X Link 2026-02-07T20:05Z [----] followers, [---] engagements
"$HIMS $HIMS has announced it will stop offering the GLP-1 pill. $NVO keeps claiming that compounded versions of Wegovy harm patients and arent effective but reality tells a different story. When it comes to weight loss conventional GLP-1s like those from $NVO often cause people https://t.co/rAEMxOGysW $HIMS has announced it will stop offering the GLP-1 pill. $NVO keeps claiming that compounded versions of Wegovy harm patients and arent effective but reality tells a different story. When it comes to weight loss conventional GLP-1s like those from $NVO often cause people https://t.co/rAEMxOGysW"
X Link 2026-02-07T23:12Z [----] followers, [---] engagements
"$HIMS $UBER $HIMS versus pharma is going to make $UBER versus taxis look like Cinderella. This is the biggest disruption story since the foundation of the United States. $HIMS versus pharma is going to make $UBER versus taxis look like Cinderella. This is the biggest disruption story since the foundation of the United States"
X Link 2026-02-07T23:13Z [----] followers, [---] engagements
"$HIMS @AndrewDudum .@AndrewDudum on the culture at $HIMS: "The team has a stomach of steel. Whether the stock's $70 or $2.87 most of the executive team and myself will retire here." "We're a team that's heads down and focuses on what can be accomplished in the next decade not the next quarter." https://t.co/CgNLv8Tz1Y .@AndrewDudum on the culture at $HIMS: "The team has a stomach of steel. Whether the stock's $70 or $2.87 most of the executive team and myself will retire here." "We're a team that's heads down and focuses on what can be accomplished in the next decade not the next quarter.""
X Link 2026-02-07T23:14Z [----] followers, [---] engagements
"$HIMS Hims & Hers Health $HIMS just said it will stop selling its compounded weight-loss pill just days after initially offering it This comes after an announcement by federal regulators that they were launching an investigation into the company due to the launch - Bloomberg Hims & Hers Health $HIMS just said it will stop selling its compounded weight-loss pill just days after initially offering it This comes after an announcement by federal regulators that they were launching an investigation into the company due to the launch - Bloomberg"
X Link 2026-02-07T23:16Z [----] followers, [---] engagements
"$HIMS $HIMS back to where it was [--] days ago But now the world knows $HIMS No need for the superbowl ad now Monday we are green $HIMS back to where it was [--] days ago But now the world knows $HIMS No need for the superbowl ad now Monday we are green"
X Link 2026-02-07T23:17Z [----] followers, [---] engagements
"$HIMS $NVO $HIMS $NVO $HIMS was able to offer the weight loss pill for just $49. Why is nobody talking about how bullish this is for $NVO $NVO clearly has a lot of flexibility now with the pricing etc and margins. I'm even more bullish on $NVO than I was before https://t.co/sVLPsZ7rFZ $HIMS $NVO $HIMS was able to offer the weight loss pill for just $49. Why is nobody talking about how bullish this is for $NVO $NVO clearly has a lot of flexibility now with the pricing etc and margins. I'm even more bullish on $NVO than I was before https://t.co/sVLPsZ7rFZ"
X Link 2026-02-07T23:19Z [----] followers, [---] engagements
"$HIMS we have decided 🤣 $HIMS we have decided 🤣 $HIMS"
X Link 2026-02-07T23:20Z [----] followers, [---] engagements
"$HIMS $NVO 🦉 Hims & Hers halts $49 Wegovy copycat pill after FDA threatened action. The telehealth firm reversed course days after launching the semaglutide offering as regulators warned of safety and legal risks"
X Link 2026-02-07T23:32Z [----] followers, [---] engagements
"$HIMS $NVO 🚨 NOVO NORDISK vs. $HIMS & HERS The lawsuit is [---] pages Filed in the US District Court for the District of Delaware It is a patent-only lawsuit; Novo is NOT suing for trademark or advertising issues The patent at issue is U.S. Patent No. [-------] ('343 patent) -- Novo's https://t.co/a4cszxRkcz 🚨 NOVO NORDISK vs. $HIMS & HERS The lawsuit is [---] pages Filed in the US District Court for the District of Delaware It is a patent-only lawsuit; Novo is NOT suing for trademark or advertising issues The patent at issue is U.S. Patent No. [-------] ('343 patent) -- Novo's"
X Link 2026-02-09T22:47Z [----] followers, [---] engagements
"$HIMS $HIMS Adjustment on Growth toward 2030🧵 Not Financial Advice FY2025: Revenue: $2.35B or 58% YoY (weightloss $740) Core $1.61B FY2026: Revenue $3.2B(36%) where weightloss may be down by 10-15% or flat. FY2027: Revenue $4.16B(30%) FY2028: Revenue: $5.2B(25%) FY2029 https://t.co/1vwVhdRONz $HIMS Adjustment on Growth toward 2030🧵 Not Financial Advice FY2025: Revenue: $2.35B or 58% YoY (weightloss $740) Core $1.61B FY2026: Revenue $3.2B(36%) where weightloss may be down by 10-15% or flat. FY2027: Revenue $4.16B(30%) FY2028: Revenue: $5.2B(25%) FY2029 https://t.co/1vwVhdRONz"
X Link 2026-02-09T22:49Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS partner sues Eli Lilly and Novo Nordisk. DAMNING for Big Pharma $LLY and $NVO. The time is now. Today is the day we start to apply MAXIMUM pressure to our congressmen and women in a stern but THOUGHTFUL manner. I will posst more information in a bit after I get off a few https://t.co/ksRz62lB2a $HIMS partner sues Eli Lilly and Novo Nordisk. DAMNING for Big Pharma $LLY and $NVO. The time is now. Today is the day we start to apply MAXIMUM pressure to our congressmen and women in a stern but THOUGHTFUL manner. I will posst more information in a bit after I get off a few"
X Link 2026-02-09T22:49Z [----] followers, [---] engagements
"$HIMS $NVO $HIMS extends losses to 22% after $NVO said it is suing over knockoff obesity drugs. This comes as the FDA signals full enforcement on compounded GLP 1s and the company exits compounded semaglutide. https://t.co/1WKROCRbtU $HIMS extends losses to 22% after $NVO said it is suing over knockoff obesity drugs. This comes as the FDA signals full enforcement on compounded GLP 1s and the company exits compounded semaglutide. https://t.co/1WKROCRbtU"
X Link 2026-02-09T22:50Z [----] followers, [---] engagements
"$LLY Eli Lilly $LLY to buy Orna Therapeutics (private) for $2.4 billion. Circular RNA CAR-T therapies. https://t.co/6iPghcwUuM via @matthewherper Eli Lilly $LLY to buy Orna Therapeutics (private) for $2.4 billion. Circular RNA CAR-T therapies. https://t.co/6iPghcwUuM via @matthewherper"
X Link 2026-02-09T22:50Z [----] followers, [--] engagements
"$HIMS @AndrewDudum This is EXACTLY the opposite of what you wanted to see from $HIMS management this morning I am beginning to think that @AndrewDudum has some sort of main-character narcissism flaw. I expected the ORAL PILL take-down to be a sign of them trying to make a mea culpa but this is https://t.co/67at1JNg8E This is EXACTLY the opposite of what you wanted to see from $HIMS management this morning I am beginning to think that @AndrewDudum has some sort of main-character narcissism flaw. I expected the ORAL PILL take-down to be a sign of them trying to make a mea culpa but this is"
X Link 2026-02-09T22:51Z [----] followers, [---] engagements
"$HIMS $HIMS When the Dept of treasury increases count of stocks by 50% within one quarter (Q4 13F) then you can imagine how confident are they in the company. HIMS is their top [--] investment now in terms of dollar value with avg cost $36 https://t.co/S8LhuqN118 $HIMS When the Dept of treasury increases count of stocks by 50% within one quarter (Q4 13F) then you can imagine how confident are they in the company. HIMS is their top [--] investment now in terms of dollar value with avg cost $36 https://t.co/S8LhuqN118"
X Link 2026-02-09T22:51Z [----] followers, [---] engagements
"$HIMS $HIMS & : BTIG reiterates maintains $ Analyst weighs in on semaglutide pill withdrawal cites regulatory risk as FDA ramps up GLP-1 compounding enforcement. https://t.co/F4jTHGtuIa $HIMS & : BTIG reiterates maintains $ Analyst weighs in on semaglutide pill withdrawal cites regulatory risk as FDA ramps up GLP-1 compounding enforcement. https://t.co/F4jTHGtuIa"
X Link 2026-02-09T22:52Z [----] followers, [---] engagements
"$HIMS $HIMS https://t.co/kn4ItGeV2m $HIMS https://t.co/kn4ItGeV2m"
X Link 2026-02-09T22:52Z [----] followers, [---] engagements
"$HIMS #App $HIMS App downloads are surging post superbowl ad. jumped to #5 most downloaded on the App Store. It was #22 yesterday. This is huge. https://t.co/hexPfKxEj5 $HIMS App downloads are surging post superbowl ad. jumped to #5 most downloaded on the App Store. It was #22 yesterday. This is huge. https://t.co/hexPfKxEj5"
X Link 2026-02-09T22:53Z [----] followers, [---] engagements
"$HIMS #GLP1s 🚨 BREAKING: $HIMS IS NOW OFFERING 20% OFF ON ORDERS OF $500+ Promo includes GLP-1s which brings price to $159/mo - the lowest we've seen in a while maybe ever Hims just kicked off this text message campaign with GLP-1 photo: https://t.co/AB1CQOXqzR 🚨 BREAKING: $HIMS IS NOW OFFERING 20% OFF ON ORDERS OF $500+ Promo includes GLP-1s which brings price to $159/mo - the lowest we've seen in a while maybe ever Hims just kicked off this text message campaign with GLP-1 photo: https://t.co/AB1CQOXqzR"
X Link 2026-02-09T22:54Z [----] followers, [---] engagements
"$HIMS Jeff Bezos says that if you have a 10% chance of making a 100x you should take that bet every single time. This is the case with $HIMS. Down 75% from its highs $4B market cap and a P/S ratio below [--]. $HIMS trades as if its destined to fail all the pessimism is already https://t.co/U7eCnL3Dpb Jeff Bezos says that if you have a 10% chance of making a 100x you should take that bet every single time. This is the case with $HIMS. Down 75% from its highs $4B market cap and a P/S ratio below [--]. $HIMS trades as if its destined to fail all the pessimism is already https://t.co/U7eCnL3Dpb"
X Link 2026-02-09T22:55Z [----] followers, [---] engagements
"$NVO 🚨BREAKING: $NVO THEY ACTUALLY DID IT. Novo Nordisk is asking the court to permanently ban $HIMS from selling unapproved compounded drugs that infringe our patents and is seeking to recover damages https://t.co/gvDJsOx1OT 🚨BREAKING: $NVO THEY ACTUALLY DID IT. Novo Nordisk is asking the court to permanently ban $HIMS from selling unapproved compounded drugs that infringe our patents and is seeking to recover damages https://t.co/gvDJsOx1OT"
X Link 2026-02-09T22:55Z [----] followers, [--] engagements
"$NVO $HIMS BREAKING: Novo Nordisk $NVO sues Hims & Hers $HIMS for infringing on a key Wegovy patent https://t.co/44Ndx293d4 via @pharmalot BREAKING: Novo Nordisk $NVO sues Hims & Hers $HIMS for infringing on a key Wegovy patent https://t.co/44Ndx293d4 via @pharmalot"
X Link 2026-02-09T22:56Z [----] followers, [---] engagements
"$NVO $HIMS $NVO sues $HIMS over cheaper copycat versions of Wegovy pill injections - CNBC. Stock down 20% pre-market. $18.42 - The same price as it was back in [----]. https://t.co/MuGyasfd2T $NVO sues $HIMS over cheaper copycat versions of Wegovy pill injections - CNBC. Stock down 20% pre-market. $18.42 - The same price as it was back in [----]. https://t.co/MuGyasfd2T"
X Link 2026-02-09T22:57Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: $HIMS RESPONDS TO NOVO LAWSUIT "Big Pharma is weaponizing the US judicial system to limit consumer choice" "This lawsuit attacks more than just one medication or company it directly assaults a well-established vital component of US pharmacy practice" https://t.co/NQThXxLVJi 🚨 BREAKING: $HIMS RESPONDS TO NOVO LAWSUIT "Big Pharma is weaponizing the US judicial system to limit consumer choice" "This lawsuit attacks more than just one medication or company it directly assaults a well-established vital component of US pharmacy practice" https://t.co/NQThXxLVJi"
X Link 2026-02-09T22:58Z [----] followers, [---] engagements
"$HIMS $HIMS buy companies that look like this https://t.co/KB6bQn6QrX $HIMS buy companies that look like this https://t.co/KB6bQn6QrX"
X Link 2026-02-09T22:59Z [----] followers, [---] engagements
"$NVO #FDA 🚨BREAKING - $NVO. The FDA flags Novo Nordisk for misleading Wegovy ad The FDA says that the ad misbrands Wegovy Semaglutide tablets and violates the Federal Food Drug and Cosmetic Act The FDA is really busy 😄 https://t.co/amH7Nko5Uq 🚨BREAKING - $NVO. The FDA flags Novo Nordisk for misleading Wegovy ad The FDA says that the ad misbrands Wegovy Semaglutide tablets and violates the Federal Food Drug and Cosmetic Act The FDA is really busy 😄 https://t.co/amH7Nko5Uq"
X Link 2026-02-09T23:01Z [----] followers, [---] engagements
"$NVO $HIMS 🚨 NOVO NORDISK HAS SUED $HIMS FOR INFRINGING ON U.S. PATENT [-------] The '343 patent is Novo's "crown jewel" patent This patent has already withstood an IRP patent challenge by Mylan Pharmaceuticals in [----] Novo is seeking both a permanent ban AND damages If a court 🚨 NOVO NORDISK HAS SUED $HIMS FOR INFRINGING ON U.S. PATENT [-------] The '343 patent is Novo's "crown jewel" patent This patent has already withstood an IRP patent challenge by Mylan Pharmaceuticals in [----] Novo is seeking both a permanent ban AND damages If a court"
X Link 2026-02-09T23:02Z [----] followers, [---] engagements
"$HIMS Once again misleading his followers. In the first half of [----] alone $HIMS generated $420M in GLP-1 revenue. We dont know the Q3 number because the company stopped reporting it but the vast majority of weight-loss revenue does come from GLP-1s. Source: Q2 10-Q filing https://t.co/ccli69DGT3 Once again misleading his followers. In the first half of [----] alone $HIMS generated $420M in GLP-1 revenue. We dont know the Q3 number because the company stopped reporting it but the vast majority of weight-loss revenue does come from GLP-1s. Source: Q2 10-Q filing https://t.co/ccli69DGT3"
X Link 2026-02-09T23:02Z [----] followers, [---] engagements
"$HIMS Interesting $HIMS https://t.co/Rixi46jzp5 Interesting $HIMS https://t.co/Rixi46jzp5"
X Link 2026-02-09T23:03Z [----] followers, [---] engagements
"$NVO $HIMS Former FDA Commissioner Scott Gottlieb on CNBC was blunt about the $NVO vs. $HIMS fight: Mass compounding of GLP-1s was meant as a temporary workaround for shortages not a permanent business model. He warned that using compounding to copy patented drugs undermines FDA Former FDA Commissioner Scott Gottlieb on CNBC was blunt about the $NVO vs. $HIMS fight: Mass compounding of GLP-1s was meant as a temporary workaround for shortages not a permanent business model. He warned that using compounding to copy patented drugs undermines FDA"
X Link 2026-02-09T23:05Z [----] followers, [---] engagements
"$HIMS IMO $HIMS entire GLP-1 operation is about to come down. $HIMS may backing off of the GLP-1 pill now but they opened Pandoras Box here coaxing the FDA into FINALLY cracking down on the overall GLP-1 mass compounding scam that $HIMS has been conducting/profiting from. https://t.co/QQKZm4Fslk IMO $HIMS entire GLP-1 operation is about to come down. $HIMS may backing off of the GLP-1 pill now but they opened Pandoras Box here coaxing the FDA into FINALLY cracking down on the overall GLP-1 mass compounding scam that $HIMS has been conducting/profiting from. https://t.co/QQKZm4Fslk"
X Link 2026-02-09T23:06Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: FDA WARNED $HIMS 503B FACILITY MEDISOURCERX AFTER FINDING BUGS AND FAILING TO REPORT ADVERSE EVENT - Warning issued late [----] - In Jan [----] patient reported "severe" stomach issues from GLP-1 spent [--] nights in a hospital - Event not reported to the FDA w/in [--] https://t.co/yR8YhJlpBH 🚨 BREAKING: FDA WARNED $HIMS 503B FACILITY MEDISOURCERX AFTER FINDING BUGS AND FAILING TO REPORT ADVERSE EVENT - Warning issued late [----] - In Jan [----] patient reported "severe" stomach issues from GLP-1 spent [--] nights in a hospital - Event not reported to the FDA w/in 15"
X Link 2026-02-09T23:54Z [----] followers, [---] engagements
"$NVO $NVO - Details on the share repurchase program. Novo wil repurchase up to 3.8B DKK (about 500M) shares in the period between the 4th of February and the 4th of March. This is part of the 15B DKK program (about 1% of total market cap and worth about 2B) that will be https://t.co/oqVC8ZMrFY $NVO - Details on the share repurchase program. Novo wil repurchase up to 3.8B DKK (about 500M) shares in the period between the 4th of February and the 4th of March. This is part of the 15B DKK program (about 1% of total market cap and worth about 2B) that will be https://t.co/oqVC8ZMrFY"
X Link 2026-02-09T23:55Z [----] followers, [---] engagements
"$HIMS Caesar Capital increased its position in Hims & Hers Health $HIMS today at $17.04 per share 🏛 New average cost basis: $25.77 (down from $26.10) https://t.co/JFQlQwV4ig Caesar Capital increased its position in Hims & Hers Health $HIMS today at $17.04 per share 🏛 New average cost basis: $25.77 (down from $26.10) https://t.co/JFQlQwV4ig"
X Link 2026-02-09T23:56Z [----] followers, [---] engagements
"$OSCR 🦉 Oscar put in place a $475M secured revolver maturing in [----]. The facility carries SOFR-linked pricing and quarterly covenants tied to premiums EBITDA liquidity and leverage. #form_8K"
X Link 2026-02-11T00:14Z [----] followers, [---] engagements
"$BNTC 🦉 Benitec Biopharma priced a $100M stock offering at $13.50 per share including a direct sale to Suvretta Capital. Funds will advance its ddRNAi gene therapy programs and strengthen liquidity. #pressrelease https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering"
X Link 2025-11-06T20:27Z [----] followers, [---] engagements
"$BNTC 🦉 Director Sharon Mates filed Form [--] on Nov [--] [----] disclosing no beneficial ownership in Benitec Biopharma following her appointment dated Nov [--] [----]. #form3 https://d1io3yog0oux5.cloudfront.net/benitec/sec/0001012975-25-000717/0001012975-25-000717.pdf https://d1io3yog0oux5.cloudfront.net/benitec/sec/0001012975-25-000717/0001012975-25-000717.pdf"
X Link 2025-11-08T18:07Z [----] followers, [---] engagements
"$BNTC 🦉 BB-301 didnt fade with time: the first OPMD patient kept improving two years after dosing. All four Cohort [--] patients still cleared responder bars at [--] months pointing to durable effect. https://www.benitec.com/for-investors/news-events/press-releases/detail/141/benitec-biopharma-provides-positive-long-term-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-demonstrating-robust-efficacy-and-continued-durability-of-response"
X Link 2026-01-11T16:58Z [----] followers, [---] engagements
"$BNTC 🦉 Four of four BB-301 patients met responder criteria at [--] months with one showing deeper benefit at [--] months as Benitec plans an FDA meeting to set a pivotal study mid-2026. The program remains early-stage Cohort [--] data due mid-2026. https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update"
X Link 2026-02-12T20:40Z [----] followers, [---] engagements
"$NVS $TRML 🦉 Novartis $48 per share tender offer for Tourmaline Bio expired Oct [--] with 92.94% shares tendered. Transaction expected to close Oct [--] following acceptance. #newsrelease"
X Link 2025-10-28T16:24Z [----] followers, [---] engagements
"$NUVL 🦉 Officer Alexandra Balcom plans to sell [-----] shares via cashless exercise through J.P. Morgan on Nov [--] [----]. Previous sales include [----] shares on Sep [--] and [-----] shares on Sep [--] and Oct [--] each. #form_144 https://app.quotemedia.com/data/downloadFilingwebmasterId=101533&ref=319588239&type=HTML&symbol=NUVL&cdn=9d1424dad837ebcf7218d09df88e8090&companyName=Nuvalent+Inc.&formType=144&dateFiled=2025-11-17"
X Link 2025-11-17T21:45Z [----] followers, [---] engagements
"$KURA 🚀🚨 BIOPHARM CATALYST ALERT 📆 $KURA Kura Oncology will present Phase [--] Acute Myeloid Leukemia Data for Ziftomenib (MEN1 Inhibitor - Small Molecule) tomorrow 👀 🚀🚨 BIOPHARM CATALYST ALERT 📆 $KURA Kura Oncology will present Phase [--] Acute Myeloid Leukemia Data for Ziftomenib (MEN1 Inhibitor - Small Molecule) tomorrow 👀"
X Link 2025-12-07T15:46Z [----] followers, [---] engagements
"$PCVX 🦉 Officer Elvia Cowan filed a Form [---] to sell [-----] shares about $557k via Morgan Stanley. Stock stems from RSUs and option exercises with sale slated for Dec. [--]. #form_144"
X Link 2025-12-24T22:22Z [----] followers, [---] engagements
"$GMAB #portfolio #update 🦉 Genmab is pulling the plug on acasunlimab after a portfolio reset despite encouraging data. Capital shifts to EPKINLY petosemtamab and Rina-S with [----] guidance left untouched. https://ml-eu.globenewswire.com/Resource/Download/d61a4b07-4b51-43bb-a463-e1911f63e6e9 https://ml-eu.globenewswire.com/Resource/Download/d61a4b07-4b51-43bb-a463-e1911f63e6e9"
X Link 2025-12-29T17:41Z [----] followers, [---] engagements
"$NMRA Small signal-seeking Phase 1b shows a modest overall effect on CMAI with a moderate signal only in an anxiety-enriched subgroup. $NMRA Clean safety and no sedation are positives but subgroup-dependence subjective endpoints and an outlier-exclusion in placebo are the bear Small signal-seeking Phase 1b shows a modest overall effect on CMAI with a moderate signal only in an anxiety-enriched subgroup. $NMRA Clean safety and no sedation are positives but subgroup-dependence subjective endpoints and an outlier-exclusion in placebo are the bear"
X Link 2026-01-05T14:55Z [----] followers, [---] engagements
"$NMRA $NMRA Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimers Disease Agitation https://t.co/FdvzZI1pUU $NMRA Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimers Disease Agitation https://t.co/FdvzZI1pUU"
X Link 2026-01-05T15:21Z [----] followers, [---] engagements
"$INCY Control in $INCY Frontmind (1st-line DLBCL) is R-Chop not Revlimid + R-Chop. So how do we know the (modest) PFS benefit toplined today is due to $INCY Monjuvi and not to Revlimid https://t.co/Swc41ElHFr Control in $INCY Frontmind (1st-line DLBCL) is R-Chop not Revlimid + R-Chop. So how do we know the (modest) PFS benefit toplined today is due to $INCY Monjuvi and not to Revlimid https://t.co/Swc41ElHFr"
X Link 2026-01-05T16:36Z [----] followers, [---] engagements
"$NBP $NBP (formerly called I-Mab) announced positive updated results from the Phase 1b combination study of givastomig a Claudin [----] (CLDN18.2) x 4-1BB bispecific antibody in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative first line (1L) https://t.co/Pr9lOoUqIe $NBP (formerly called I-Mab) announced positive updated results from the Phase 1b combination study of givastomig a Claudin [----] (CLDN18.2) x 4-1BB bispecific antibody in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative first line (1L) https://t.co/Pr9lOoUqIe"
X Link 2026-01-07T18:12Z [----] followers, [--] engagements
"$OMDA JUST IN: $OMDA announces preliminary Q4 results. Revenue of $72-74M vs. $69M est. 🟢 Total members at 886k up 55% YoY Both metrics accelerated further from Q3 exactly as I predicted in my recent article. The company expects to report final results on March [--] after market https://t.co/aEAMtPBa14 JUST IN: $OMDA announces preliminary Q4 results. Revenue of $72-74M vs. $69M est. 🟢 Total members at 886k up 55% YoY Both metrics accelerated further from Q3 exactly as I predicted in my recent article. The company expects to report final results on March [--] after market https://t.co/aEAMtPBa14"
X Link 2026-01-12T20:05Z [----] followers, [---] engagements
"$ABVX 🦉 Sofinnova cut its Abivax stake to 7.7% voting power after selling 684k ADS across Jan [----] at $118142. The group still holds 3.33M shares and 6.4M voting rights post-sale. #form_13D https://ir.abivax.com/static-files/0319d5cf-bd14-4c7f-93b3-b04887bc8bb3 https://ir.abivax.com/static-files/0319d5cf-bd14-4c7f-93b3-b04887bc8bb3"
X Link 2026-01-14T22:21Z [----] followers, [---] engagements
"#Sarepta $SRPT 🦉 Three years after a single dose kids with Duchenne treated with ELEVIDYS were still walking better than expected. The usual decline slowedby about 70%. That gap kept widening with time. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results"
X Link 2026-01-26T20:07Z [----] followers, [---] engagements
"#Sarepta $SRPT 🦉 At age nine when Duchenne typically speeds up boys in the EMBARK study stayed above their starting strength. Controls slipped. Gene therapy changed the curve not just the score. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results"
X Link 2026-01-26T20:08Z [----] followers, [---] engagements
"#Sarepta $SRPT"
X Link 2026-01-26T20:18Z [----] followers, [---] engagements
"$SRPT #Sarepta 🦉 Sarepta Therapeutics was upgraded to Zacks Rank #2 after earnings estimates rose 24.6% in three months. FY2025 EPS is still seen at $2.31 unchanged year over year. https://finance.yahoo.com/news/sarepta-therapeutics-srpt-upgraded-buy-170004126.html https://finance.yahoo.com/news/sarepta-therapeutics-srpt-upgraded-buy-170004126.html"
X Link 2026-01-26T20:28Z [----] followers, [---] engagements
"$RGNX #FDA 🦉 FDA placed clinical holds on RGX-111 and RGX-121 after a CNS tumor was detected in one RGX-111 patient. Causality is unestablished; both MPS programs are paused pending FDA review. #form_8K https://ir.regenxbio.com/static-files/58f6ab0b-debc-423f-9732-aed286f252a8 https://ir.regenxbio.com/static-files/58f6ab0b-debc-423f-9732-aed286f252a8"
X Link 2026-01-28T18:18Z [----] followers, [---] engagements
"$QURE #uniQure 🦉 Aberdeen Group and abrdn report [-------] uniQure shares a 5.91% stake. Voting and dispositive power are shared across the position. #form_13G https://uniqure.gcs-web.com/static-files/9b64fb3c-5db0-434b-beb2-ff5b78205abc https://uniqure.gcs-web.com/static-files/9b64fb3c-5db0-434b-beb2-ff5b78205abc"
X Link 2026-01-29T22:11Z [----] followers, [---] engagements
"$SRPT 🦉 Director Kathleen Behrens exercised [-----] options at $13.71 on Jan.27. She disposed [----] shares at $22.17 for taxes; holds [------] direct. #form_4 https://investorrelations.sarepta.com/static-files/497700f3-1eb7-42bc-8960-c895b3c011aa https://investorrelations.sarepta.com/static-files/497700f3-1eb7-42bc-8960-c895b3c011aa"
X Link 2026-01-30T15:15Z [----] followers, [---] engagements
"$PCVX 🦉Priced 11M shares at $50 for $550M gross Jan 29; grants 30-day option for 1.65M more; deal set to close Feb [--]. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-pricing-550-million-public-offering https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-pricing-550-million-public-offering"
X Link 2026-01-30T15:35Z [----] followers, [--] engagements
"$SRPT 🦉 Claude Nicaise exercised [-----] options at $13.71 Jan.29. [----] shares were withheld at $21.23 for taxes; [-----] shares remain direct. #form_4 https://investorrelations.sarepta.com/static-files/75649577-ec3e-40e1-8354-727e26eb03ff https://investorrelations.sarepta.com/static-files/75649577-ec3e-40e1-8354-727e26eb03ff"
X Link 2026-01-30T15:42Z [----] followers, [---] engagements
"$REGN 🦉 Regeneron Reports Fourth Quarter and Full Year [----] Financial and Operating Results Q4 revenue rose 3% to $3.9B; FY up 1% to $14.3B. Dupixent sales jumped 34% to $4.9B while total U.S. EYLEA franchise sales fell 28%. https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial"
X Link 2026-01-30T16:50Z [----] followers, [--] engagements
"$OKUR 🦉 Vanguard reports [------] OnKure shares equal to a 4.87% stake. Disposition power is shared across the position with only limited shared voting rights. #form_13G https://onkuretherapeutics.gcs-web.com/static-files/092b89f7-0253-466e-afe0-da0b1f6205fe https://onkuretherapeutics.gcs-web.com/static-files/092b89f7-0253-466e-afe0-da0b1f6205fe"
X Link 2026-01-30T20:00Z [----] followers, [--] engagements
"$SRPT #Sarepta"
X Link 2026-02-05T23:43Z [----] followers, [---] engagements
"$QURE 🦉 "uniQure paused mid- and high-dose AMT-191 dosing after an independent committee classified Grade [--] liver enzyme elevations as dose-limiting toxicity" https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-updated-preliminary-amt-191-phase-iiia-data https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-updated-preliminary-amt-191-phase-iiia-data"
X Link 2026-02-06T20:57Z [----] followers, [---] engagements
"$BNTX #FixVac $BMY #GVAX $NWBO #DCVax 🧬 THREE WAYS TO TEACH THE IMMUNE SYSTEM TO FIGHT CANCER AND WHY DENDRITIC CELLS DECIDE THE OUTCOME $BNTX #FixVac $BMY #GVAX and $NWBO #DCVax are a clean comparison because they sit on the same axis: all three depend on dendritic cells but they place the teaching job in 🧬 THREE WAYS TO TEACH THE IMMUNE SYSTEM TO FIGHT CANCER AND WHY DENDRITIC CELLS DECIDE THE OUTCOME $BNTX #FixVac $BMY #GVAX and $NWBO #DCVax are a clean comparison because they sit on the same axis: all three depend on dendritic cells but they place the teaching job in"
X Link 2026-02-06T21:33Z [----] followers, [---] engagements
"$IBRX #ANKTIVA In this JAMA study of over [-----] Americans a clear demonstration of survival related to lymphocyte levels is seen in this graph. When lymphocyte levels fall between [---] to [---] the survival rate plummets. ALC matters https://t.co/1o0eaQ4K7M https://t.co/hMuiuUrVyc In this JAMA study of over [-----] Americans a clear demonstration of survival related to lymphocyte levels is seen in this graph. When lymphocyte levels fall between [---] to [---] the survival rate plummets. ALC matters https://t.co/1o0eaQ4K7M https://t.co/hMuiuUrVyc"
X Link 2026-02-06T21:59Z [----] followers, [----] engagements
"$QURE $SGMO $SNY $IDEA [--] week [--] #Fabry headlines from #worldsymposium $SNY Fabry #fails to meet expectations $IDEA no renal benefit in Fabry $QURE Fabry #stops dosing on #tox do not report eGFR #high variability path forwar #unclear. $SGMO cures Fabry and stabilizes cardiac functions https://t.co/MiDhbP8tDx [--] week [--] #Fabry headlines from #worldsymposium $SNY Fabry #fails to meet expectations $IDEA no renal benefit in Fabry $QURE Fabry #stops dosing on #tox do not report eGFR #high variability path forwar #unclear. $SGMO cures Fabry and stabilizes cardiac functions https://t.co/MiDhbP8tDx"
X Link 2026-02-07T20:08Z [----] followers, [---] engagements
"$IBRX #ImmunityBio"
X Link 2026-02-09T23:00Z [----] followers, [---] engagements
"$IBRX $IBRX REMINDER - ImmunityBio will participate in the three-day [----] ASCO Genitourinary Cancers Symposium on February [--] - [--] at the Moscone West in San Francisco California. Held annually the event focuses on the latest research and treatments for cancers including prostate $IBRX REMINDER - ImmunityBio will participate in the three-day [----] ASCO Genitourinary Cancers Symposium on February [--] - [--] at the Moscone West in San Francisco California. Held annually the event focuses on the latest research and treatments for cancers including prostate"
X Link 2026-02-10T22:19Z [----] followers, [---] engagements
"$IBRX $IBRX right now you can buy this company that will be worth over a trillion dollars soon (within [--] years) for only $6.83B. Knowing full well how massive GLP-1s have been for obesity treatment I firmly believe that $IBRX's IL-15s broad spectrum anti-cancer peptide will become a https://t.co/ReOLBADeyG $IBRX right now you can buy this company that will be worth over a trillion dollars soon (within [--] years) for only $6.83B. Knowing full well how massive GLP-1s have been for obesity treatment I firmly believe that $IBRX's IL-15s broad spectrum anti-cancer peptide will become a"
X Link 2026-02-10T22:40Z [----] followers, [---] engagements
"$UNH $UNH Superinvestors should file remaining 13Fs by Monday 16th. I expect to see some large buys in UnitedHealth Group last quarter especially from Berkshire Hathaway-Warren Buffett. This is the same group of buyers that helped push the stock up more than 15% in Q3 after https://t.co/uh33Wr2MJZ $UNH Superinvestors should file remaining 13Fs by Monday 16th. I expect to see some large buys in UnitedHealth Group last quarter especially from Berkshire Hathaway-Warren Buffett. This is the same group of buyers that helped push the stock up more than 15% in Q3 after https://t.co/uh33Wr2MJZ"
X Link 2026-02-10T23:54Z [----] followers, [---] engagements
"$OSCR This $OSCR Guidance is INSANE 📈 - $19B Revenues +48% above estimates - $250-450M EBIT vs $5M estimate 50-100x Mark Bertolini is making a huge promise but most don't trust him. Those who do could be rewarded https://t.co/VWcnaj0Dhd This $OSCR Guidance is INSANE 📈 - $19B Revenues +48% above estimates - $250-450M EBIT vs $5M estimate 50-100x Mark Bertolini is making a huge promise but most don't trust him. Those who do could be rewarded https://t.co/VWcnaj0Dhd"
X Link 2026-02-10T23:54Z [----] followers, [---] engagements
"$IBRX @DrPatrick How does $IBRX benefit from the Saudi FDA approval of Anktiva What say the fanboys/girls of @DrPatrick on this question I'm not talking about the stock price so spare me that reply. What material benefit will ImmunityBio gain from focusing on Saudi Arabia How does $IBRX benefit from the Saudi FDA approval of Anktiva What say the fanboys/girls of @DrPatrick on this question I'm not talking about the stock price so spare me that reply. What material benefit will ImmunityBio gain from focusing on Saudi Arabia"
X Link 2026-02-11T17:20Z [----] followers, [---] engagements
"$UNH Hedge funds are heavily overweight healthcare stocks. For reference $UNH was the most bought stock by hedge funds in Q3 [----]. The sector is now valued at just 18x forward earnings against 22x of S&P [---]. Long healthcare. $UNH $OSCR $CNC $CI $MOH $ELV https://t.co/R16TYkEpiM Hedge funds are heavily overweight healthcare stocks. For reference $UNH was the most bought stock by hedge funds in Q3 [----]. The sector is now valued at just 18x forward earnings against 22x of S&P [---]. Long healthcare. $UNH $OSCR $CNC $CI $MOH $ELV https://t.co/R16TYkEpiM"
X Link 2026-02-11T17:51Z [----] followers, [---] engagements
"$IBRX $IBRX 🚨🤯🚨 OMG Everyone must see this Current free float is [---] million shares short interest is [---] million shares That means over the stock run up shorts have increased their shorting and right now there's more shorts than shares in free float We are set up for most https://t.co/2YYApSmBNe $IBRX 🚨🤯🚨 OMG Everyone must see this Current free float is [---] million shares short interest is [---] million shares That means over the stock run up shorts have increased their shorting and right now there's more shorts than shares in free float We are set up for most https://t.co/2YYApSmBNe"
X Link 2026-02-11T17:52Z [----] followers, [---] engagements
"$NVO $LLY Motley Fool says there are [--] healthcare stocks to buy on the dip and $NVO is one of them. Their take: Novo is now second fiddle to $LLY. Lillys Mounjaro +99% sales growth Zepbound +175% Novos obesity portfolio +31% They argue pricing pressure in the U.S. will Motley Fool says there are [--] healthcare stocks to buy on the dip and $NVO is one of them. Their take: Novo is now second fiddle to $LLY. Lillys Mounjaro +99% sales growth Zepbound +175% Novos obesity portfolio +31% They argue pricing pressure in the U.S. will"
X Link 2026-02-11T17:54Z [----] followers, [---] engagements
"$OSCR $OSCR guided for [---] million members but 400K of those are expected to drop off by end of Q1. They were $0 premium enrollees who got passively renewed into plans that now cost actual money. They're in a grace period through March. If they don't pay they're off the books. So https://t.co/SLkYw0Qp3L $OSCR guided for [---] million members but 400K of those are expected to drop off by end of Q1. They were $0 premium enrollees who got passively renewed into plans that now cost actual money. They're in a grace period through March. If they don't pay they're off the books. So"
X Link 2026-02-11T17:54Z [----] followers, [---] engagements
"$OSCR #Oscar Here are a few highlights from Oscars latest earnings call as reported this week. 👉 FY25 revenue: Increased to approximately $11.7B up 28% year-over-year 👉 FY25 SG&A expense ratio: 17.5% improved approximately [---] basis points year-over-year In addition as of February https://t.co/Ut5QTUpGqy Here are a few highlights from Oscars latest earnings call as reported this week. 👉 FY25 revenue: Increased to approximately $11.7B up 28% year-over-year 👉 FY25 SG&A expense ratio: 17.5% improved approximately [---] basis points year-over-year In addition as of February"
X Link 2026-02-11T17:58Z [----] followers, [---] engagements
"$UNH $UNH UnitedHealth Group is going to do very well on earnings this year which should shock the market at a $250 Billion MC Exactly what $META MC was at when it was trading near the $90s. MA Increase % this year is nearly 7.5% including all factors which is huge. Deep Value. https://t.co/1CGvz31jhl $UNH UnitedHealth Group is going to do very well on earnings this year which should shock the market at a $250 Billion MC Exactly what $META MC was at when it was trading near the $90s. MA Increase % this year is nearly 7.5% including all factors which is huge. Deep Value. https://t.co/1CGvz31jhl"
X Link 2026-02-12T19:07Z [----] followers, [---] engagements
"$UNH Mizuho cut its price recommendation on $UNH to $350 from $430 but kept an Outperform rating on the stock. The revision came after the companys Q4 results with the firm pointing to a slower-than-expected earnings recovery as the main reason for the https://t.co/ooKxI9ImgP Mizuho cut its price recommendation on $UNH to $350 from $430 but kept an Outperform rating on the stock. The revision came after the companys Q4 results with the firm pointing to a slower-than-expected earnings recovery as the main reason for the https://t.co/ooKxI9ImgP"
X Link 2026-02-12T19:08Z [----] followers, [---] engagements
"$IBRX @DrPatrick @ImmunityBio #ImmunityBio doesn't just deliver a drug; it utilizes second-generation adenovirus (hAd5) vector technology to transform our bodies into a "special forces unit" for hunting viruses. The company uses adenoviruses genetically modified to be harmless to humans as a type of #ImmunityBio doesn't just deliver a drug; it utilizes second-generation adenovirus (hAd5) vector technology to transform our bodies into a "special forces unit" for hunting viruses. The company uses adenoviruses genetically modified to be harmless to humans as a type of"
X Link 2026-02-12T19:10Z [----] followers, [---] engagements
"$NVO $HIMS $NVO CEO Mike Doustdar to compounders: time to partner not copy. Despite suing 130+ copycat sellers (incl. $HIMS) he says many built patient access Novo couldnt reach. Example: Ro now sells the branded drug and became a very good partner. But nothing in his comments $NVO CEO Mike Doustdar to compounders: time to partner not copy. Despite suing 130+ copycat sellers (incl. $HIMS) he says many built patient access Novo couldnt reach. Example: Ro now sells the branded drug and became a very good partner. But nothing in his comments"
X Link 2026-02-12T19:11Z [----] followers, [---] engagements
"$OSCR #Oscar As we shared with our full-year [----] results and [----] outlook Oscars vision remains clear: were leading the individual market with a consumer-first experience member-focused tools powered by AI and a clear path back to profitability. Read our full earnings release here: https://t.co/Ev1o5QtLFD As we shared with our full-year [----] results and [----] outlook Oscars vision remains clear: were leading the individual market with a consumer-first experience member-focused tools powered by AI and a clear path back to profitability. Read our full earnings release here:"
X Link 2026-02-12T19:12Z [----] followers, [---] engagements
"$IBRX $IBRX is actively advancing clinical research in glioblastoma an aggressive Grade [--] brain tumor with limited treatment options and median survival typically just over one year post-diagnosis. Full focus on Innovative immunotherapy combinations in ongoing Ph [--] trial $IBRX is actively advancing clinical research in glioblastoma an aggressive Grade [--] brain tumor with limited treatment options and median survival typically just over one year post-diagnosis. Full focus on Innovative immunotherapy combinations in ongoing Ph [--] trial"
X Link 2026-02-12T19:28Z [----] followers, [---] engagements
"$VKTX $VKTX Huge news for shareholders- Boom Oral drug moving to Ph3 guys https://t.co/DHczsATn4F $VKTX Huge news for shareholders- Boom Oral drug moving to Ph3 guys https://t.co/DHczsATn4F"
X Link 2026-02-12T19:30Z [----] followers, [---] engagements
"$NVO #Wegovy $NVO oral version of Wegovy (semaglutide) launched in January has seen significant uptake with approximately 36% of users being new to GLP-1 therapies. A study by Truveta reveals that 21% of users transitioned from the injectable Wegovy while 16% came from $LLY Zepbound https://t.co/VIP0XF8vj8 $NVO oral version of Wegovy (semaglutide) launched in January has seen significant uptake with approximately 36% of users being new to GLP-1 therapies. A study by Truveta reveals that 21% of users transitioned from the injectable Wegovy while 16% came from $LLY Zepbound"
X Link 2026-02-12T19:31Z [----] followers, [---] engagements
"$VKTX $VKTX new slides & nice pic from piper that sums it up well on catalysts https://t.co/DmzAtMVv8P https://t.co/79HABADM4h $VKTX new slides & nice pic from piper that sums it up well on catalysts https://t.co/DmzAtMVv8P https://t.co/79HABADM4h"
X Link 2026-02-12T19:35Z [----] followers, [---] engagements
"$AGIO 🦉 Agios posted a $108M Q4 net loss as cash fell to $1.2B while PYRUKYND and newly launched AQVESME drove $20M in quarterly sales. The company heads into a pre-sNDA FDA meeting for mitapivat in sickle cell after reporting $54M full-year revenue. https://investor.agios.com/news-releases/news-release-details/agios-reports-fourth-quarter-and-full-year-2025-financial https://investor.agios.com/news-releases/news-release-details/agios-reports-fourth-quarter-and-full-year-2025-financial"
X Link 2026-02-12T19:44Z [----] followers, [--] engagements
"$ZYME 🦉 Zymeworks will report Q4 and full-year [----] results pre-market March [--] with a call at 8:30 a.m. ET. The company has yet to publish year-end figures leaving updated cash revenue and pipeline data pending. https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-report-fourth-quarter-and-full-year-2025-financial https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-report-fourth-quarter-and-full-year-2025-financial"
X Link 2026-02-12T19:47Z [----] followers, [--] engagements
"$CGEN 🦉 Compugen appointed Michele Holcomb to its board as an independent director effective Feb. [--]. The addition comes as the company remains clinical-stage reliant on partnered programs and without approved products generating revenue. https://cgen.com/investors-and-media/press-releases/news-details/2026/Compugen-Announces-the-Appointment-of-Michele-Holcomb-Ph-D--to-its-Board-of-Directors/default.aspx https://cgen.com/investors-and-media/press-releases/news-details/2026/Compugen-Announces-the-Appointment-of-Michele-Holcomb-Ph-D--to-its-Board-of-Directors/default.aspx"
X Link 2026-02-12T19:56Z [----] followers, [--] engagements
"$BBIO 🦉 BBIO said Phase [--] PROPEL [--] met its goal; infigratinib added +1.74 cm/year vs placebo and was first to show significant body proportionality gains. No oral FGFR3 drug has done this; FDA filing talks set for 2H26."
X Link 2026-02-12T20:22Z [----] followers, [---] engagements
"$BBIO $BMRN BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase [--] success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase [--] success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde"
X Link 2026-02-12T20:23Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS $LLY $NVO 🚨 FOUNDER & CEO OF MOCHI HEALTH: EXPECT "WAY HIGHER" CHURN ON NOVO'S GLP-1 PILL " The orals just don't work very well. Rybelsus has been on the market for years. And nobody takes it" " I think the pill is a great on-ramp but it also just doesn't really https://t.co/wVjd6ByJIX $HIMS $LLY $NVO 🚨 FOUNDER & CEO OF MOCHI HEALTH: EXPECT "WAY HIGHER" CHURN ON NOVO'S GLP-1 PILL " The orals just don't work very well. Rybelsus has been on the market for years. And nobody takes it" " I think the pill is a great on-ramp but it also just doesn't really"
X Link 2026-02-12T20:23Z [----] followers, [---] engagements
"$SPRB 🦉Spruce Biosciences posted a Q3 [----] net loss of $8.2M as R&D spending fell to $5M after ending tildacerfont work. Cash totaled $10.7M extended to 4Q26 with $50M financing. #pressrelease #Q3 #report https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-reports-third-quarter-2025-financial-results https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-reports-third-quarter-2025-financial-results"
X Link 2025-11-10T21:11Z [----] followers, [---] engagements
"$CNTA 🦉 Centessa names Mario Accardi CEO as it pivots fully to its orexin franchise effective Jan. [--] [----]. Outgoing chief Saurabh Saha becomes advisor while ORX750 heads toward a Q1 [----] registrational start. https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-ceo-transition-company https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-ceo-transition-company"
X Link 2025-12-11T19:13Z [----] followers, [---] engagements
"$CNTA #Centessa 🦉 Centessa showed preclinical data at ACNP where OX2R activation cut depressive-like behavior and boosted wakefulness in animal models. The results support expanding its orexin pipeline beyond hypersomnia into neuropsychiatric disease. https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-poster-presentation-new https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-poster-presentation-new"
X Link 2026-01-15T18:36Z [----] followers, [---] engagements
"$ROG $RHHBY 🦉 Roche booked CHF61.5B in [----] sales up 7% CER with Phesgo Ocrevus and Vabysmo carrying growth. Core profit rose 13% and the board put up a CHF9.80 dividend while guiding [----] to mid-single-digit CER gains. https://www.roche.com/investors/updates/inv-update-2026-01-29 https://www.roche.com/investors/updates/inv-update-2026-01-29"
X Link 2026-01-29T18:33Z [----] followers, [--] engagements
"$UNCY @FDA 🦉 Jan [--] 2026: FDA accepted OLC NDA resubmission; set PDUFA June [--] [----]. Agency classified as Class II CRL; six-month review. Company reported $41.3M cash at [----] end runway into [----]. https://ir.unicycive.com/news/detail/117/unicycive-therapeutics-announces-fda-acceptance-of https://ir.unicycive.com/news/detail/117/unicycive-therapeutics-announces-fda-acceptance-of"
X Link 2026-01-29T18:44Z [----] followers, [--] engagements
"$UNCY 🦉 Jan [--] 2026: Unicycive Therapeutics said U.S. Food and Drug Administration accepted its OLC NDA resubmission and set a June [--] [----] PDUFA date. Filing marked Class II with six-month review. Company reported $41.3M cash at [----] end. https://ir.unicycive.com/news/detail/118/update---unicycive-therapeutics-announces-fda-acceptance-of https://ir.unicycive.com/news/detail/118/update---unicycive-therapeutics-announces-fda-acceptance-of"
X Link 2026-01-29T18:58Z [----] followers, [--] engagements
"$PALI 🦉 Franklin Resources and affiliated entities reported a combined [-------] shares (6.0% of class) beneficially owned in Palisade Bio as of Dec [--] [----] under a Schedule 13G. Ownership includes warrants exercisable for [-------] shares. #form_13G https://s3.amazonaws.com/sec.irpass.cc/2827/0000038777-26-000014.htm https://s3.amazonaws.com/sec.irpass.cc/2827/0000038777-26-000014.htm"
X Link 2026-01-29T19:06Z [----] followers, [---] engagements
"$BNTC 🦉 Franklin Resources reported [-------] Benitec shares a 10.6% stake including [-------] warrant shares. Voting and dispositive power sit with Franklin Advisers as investment manager. #form_13G https://d1io3yog0oux5.cloudfront.net/benitec/sec/0000038777-26-000024/0000038777-26-000024.pdf https://d1io3yog0oux5.cloudfront.net/benitec/sec/0000038777-26-000024/0000038777-26-000024.pdf"
X Link 2026-01-29T19:14Z [----] followers, [--] engagements
"$HIMS #GLP1 In an emergency Hims House episode Crmieux joined Jonathan Stern to discuss all things $HIMS GLP-1s and the legalities of everything that unfolded today between Hims Novo Nordisk and the FDA. This clip summarizes their conversation. https://t.co/LscFxvpA0m In an emergency Hims House episode Crmieux joined Jonathan Stern to discuss all things $HIMS GLP-1s and the legalities of everything that unfolded today between Hims Novo Nordisk and the FDA. This clip summarizes their conversation. https://t.co/LscFxvpA0m"
X Link 2026-02-06T13:20Z [----] followers, [---] engagements
"$IBRX 🚀 $IBRX [----] Catalyst Rocket: FDA Resub INCOMING ASCO GU Buzz Saudi Rollout Heating Up Earnings Beat Potential Major BLA Path & Global Expansion This Dip Is Pure Setup for Explosive Leg Up 💥 Todays dip stings after that breakout pure profit-taking + volatility no https://t.co/3w7ouusihX 🚀 $IBRX [----] Catalyst Rocket: FDA Resub INCOMING ASCO GU Buzz Saudi Rollout Heating Up Earnings Beat Potential Major BLA Path & Global Expansion This Dip Is Pure Setup for Explosive Leg Up 💥 Todays dip stings after that breakout pure profit-taking + volatility no https://t.co/3w7ouusihX"
X Link 2026-02-11T17:55Z [----] followers, [---] engagements
"$IBRX @ImmunityBio"
X Link 2026-02-12T19:02Z [----] followers, [---] engagements
"$IBRX $IBRX - Feb 11th [----] Short Data Analysis based on real data . 1- Utilization is now 100%. What does that mean What Does "100% Utilization" Mean Think of the stock market like a car rental lot. 100% Utilization means every single car (share) available for rent (shorting) https://t.co/Gj6iCRwccP $IBRX - Feb 11th [----] Short Data Analysis based on real data . 1- Utilization is now 100%. What does that mean What Does "100% Utilization" Mean Think of the stock market like a car rental lot. 100% Utilization means every single car (share) available for rent (shorting) https://t.co/Gj6iCRwccP"
X Link 2026-02-12T19:03Z [----] followers, [---] engagements
"$PEPG #PepGen $pepg up 50% in [--] trading days. Data ANY day now. https://t.co/gh6IgYfpPa $pepg up 50% in [--] trading days. Data ANY day now. https://t.co/gh6IgYfpPa"
X Link 2026-02-12T19:04Z [----] followers, [--] engagements
"$IBRX #Anktiva $MRK FDA encouraged Merck to proceed based on breakthrough therapy designation. Anktiva has Breakthrough Therapy Designation (BTD). Priority review was denied in [----] when BLA was filed despite BTD. Now Anktiva has RMAT status and Expanded Access Authorization across multiple tumor https://t.co/YgYY5nsx3r FDA encouraged Merck to proceed based on breakthrough therapy designation. Anktiva has Breakthrough Therapy Designation (BTD). Priority review was denied in [----] when BLA was filed despite BTD. Now Anktiva has RMAT status and Expanded Access Authorization across multiple tumor"
X Link 2026-02-12T19:06Z [----] followers, [---] engagements
"$IBRX $IBRX Call volume 📈 "Financial giants have made a bullish move on ImmunityBio. Our analysis of options history reveal 57% of traders were bullish while 26% showed bearish tendencies." - @Benzinga Trades spotted: [--] puts valued at $71500 [--] calls valued at $1230478 https://t.co/7hnFH8nCXK $IBRX Call volume 📈 "Financial giants have made a bullish move on ImmunityBio. Our analysis of options history reveal 57% of traders were bullish while 26% showed bearish tendencies." - @Benzinga Trades spotted: [--] puts valued at $71500 [--] calls valued at $1230478 https://t.co/7hnFH8nCXK"
X Link 2026-02-12T19:08Z [----] followers, [---] engagements
"$VKTX $VKTX excellent execution i I take $VKTX CEO any day his execution has been spectacular in getting these trials up and running and FDA blessings done VANQUISH-1: Enrollment complete [----] patients (exceeded target) - VANQUISH-2: Nearing full enrollment in 1Q26 - Oral VK2735: $VKTX excellent execution i I take $VKTX CEO any day his execution has been spectacular in getting these trials up and running and FDA blessings done VANQUISH-1: Enrollment complete [----] patients (exceeded target) - VANQUISH-2: Nearing full enrollment in 1Q26 - Oral VK2735:"
X Link 2026-02-12T19:13Z [----] followers, [---] engagements
"$SNY $XBI 🚨WOW @Sanofi's CEO was just ousted The companys board of directors met on February [--] [----] and decided not to renew the Director mandate of Paul Hudson As a result Paul Hudsons last day as $SNY CEO will be on February [--] [----] at the end of business. The board has https://t.co/blC4H7PjhG 🚨WOW @Sanofi's CEO was just ousted The companys board of directors met on February [--] [----] and decided not to renew the Director mandate of Paul Hudson As a result Paul Hudsons last day as $SNY CEO will be on February [--] [----] at the end of business. The board has https://t.co/blC4H7PjhG"
X Link 2026-02-12T19:27Z [----] followers, [---] engagements
"$IBRX #ImmunityBio $MRK #ANKTIVA #ImmunityBio has saved patients who had failed even Keytruda the world's number one cancer drug. In recently released lung cancer data patients achieved a median overall survival of [----] monthsstretching up to [----] monthswhich is more than double the [--] to [--] months seen with #ImmunityBio has saved patients who had failed even Keytruda the world's number one cancer drug. In recently released lung cancer data patients achieved a median overall survival of [----] monthsstretching up to [----] monthswhich is more than double the [--] to [--] months seen with"
X Link 2026-02-12T19:29Z [----] followers, [---] engagements
"Welcome to @AponiaAnalytics 🦉🦉🦉 Curious about how emerging diseases and breakthrough innovations shape tomorrows healthcare worldwide Follow along for the latest news real-time trends and unbiased analysis. 🦉📈💊⚕ Your provider of holistic intelligence in healthcare and biotech. We cover: - #BreakingNews in biotech medtech and healthcare. - Health threat reports emerging #diseases #outbreaks #epidemiology. - #MarketAnalysis - Trending companies and #startups. Follow us @aponia_analytics team 🦉🦉🦉"
X Link 2024-12-20T20:48Z [----] followers, 30.4K engagements
"$IBRX $IBRX Blackrock ImmunityBio Second Largest Institutional Holder Increases Its Stake By 5.8mil Shares In 4Q25 ie +29% Reaching Up 25.6mil Shares Overall. https://t.co/cLFTH7p6J3 $IBRX Blackrock ImmunityBio Second Largest Institutional Holder Increases Its Stake By 5.8mil Shares In 4Q25 ie +29% Reaching Up 25.6mil Shares Overall. https://t.co/cLFTH7p6J3"
X Link 2026-02-13T15:53Z [----] followers, [---] engagements
"$NVO #Wegovy 🚨BREAKING - Wegovy Pill sales are up 34% $NVO TRx came in at [------] in the 5th week after launch. Up from TRx [-----] last week. This is the IQVIA data which is widely regarded as the most trustworthy and accurate Remember this still without the effect of the Superbowl https://t.co/ewCLNIS0xG 🚨BREAKING - Wegovy Pill sales are up 34% $NVO TRx came in at [------] in the 5th week after launch. Up from TRx [-----] last week. This is the IQVIA data which is widely regarded as the most trustworthy and accurate Remember this still without the effect of the Superbowl https://t.co/ewCLNIS0xG"
X Link 2026-02-13T15:54Z [----] followers, [---] engagements
"$HIMS Wild to see that $HIMS is down 30% over the past five years https://t.co/dG3Ur6LVzD Wild to see that $HIMS is down 30% over the past five years https://t.co/dG3Ur6LVzD"
X Link 2026-02-13T15:55Z [----] followers, [---] engagements
"$LLY $NVO $VKTX $LLY builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision. $NVO $VKTX https://t.co/7PyoEtEw5D $LLY builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision. $NVO $VKTX https://t.co/7PyoEtEw5D"
X Link 2026-02-13T15:58Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS $LLY $NVO 🚨 SABINA HEMMI (@LAWLIEPOP) ON THE FDA's GLP-1 ANNOUNCEMENT LAST FRIDAY: "It's clearly been sparked by Hims's actions." "While the most concerning part of the FDA statement is its mention of API's it seems to primarily be focused on marketing. They directly https://t.co/VJ0ufiWvNR $HIMS $LLY $NVO 🚨 SABINA HEMMI (@LAWLIEPOP) ON THE FDA's GLP-1 ANNOUNCEMENT LAST FRIDAY: "It's clearly been sparked by Hims's actions." "While the most concerning part of the FDA statement is its mention of API's it seems to primarily be focused on marketing. They directly"
X Link 2026-02-12T20:44Z [----] followers, [---] engagements
"$VKTX $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY"
X Link 2026-02-12T20:44Z [----] followers, [---] engagements
"$CRBU 🦉 Caribou Biosciences will speak at Citi and Leerink investor events; no clinical data no FDA update no capital raise disclosed. The stock had no fresh catalyst after prior CAR-T updates. https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-participate-upcoming-investor-conferences-12 https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-participate-upcoming-investor-conferences-12"
X Link 2026-02-12T21:31Z [----] followers, [---] engagements
"$NWBO #DCVax 🧬 Why the New Nature #mRNA Study Quietly Proves the Superiority of $NWBO #DCVax And Why mRNA Cancer Vaccines Cannot Match Dendritic-Cell Immunotherapy. and why the #FDA is correct. 🔗https://t.co/v451mF4xqH https://t.co/bxycWLb7Hs 🧬 Why the New Nature #mRNA Study Quietly Proves the Superiority of $NWBO #DCVax And Why mRNA Cancer Vaccines Cannot Match Dendritic-Cell Immunotherapy. and why the #FDA is correct. 🔗https://t.co/v451mF4xqH https://t.co/bxycWLb7Hs"
X Link 2026-02-13T15:52Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing